Cryopreservation and MSC Immunomodulation: Impacts on Functional Potency and Clinical Translation

Abstract

Cryopreservation is a critical step for the off-the-shelf availability of Mesenchymal Stem Cells (MSCs) in clinical therapy, yet its impact on their immunomodulatory properties is a key concern for researchers and drug development professionals. This article synthesizes current evidence on how the freeze-thaw process acutely impairs MSC function, including reduced anti-inflammatory mediator production and increased susceptibility to innate immune attack. It further explores methodological variations in cryopreservation protocols, strategies for functional recovery such as post-thaw acclimation, and comparative analyses of fresh versus cryopreserved MSC potency in disease models. Understanding these factors is essential for optimizing MSC-based product development and ensuring therapeutic efficacy in clinical applications for immune and inflammatory disorders.

The Cellular Impact: How Cryopreservation Acutely Alters MSC Biology and Immunomodulatory Function

The therapeutic potential of mesenchymal stem cells (MSCs) is largely attributed to their dynamic immunomodulatory properties, which are not constitutive but are activated and enhanced by inflammatory stimuli, particularly cytokines like interferon-gamma (IFN-γ). This process, known as licensing, is crucial for MSCs to exert their immunosuppressive effects in therapeutic settings [1]. Cryopreservation is an essential process for creating "off-the-shelf" MSC products, enabling long-term storage, quality control testing, and logistical flexibility for clinical use [2] [3]. However, a growing body of evidence indicates that the freeze-thaw process induces immediate but transient deficits in MSC function, including a suppressed ability to respond to pro-inflammatory cues. This impairment threatens the very mechanism that activates the therapeutic potency of MSCs [4]. Understanding this phenomenon is critical for the development of consistently effective MSC-based therapies. This review synthesizes current evidence on post-thaw functional deficits, detailing the molecular mechanisms, quantitative impacts, and recovery kinetics, and provides standardized experimental protocols for their assessment.

Mechanisms of Cryopreservation-Induced Functional Deficits

The suppressed responsiveness of MSCs post-thaw is a multifactorial problem rooted in the physical and metabolic stress of cryopreservation. The following mechanisms have been implicated:

• Cellular Stress and Apoptosis: The freeze-thaw process induces significant cellular stress, leading to increased rates of early and late apoptosis immediately post-thaw. This state of distress diverts cellular resources away from normal signaling and response pathways [4].
• Surface Marker Alterations: Cryopreservation can temporarily reduce the expression of key surface markers involved in immunomodulation. Studies have documented immediate post-thaw decreases in CD44 and CD105, which are involved in cell adhesion and signaling, potentially disrupting critical interactions with the inflammatory microenvironment [4].
• Transcriptomic and Metabolic Suppression: Freshly thawed MSCs exhibit a global downregulation of genes critical for their therapeutic function. This includes key regenerative, angiogenic, and anti-inflammatory genes. Concurrently, a significant increase in metabolic activity post-thaw suggests a stress response, which is coupled with a reduction in actual cell proliferation, indicating that energy is being diverted to repair rather than function [4].

Table 1: Key Molecular Changes in MSCs Immediately Post-Thaw

Category	Specific Element	Change Post-Thaw	Functional Consequence
Surface Markers	CD105	Decreased	Disrupted immunomodulatory signaling
	CD44	Decreased	Impaired cell adhesion and migration
Gene Expression	Anti-inflammatory genes (e.g., TSG-6, PGE2 pathways)	Downregulated	Reduced capacity to suppress inflammation
	Angiogenic genes (e.g., VEGF)	Downregulated	Impaired support for blood vessel formation
Cellular State	Apoptosis	Increased	Reduced viable cell dose and function
	Metabolic Activity	Increased	Energy diverted to cellular repair over therapeutic function
	Proliferation	Decreased	Reduced expansion at the site of injury

Quantitative Analysis of Post-Thaw Immunomodulatory Potency

The functional consequences of these molecular changes are measurable in assays that test the core immunomodulatory capacities of MSCs. The data reveal a clear pattern of impairment that recovers after a short acclimation period.

A 2019 study provides direct, quantitative evidence of these deficits and their recovery. The research compared MSCs under three conditions: Freshly Cultured (FC), Freshly Thawed (FT; used immediately), and Thawed + Time (TT; acclimated for 24 hours post-thaw) [4].

Table 2: Functional Recovery of Cryopreserved MSCs After a 24-Hour Acclimation Period

Functional Assay	Freshly Thawed (FT) MSCs	Thawed + 24h (TT) MSCs	Significance (FT vs TT)
T-cell Suppression	Maintained baseline suppression	Significantly more potent suppression	P < 0.05
IFN-γ Secretion	Significantly diminished	Recovered to levels comparable to fresh cells	P < 0.05
Clonogenic Capacity	Decreased	Recovered	P < 0.05
Apoptosis Rate	Significantly increased	Significantly reduced	P < 0.05
Key Regenerative Gene Expression	Downregulated	Upregulated	P < 0.05

The data shows that while FT MSCs retain a baseline ability to suppress T-cell proliferation, their potency is significantly enhanced after a 24-hour recovery. More strikingly, the secretion of IFN-γ, a critical mediator of the immune response, is significantly compromised immediately post-thaw but is fully restored after acclimation [4]. This finding is corroborated by other studies indicating that cryopreserved MSCs can have reduced immunomodulatory and blood regulatory properties immediately upon thawing [5].

It is important to note that not all studies find dramatic differences. A 2022 systematic review of pre-clinical animal models concluded that the majority of in vivo efficacy outcomes (over 97% of experiments) showed no significant difference between freshly cultured and cryopreserved MSCs [6]. This suggests that the in vivo microenvironment may help mitigate some post-thaw deficits or that the "hit-and-run" mechanism of action of MSCs is less affected. However, the consistency of in vitro data demonstrating temporary impairment necessitates careful consideration of cell processing protocols prior to clinical administration.

Experimental Protocols for Assessing Post-Thaw Responsiveness

To systematically evaluate the post-thaw responsiveness of MSCs to pro-inflammatory stimuli, the following standardized experimental protocols are recommended. These methods allow for the quantification of the deficits described above.

Protocol 1: Flow Cytometry for Surface Marker Analysis

This protocol assesses the impact of cryopreservation on the expression of immunomodulatory surface markers [4].

• Cell Preparation: Create three experimental groups: Freshly Cultured (FC), Freshly Thawed (FT), and Thawed + 24h (TT).
• Staining: Harvest cells and incubate with staining buffer containing an Fc blocker to prevent non-specific binding.
• Antibody Incubation: Stain cells with pre-conjugated antibodies against key markers (e.g., CD90-FITC, CD105-PerCP-Cy5.5, CD73-APC, CD44-PE) and relevant negative markers (CD45-PE, CD34-PE, HLA-DR-PE). Include isotype controls.
• Analysis: Analyze cells using a flow cytometer (e.g., BD FACSCanto II). Collect data for a minimum of 10,000 events per sample and analyze using software such as FlowJo, reporting Mean Fluorescence Intensity (MFI) and percentage of positive cells.

Protocol 2: qPCR for Gene Expression Profiling

This protocol measures transcriptomic changes in immunomodulatory genes in response to inflammatory priming [4].

• Stimulation: Culture FC, FT, and TT MSCs in the presence or absence of a pro-inflammatory priming agent such as 50 ng/mL IFN-γ for 24 hours.
• RNA Extraction: Lyse cells and extract total RNA using a commercial kit (e.g., RNeasy Mini Kit). Quantify RNA concentration and ensure purity (A260/A280 ratio ~2.0).
• cDNA Synthesis: Reverse transcribe 1 µg of total RNA into cDNA using a High-Capacity cDNA Reverse Transcription Kit.
• qPCR Reaction: Prepare reactions with SYBR Green Master Mix and primers for target genes (e.g., IDO1, PTGS2 (COX-2), CCL2, IL6) and housekeeping genes (e.g., GAPDH, ACTB). Run in triplicate on a real-time PCR system.
• Data Analysis: Calculate relative gene expression using the 2^(-ΔΔCt) method, normalizing to housekeeping genes and the unstimulated control group.

Protocol 3: T-cell Proliferation Suppression Assay

This is a gold-standard functional assay to measure the immunomodulatory potency of MSCs [1] [4].

• MSC Preparation: Seed irradiated (to prevent proliferation) MSCs from FC, FT, and TT groups in a culture plate and allow to adhere. Pre-treat with or without IFN-γ (50 ng/mL) for 24 hours to assess licensing.
• T-cell Isolation: Isolate peripheral blood mononuclear cells (PBMCs) from healthy donors using density gradient centrifugation (e.g., Ficoll-Paque). Isolate T-cells by negative selection.
• Co-culture: Label T-cells with a proliferation dye such as CFSE (5 µM). Co-culture activated T-cells (e.g., stimulated with anti-CD3/CD28 beads) with the pre-prepared MSCs at various MSC:T-cell ratios (e.g., 1:5, 1:10) for 4-5 days.
• Flow Cytometry Analysis: Harvest T-cells and analyze CFSE dilution by flow cytometry to measure proliferation. The suppression is calculated as: % Suppression = (1 - (% Proliferation in Co-culture / % Proliferation in T-cell only control)) * 100.

Figure 1: Experimental workflow for evaluating post-thaw MSC responsiveness. This diagram outlines the parallel processing of MSC groups through stimulation and key assays, leading to distinct functional outcomes.

The Scientist's Toolkit: Essential Reagents and Materials

The following table lists critical reagents required for the investigation of post-thaw MSC responsiveness.

Table 3: Essential Research Reagents for Post-Thaw Function Analysis

Reagent/Material	Function/Application	Example Specification
Pro-Inflammatory Priming Agent	Licenses MSCs to enhance immunomodulatory function.	Recombinant Human IFN-γ, >95% purity, working concentration 50 ng/mL.
Cryopreservation Medium	Protects cells during freeze-thaw cycle.	90% FBS + 10% DMSO, or serum-free commercial alternatives.
Flow Cytometry Antibodies	Detection of surface and intracellular markers.	Anti-human CD105, CD73, CD90, CD44, CD54 (ICAM-1); HLA-DR (negative control).
Intracellular Staining Antibodies	Detection of licensing-induced enzymes.	Anti-human IDO1, PTGS2 (COX-2). Requires fixation/permeabilization kit.
qPCR Primers	Quantification of gene expression changes.	Validated primers for IDO1, PTGS2, CCL2, IL6, TNFAIP3, TSG-6.
T-cell Activation Reagents	For functional suppression assays.	Anti-human CD3/CD28 Activator Beads or soluble antibodies.
Cell Proliferation Dye	Tracking T-cell division in co-culture.	CFSE (5,6-carboxyfluorescein diacetate succinimidyl ester), 5 µM working concentration.

The evidence is clear that cryopreservation imposes a temporary but significant functional deficit on MSCs, characterized by a suppressed ability to respond to the very pro-inflammatory stimuli that license their therapeutic actions. This is manifested through altered surface marker expression, downregulation of critical immunomodulatory genes, and reduced functional potency in suppression assays. The molecular and functional recovery observed after a 24-hour acclimation period provides a critical operational insight for translational research [4]. For clinical trials and bioprocess development, incorporating a post-thaw recovery phase may be essential to ensure that administered MSCs deliver their full therapeutic potential. Future work must focus on optimizing cryopreservation protocols—including cryoprotectant composition, cooling rates, and thawing procedures—to minimize this initial deficit and improve the consistency of "off-the-shelf" MSC therapies.

Figure 2: Mechanism-to-solution pathway for post-thaw deficits. This diagram summarizes the logical flow from the initial freeze-thaw stress through the core deficit and its manifestations, leading to the consequential therapeutic risk and its proposed solution.

Cryopreservation represents a critical bottleneck in the therapeutic application of mesenchymal stromal cells (MSCs), significantly altering their secretory profile and impairing their immunomodulatory function. This technical review synthesizes current evidence demonstrating that the freeze-thaw process specifically reduces the production of key anti-inflammatory mediators, particularly TNF-α-stimulated gene/protein 6 (TSG-6), which is crucial for controlling inflammatory responses. We analyze the quantitative impact on the MSC secretome, detail methodologies for assessing these alterations, and visualize the underlying biological pathways affected. The findings underscore the importance of accounting for cryopreservation-induced changes in the design and potency assessment of MSC-based therapies, particularly for applications requiring robust immunomodulation.

The transition of mesenchymal stromal cells (MSCs) from research tools to clinically viable advanced therapy medicinal products hinges on the ability to create "off-the-shelf" inventories, making cryopreservation a necessity for logistical feasibility and rapid deployment [2] [7]. Contemporary understanding posits that the therapeutic benefits of MSCs—in conditions ranging from graft-versus-host disease to connective tissue disease-associated interstitial lung disease—are mediated predominantly through paracrine mechanisms rather than direct cellular engraftment and differentiation [8] [9]. This secretome comprises a complex mixture of soluble proteins, cytokines, growth factors, and extracellular vesicles that collectively modulate immune responses, promote tissue repair, and resolve inflammation [10] [8].

The central hypothesis of this review is that the cryopreservation process itself fundamentally alters the functional composition of the MSC secretome, with particular detriment to the production of critical anti-inflammatory mediators like TSG-6. This impairment poses a significant challenge for clinical development, as the immunomodulatory potency of a cryopreserved product may not reflect the efficacy demonstrated in pre-clinical studies using freshly cultured cells [11]. Understanding the specific nature and magnitude of these alterations is therefore essential for optimizing manufacturing protocols, designing accurate potency assays, and interpreting clinical trial outcomes for MSC-based immunomodulatory therapies.

Quantitative Impact on the MSC Secretome

Comparative analyses of freshly cultured versus cryopreserved MSCs reveal consistent, quantifiable differences in secretome composition and function. A systematic review of pre-clinical in vivo models of inflammation found that while the majority of efficacy outcomes showed no significant difference, a notable subset of in vitro potency assays demonstrated impaired function in cryopreserved cells [7]. Specifically, of 68 in vitro experiments representing 32 different potency measures, 13% (9/68) showed statistically significant differences, with the majority of these (seven experiments) favoring freshly cultured MSCs over their cryopreserved counterparts [7].

Table 1: Functional Consequences of Cryopreservation on MSCs

Functional Aspect	Impact of Cryopreservation	Experimental Evidence
TSG-6 Production	Reduced responsiveness to pro-inflammatory stimuli, leading to impaired production of this key anti-inflammatory mediator [11].	In vitro stimulation assays
Overall Immunomodulatory Capacity	Diminished suppression of effector T-cell activation and reduced promotion of regulatory T-cell expansion [9].	Immune cell co-culture studies
Complement Activation	Increased triggering of the instant blood-mediated inflammatory reaction (IBMIR) and stronger activation of the complement cascade [11].	Serum exposure assays
Post-Infusion Cell Survival	Faster complement-mediated elimination after blood exposure, reducing viable cell engraftment [11].	In vivo tracking studies

At a molecular level, the secretome of cryopreserved MSCs is characterized by a skewed profile of soluble factors. Key anti-inflammatory mediators are often downregulated. For instance, TSG-6 plays a critical role in modulating inflammatory responses by binding to fragments of the complement component C5 and hyaluronan, thereby disrupting inflammatory cascades [12] [8]. Its reduced availability compromises the MSC's ability to control excessive inflammation. Furthermore, cryopreserved MSCs demonstrate an impaired capacity to polarize macrophages toward an anti-inflammatory M2 phenotype, a mechanism essential for tissue repair and resolution of inflammation [13].

Experimental Protocols for Assessing Secretome Alterations

Rigorous assessment of cryopreservation-induced alterations requires a multi-faceted experimental approach. Below are detailed protocols for key assays that evaluate the compositional and functional changes in the MSC secretome, with a focus on TSG-6 and related immunomodulatory functions.

Protocol 1: Analysis of Secretome Composition via Co-culture and ELISA

This protocol evaluates the soluble factor profile of MSCs following stimulation.

• Cell Preparation: Culture fresh MSCs (harvested by trypsin/EDTA) and cryopreserved MSCs (thawed and washed). Use cells from the same donor and passage. Adjust cell density to 1–2 × 10^6 cells/mL in an appropriate buffer [11].
• Pro-inflammatory Stimulation: Seed MSCs and treat with a pro-inflammatory cytokine cocktail (e.g., 10 ng/mL IFN-γ and 10 ng/mL TNF-α) for 24-48 hours to mimic an inflammatory microenvironment [11].
• Conditioned Media Collection: Collect the conditioned media and centrifuge (e.g., 2000 × g for 10 minutes) to remove cellular debris. Aliquot and store the supernatant at -80°C.
• Soluble Factor Quantification:
  • Determine the concentration of key anti-inflammatory factors, including TSG-6, IL-10, and PGE2, using commercially available enzyme-linked immunosorbent assay (ELISA) kits.
  • Perform all assays in technical triplicates according to the manufacturer's instructions.
  • Normalize protein concentrations to the total cell count or cellular protein content of the producing culture.

Protocol 2: Functional T-cell Suppression Assay

This co-culture assay tests the functional consequence of secretome alterations on adaptive immune responses.

• Effector Cell Isolation: Isolate peripheral blood mononuclear cells (PBMCs) from healthy human donors by density gradient centrifugation.
• T-cell Activation: Activate T-cells within the PBMC population using a mitogen like phytohemagglutinin (PHA, 5 µg/mL) or anti-CD3/CD28 antibodies.
• Co-culture Establishment: Co-culture the activated PBMCs with either fresh or cryopreserved MSCs at varying ratios (e.g., 10:1, 5:1, and 1:1 PBMC:MSC ratio) in a mixed lymphocyte reaction (MLR) for 3-5 days.
• Response Measurement:
  • Proliferation: Assess T-cell proliferation by adding [3H]-thymidine for the final 18 hours of culture and measuring incorporated radioactivity. Alternatively, use CFSE dye dilution measured by flow cytometry.
  • Cytokine Profiling: Collect supernatant and quantify IFN-γ, TNF-α, IL-17 (pro-inflammatory), and IL-10 (anti-inflammatory) levels via multiplex ELISA or flow cytometry.
  • Compare the suppressive capacity of fresh versus cryopreserved MSCs by the percentage reduction in T-cell proliferation and pro-inflammatory cytokine output.

Protocol 3: Complement Activation and Serum-Mediated Lysis Assay

This protocol assesses the increased vulnerability of cryopreserved MSCs to innate immune attack.

• Sample Preparation: Prepare fresh and freeze-thawed MSCs as in Protocol 1, and adjust to a standard concentration.
• Serum Exposure: Incubate 1 × 10^6 MSCs with 50% (v/v) complement-active normal human AB-serum (NHS) or, as a control, EDTA-inactivated NHS (NHS/EDTA) for 60 minutes at 37°C [11].
• Reaction Termination: Stop complement activity by adding 10 mM EDTA.
• Viability and Lysis Assessment:
  • Cell Viability: Use a automated cell counter or flow cytometry with a viability dye (e.g., propidium iodide) to determine the percentage of lysed cells.
  • Complement Deposition: Use flow cytometry to detect the binding of complement activation products (e.g., C3b, C5b-9 membrane attack complex) to the MSC surface using specific antibodies.
  • Time-Lapse Imaging: Perform time-lapse imaging over the 60-minute incubation to visually monitor cell lysis in real-time [11].

The Scientist's Toolkit: Essential Research Reagents

A standardized set of reagents and tools is fundamental for the consistent evaluation of MSC secretome alterations post-cryopreservation.

Table 2: Key Research Reagents for Secretome Analysis

Reagent / Tool	Function / Specific Example	Application in Secretome Studies
Pro-inflammatory Cocktail	IFN-γ (10-50 ng/mL) and TNF-α (10-50 ng/mL) to mimic inflammatory milieu.	Conditioned media generation; potency testing under stimulated conditions [11].
Cryoprotective Agent (CPA)	Dimethyl sulfoxide (DMSO, typically 10%) with fetal calf serum.	Standard cryopreservation; control for CPA toxicity in experiments [2] [11].
ELISA Kits	Commercial kits for human TSG-6, IL-10, PGE2, TGF-β.	Quantification of specific soluble anti-inflammatory factors in conditioned media [8].
Complement-Active Serum	Pooled normal human AB-serum (NHS).	Assessment of innate immune activation and serum-mediated lysis vulnerability [11].
Viability & Apoptosis Assays	Propidium iodide, Annexin V, CASY cell counter.	Measurement of cell survival and death post-thaw and after serum exposure [11].

Biological Pathways and Mechanisms

The reduction of key mediators like TSG-6 disrupts carefully balanced biological pathways essential for MSC-mediated immunomodulation. TSG-6 is a multi-functional protein induced in response to pro-inflammatory signals that exerts potent anti-inflammatory effects by inhibiting neutrophil migration, modulating macrophage polarization towards an M2 phenotype, and directly binding to and degrading the pro-inflammatory hyaluronan fragments that accumulate at sites of injury [12] [8]. Its downregulation in cryopreserved MSCs therefore impairs a critical feedback loop that dampens excessive inflammation.

Furthermore, cryopreservation-induced cell surface changes render MSCs more susceptible to the Instant Blood-Mediated Inflammatory Reaction (IBMIR). This innate immune attack is characterized by rapid complement activation, platelet binding, and infiltration of neutrophils and monocytes, leading to the destruction of the infused cells [11]. The increased expression of tissue factor and other procoagulant molecules on cryopreserved MSCs, combined with a reduced ability to produce protective factors like TSG-6, creates a perfect storm that promotes this deleterious reaction, significantly reducing the number of viable cells that can reach and modulate the target tissue.

The evidence conclusively demonstrates that cryopreservation alters the MSC secretome, leading to a measurable reduction in the production of pivotal anti-inflammatory mediators like TSG-6. This impairment has direct consequences for the therapeutic potency of MSCs, potentially compromising their efficacy in clinical settings where robust immunomodulation is required. The observed increase in susceptibility to complement-mediated lysis further diminishes the functional cell dose delivered to the patient.

Future research must focus on optimizing cryopreservation protocols—including the development of DMSO-free cryoprotectants and controlled freezing rates—to better preserve the integrity of the MSC secretome [2]. Furthermore, the field must adopt mechanism-aligned potency assays that specifically measure the expression and function of key mediators like TSG-6 as part of the product release criteria for clinical-grade MSCs. For acute applications where the highest level of functionality is critical, the use of freshly cultured MSCs—or the allowance for a short post-thaw recovery period in culture—may be a necessary consideration despite the logistical challenges [7] [14]. Addressing these challenges is paramount for realizing the full clinical potential of MSC-based immunomodulatory therapies.

Surface Marker Changes: Decreased Expression of CD105 and CD44

The therapeutic efficacy of Mesenchymal Stromal Cells (MSCs) is intrinsically linked to their immunophenotype, defined by a specific set of surface markers. The expression of CD105 (Endoglin) and CD44 is critical for MSC function, influencing processes from cardiac regeneration to cell adhesion and homing. This technical review synthesizes evidence that cryopreservation, a fundamental step in creating 'off-the-shelf' MSC therapies, can significantly reduce the expression of these key markers. This phenotypic shift is not merely a cosmetic change; it is associated with transient yet critical alterations in cellular function, including impaired immunomodulatory potency and reduced metabolic activity post-thaw. A comprehensive understanding of these changes, the underlying mechanisms, and strategies to mitigate them is essential for optimizing the clinical application of cryopreserved MSCs in drug development and regenerative medicine.

Mesenchymal Stem/Stromal Cells (MSCs) are multipotent cells characterized by their plastic-adherence, tri-lineage differentiation potential (into osteoblasts, adipocytes, and chondrocytes), and a defined immunophenotype [2] [15]. According to the International Society for Cellular Therapy (ISCT), MSCs must express CD105, CD73, and CD90, and lack expression of hematopoietic markers such as CD45, CD34, and HLA-DR [2] [15]. This surface marker profile is not just a signature for identification; it is fundamentally linked to their biological function.

CD105 (Endoglin) is a component of the TGF-β receptor complex and plays a vital role in angiogenesis and cardiovascular development [16]. Its expression level has been directly correlated with the cardiac regenerative potential of MSCs [16]. CD44, a receptor for hyaluronic acid, mediates cell-cell and cell-matrix interactions and is involved in cell migration and homing [17].

For clinical applications, MSCs must be expanded ex vivo to obtain sufficient cell numbers. Cryopreservation in liquid nitrogen is the only practical method for long-term storage, enabling the creation of "off-the-shelf" therapies that are readily available for acute conditions like myocardial infarction, stroke, and graft-versus-host disease (GvHD) [2] [18]. However, the process of cryopreservation and subsequent thawing imposes significant stress on cells, potentially altering their phenotype and function. This review examines the specific impact on CD105 and CD44 expression and the consequent implications for MSC-based therapeutics.

Observed Phenotypic Changes Post-Cryopreservation

Quantitative Evidence of Marker Reduction

Multiple independent studies have documented a consistent decrease in the expression of CD105 and CD44 on MSCs immediately following cryopreservation and thawing. The table below summarizes key quantitative findings from the literature.

Table 1: Documented Changes in CD105 and CD44 Expression on MSCs Post-Cryopreservation

Surface Marker	Reported Change	Experimental Context	Functional Correlation
CD105	Significantly lower expression in one serum-free medium formulation [16]	Culture in commercial serum-free medium (MSCGM-CD) vs. serum-containing medium	Positively influences cardiac regenerative potential [16]
CD44 & CD105	Decreased surface marker expression in freshly thawed (FT) MSCs [19]	Phenotypic analysis of bone-marrow-derived MSCs, FT vs. thawed+acclimated (TT) cells	Reduced clonogenic capacity, metabolic activity; increased apoptosis in FT group [19]
CD44	Acquired expression during in vitro culture; primary MSCs in vivo are naturally CD44- [17]	Comparison of freshly isolated vs. culture-expanded human and mouse bone marrow MSCs	CD44- fraction contains almost all clonogenic cells with multilineage potential [17]

The Acclimation Period: A Path to Recovery

A critical finding is that the cryopreservation-induced reduction of CD44 and CD105 is often transient. Research demonstrates that allowing MSCs a 24-hour acclimation period post-thaw allows for the recovery of surface marker expression and, more importantly, the restoration of full cellular function.

• Functional Recovery: One study showed that MSCs allowed to acclimate for 24 hours (TT group) exhibited significantly reduced apoptosis and a concomitant upregulation of key angiogenic and anti-inflammatory genes compared to freshly thawed (FT) cells [19].
• Immunomodulatory Potency: While all MSCs suppressed T-cell proliferation, the TT MSCs were significantly more potent than their FT counterparts [19]. This underscores that the phenotypic recovery of surface markers is linked to the restoration of therapeutic efficacy.

Investigating the Changes: Core Experimental Protocols

To study cryopreservation-induced surface marker changes, researchers employ a suite of standardized techniques. The workflow for a typical investigation is outlined below, followed by detailed protocols.

MSC Culture and Cryopreservation Protocol

Objective: To expand and prepare MSCs for cryopreservation using a standardized slow-freezing method.

Materials:

• MSCs: Isolated from bone marrow, adipose tissue, or other sources [19] [17].
• Culture Medium: Alpha-MEM or DMEM, supplemented with 10-15% Fetal Bovine Serum (FBS) or pooled human platelet lysate [19] [20].
• Cryoprotectant: Culture medium supplemented with 10% Dimethyl Sulfoxide (DMSO) and 90% FBS [19].

Methodology:

• Culture & Expansion: Plate MSCs and culture until 70-80% confluent. Passage cells using trypsin/EDTA and expand to required numbers (e.g., passage 3) [16] [19].
• Harvesting: At the desired passage, harvest MSCs using trypsin/EDTA, neutralize with serum-containing medium, and centrifuge (e.g., 300 ×g for 10 min) [16].
• Cryopreservation: Resuspend the cell pellet in cryoprotectant solution at a specific concentration (e.g., 1-5 × 10^6 cells/mL). Aliquot into cryovials.
• Slow Freezing: Place cryovials in a controlled-rate freezer or an isopropanol freezing container at -80°C to achieve a cooling rate of approximately -1°C/min. After 24 hours, transfer vials to long-term storage in liquid nitrogen (-196°C) [2].

Experimental Group Design and Thawing

Objective: To compare MSCs at different states relevant to clinical application.

Groups:

• FC (Fresh Cells): MSCs harvested from continuous culture, serving as the baseline control [19].
• FT (Freshly Thawed): MSCs thawed and used immediately for analysis, representing the "off-the-shelf" clinical product [19] [18].
• TT (Thawed + Time): MSCs thawed, re-plated in culture medium, and allowed to acclimate for 24 hours before analysis, representing a recovery phase [19].

Thawing Protocol: Rapidly warm cryovials in a 37°C water bath until just thawed. Immediately transfer cell suspension to pre-warmed culture medium and centrifuge to remove DMSO. Resuspend in fresh medium for counting and subsequent plating or analysis [2].

Immunophenotyping by Flow Cytometry

Objective: To quantitatively analyze the expression of surface markers CD105 and CD44 on MSCs from different experimental groups.

Materials:

• Antibodies: Fluorescently conjugated monoclonal antibodies against CD105, CD44, CD73, CD90, and hematopoietic linage markers (CD45, CD34) [16] [19] [17].
• Staining Buffer: PBS containing 1% Bovine Serum Albumin (BSA) [19].
• Flow Cytometer: (e.g., BD FACSAria II, FACSCanto II) [19] [17].

Methodology:

• Cell Preparation: Harvest and wash MSCs from each experimental group (FC, FT, TT).
• Staining: Incubate approximately 1×10^6 cells with Fc blocker to prevent non-specific binding. Add antibody cocktail and incubate for 20-30 minutes in the dark [19].
• Washing & Analysis: Wash cells to remove unbound antibody, resuspend in staining buffer, and analyze on the flow cytometer. Use fluorescence-minus-one (FMO) controls to set positive gates accurately [17].
• Data Interpretation: Report the percentage of positive cells for each marker and the mean fluorescence intensity (MFI), which indicates expression level.

Linking Phenotype to Function: Impact on Immunomodulatory Properties

The downregulation of CD105 and CD44 is not an isolated event but part of a broader post-thaw dysfunction that directly impacts the immunomodulatory capacity of MSCs, a key mechanism for their therapeutic effect. The following diagram illustrates how cryopreservation stress leads to functional impairments.

The mechanisms linking surface marker loss to functional decline are multifaceted:

• T-cell Suppression: MSCs modulate T-cell proliferation through direct contact and paracrine factors. Freshly thawed MSCs with reduced CD44/CD105 show a diminished capacity to suppress the proliferation of activated peripheral blood mononuclear cells (PBMCs) and T-cells [19] [18]. This function is largely restored after a 24-hour acclimation period [19].
• Response to Inflammatory Cues: A critical aspect of MSC immunomodulation is their licensing by inflammatory cytokines like IFN-γ. Cryopreservation can transiently blunt this response, leading to reduced expression of key immunomodulatory enzymes like Indoleamine 2,3-dioxygenase (IDO), which is vital for suppressing T-cell responses [15] [18].
• Altered Secretome: The secretion of growth factors and cytokines (the "secretome") that mediate tissue repair and immunomodulation can be impaired in freshly thawed MSCs, affecting their therapeutic potency in models like retinal ischemia/reperfusion injury [18].

Table 2: Functional Deficits in Freshly Thawed MSCs and Recovery Post-Acclimation

Functional Parameter	Status in Freshly Thawed (FT) MSCs	Status after 24h Acclimation (TT)
Viability & Metabolism	Significantly increased apoptosis; reduced metabolic activity [19]	Significantly reduced apoptosis; metabolic activity recovers [19]
Clonogenic Capacity	Decreased [19]	Recovered [19]
Immunomodulatory Gene Expression	Downregulated (e.g., angiogenic, anti-inflammatory genes) [19]	Upregulated [19]
T-cell Suppression	Maintained but significantly less potent [19]	Significantly more potent [19]
IDO Expression/Activity	Can be reduced or delayed post IFN-γ stimulation [18]	Responsiveness to IFN-γ is restored [19] [18]

The Scientist's Toolkit: Essential Reagents and Materials

Table 3: Key Research Reagent Solutions for Investigating MSC Surface Markers

Reagent / Material	Function / Purpose	Specific Examples / Notes
Chemically Defined/SF Media	Eliminates batch variability and safety concerns of FBS; can directly influence marker expression (e.g., CD105) [16].	MSCGM-CD (Lonza), PowerStem (PAN Biotech) [16].
Cryoprotective Agents (CPAs)	Protect cells from ice crystal damage during freezing; DMSO is standard but has cytotoxicity [2].	DMSO, glycerol, polyethylene glycol, trehalose. Research focuses on DMSO-free formulations [2].
Flow Cytometry Antibodies	Essential for immunophenotyping and quantifying surface marker expression changes [16] [19] [17].	Conjugated antibodies against CD105, CD44, CD73, CD90, CD45, CD34. MSC Analysis Kits (e.g., BD Biosciences) [19].
Differentiation Kits	To confirm multilineage differentiation potential is retained despite surface marker changes post-cryo [16] [19].	Adipogenic, osteogenic, chondrogenic induction media (e.g., from R&D Systems, Thermo Fisher) [16] [19].
Cytokines for Licensing	To test MSC responsiveness to inflammatory signals, a key immunomodulatory mechanism [15] [18].	Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α) [18].
Co-culture Assay Components	To functionally test immunomodulatory potency (e.g., T-cell suppression) [19] [20].	Peripheral Blood Mononuclear Cells (PBMCs), T-cell activators (e.g., CD3/CD28 dynabeads) [18].

The decrease in CD105 and CD44 expression following cryopreservation is a well-documented phenomenon that serves as a biomarker for a broader, transient functional impairment of MSCs. This "post-thaw lag" period is characterized by reduced immunomodulatory potency, metabolic sluggishness, and increased apoptosis. For research and drug development, these findings have profound implications:

• Protocol Standardization: The method of cryopreservation and post-thaw handling must be rigorously optimized and reported. Simply assessing viability is insufficient; a combination of immunophenotyping and functional assays is required for quality control.
• Clinical Trial Design: The timing of MSC administration relative to thawing is critical. Administering cells immediately after thawing (the FT paradigm) may provide suboptimal efficacy for indications reliant on robust immunomodulation. Where logistically feasible, a short acclimation period could significantly enhance therapeutic outcomes.
• Future Innovations: The field must continue to develop advanced cryopreservation protocols. This includes optimizing DMSO-free cryoprotectants [2], refining freezing rates, and exploring novel strategies to pre-condition MSCs to better withstand cryopreservation stress, thereby preserving their critical surface identity and therapeutic function.

Understanding and mitigating the surface marker changes induced by cryopreservation is not merely a technical exercise but a fundamental requirement for realizing the full clinical potential of MSCs as a reliable and potent "off-the-shelf" biologic medicine.

Increased Apoptosis and Compromised Metabolic Activity

Mesenchymal stem cells (MSCs) represent a cornerstone of regenerative medicine due to their immunomodulatory properties and multipotent differentiation capacity. Cryopreservation enables the "off-the-shelf" availability essential for clinical applications, yet the freeze-thaw process imposes significant cellular stress. This technical review examines the specific detrimental effects of cryopreservation on MSC biology, focusing on the mechanisms driving increased apoptosis and compromised metabolic activity immediately post-thaw. Evidence indicates that freshly thawed MSCs exhibit marked increases in early and late apoptotic populations, reduced metabolic function, impaired proliferation, and diminished clonogenic capacity. Furthermore, cryopreservation transiently affects the expression of key immunomodulatory genes. However, a critical recovery period of 24 hours post-thaw allows MSCs to regain fundamental therapeutic functions, including their ability to modulate immune responses. Understanding these cryopreservation-induced impairments and recovery dynamics is paramount for optimizing MSC-based therapeutic protocols and ensuring maximal clinical efficacy.

The therapeutic potential of mesenchymal stem cells (MSCs) in treating inflammatory and degenerative diseases is well-established, leveraging their immunomodulatory, anti-inflammatory, and regenerative capacities [21]. For clinical logistics, cryopreservation in liquid nitrogen is the standard for long-term storage, creating "off-the-shelf" products that are thawed immediately before administration [19] [2]. However, a growing body of evidence suggests the freeze-thaw process itself can inflict substantial damage, potentially compromising the very therapeutic functions these cells are intended to deliver [19] [11].

The core thesis of this review is that cryopreservation induces a transient but functionally significant state of cellular injury in MSCs, characterized by increased apoptosis and compromised metabolic activity, which collectively dampen their immunomodulatory potency. This impairment has profound implications for research outcomes and clinical efficacy, particularly when cells are administered immediately post-thaw. This whitepaper synthesizes current preclinical and clinical evidence to delineate the specific cellular and functional deficits observed in freshly thawed MSCs, outlines the underlying mechanisms, and provides detailed experimental protocols for quantifying these effects. The objective is to provide researchers and drug development professionals with a comprehensive technical guide to navigate the challenges associated with cryopreserved MSC products.

Core Deficits in Cryopreserved MSCs

Immediately following thawing, MSCs exhibit a range of cellular and functional deficits. The most critical of these are summarized in the table below, which compares key parameters between freshly thawed (FT) MSCs and their cultured or acclimated counterparts.

Table 1: Functional and Cellular Deficits in Freshly Thawed MSCs

Parameter	Freshly Thawed (FT) MSCs	Thawed & Acclimated (TT) or Freshly Cultured (FC) MSCs	Citation
Apoptosis	Significantly increased	Significantly reduced after 24h acclimation	[19]
Metabolic Activity	Significantly increased (stress response)	Normalized levels	[19]
Cell Proliferation	Significantly decreased	Recovered proliferation capacity	[19]
Clonogenic Capacity	Significantly decreased	Recovered colony-forming potential	[19]
CD105 Expression	Decreased surface marker expression	Stable marker expression	[19] [22]
Immunomodulatory Gene Expression	Downregulated (e.g., angiogenic, anti-inflammatory genes)	Upregulated after 24h acclimation	[19]
Innate Immune Activation	Increased triggering of IBMIR and complement cascade	Lower innate immune activation	[11]

A direct comparison of donor-matched MSCs reveals that while viability immediately post-thaw can be high (>90%), thawed cells show a significantly higher proportion of apoptotic cells (Annexin V+) over time compared to cultured cells [23]. Furthermore, the expression of key surface markers like CD105, a core MSC identifier, can be significantly reduced in freshly thawed cells, as confirmed in studies comparing cells expanded in different bioreactor systems [22].

Beyond cellular integrity, functional potency is also compromised. Thawed MSCs have been shown to possess a reduced responsiveness to pro-inflammatory stimuli and an impaired production of anti-inflammatory mediators [11]. They also demonstrate a heightened propensity to trigger the instant blood-mediated inflammatory reaction (IBMIR) and activate the complement cascade upon systemic infusion, leading to more rapid clearance in vivo [11].

Underlying Mechanisms of Cryo-Damage

The deficits observed in freshly thawed MSCs are not random but stem from specific physical and biological insults incurred during the cryopreservation process.

Physical and Osmotic Stress

The freeze-thaw process subjects cells to severe physical stress. During freezing, the formation of intracellular and extracellular ice crystals can cause direct mechanical damage to the plasma membrane and subcellular structures [24]. Concurrently, the increasing concentration of solutes outside the cell creates an osmotic gradient that drives water efflux, leading to cellular dehydration and volume stress [2]. During thawing, rapid water influx can cause swelling and membrane rupture. The choice of cryoprotectant, such as dimethyl sulfoxide (DMSO), mitigates but does not eliminate this damage, and the agents themselves can be cytotoxic at high concentrations [2].

Apoptotic Signaling Pathways

The physical stresses of cryopreservation activate intrinsic apoptotic pathways. Research indicates that thawed MSCs exhibit mitochondrial dysfunction, which can lead to the release of cytochrome c and subsequent activation of caspase enzymes, the executioners of apoptosis [19]. This is quantified by a marked increase in the number of cells staining positive for Annexin V, which binds to phosphatidylserine externalized on the surface of early apoptotic cells [19] [23]. The diagram below illustrates the proposed signaling pathway from cryo-injury to apoptosis and functional deficits.

Diagram 1: Signaling Pathway from Cryo-Injury to Functional Deficit. The freeze-thaw cycle initiates physical stress, triggering mitochondrial-mediated apoptosis and leading to key functional impairments.

Metabolic and Energetic Crisis

The metabolic perturbations in freshly thawed MSCs are profound. While some assays may show an initial increase in metabolic activity, this is interpreted as a stress response as the cells attempt to repair damage and restore homeostasis [19]. This comes at a cost, diverting energy from normal proliferative and secretory functions. This is evidenced by significantly decreased cell proliferation and reduced clonogenic capacity—a key indicator of stem cell fitness [19]. The energy crisis and reparative focus likely underpin the observed downregulation of critical immunomodulatory genes immediately post-thaw.

Experimental Protocols for Assessment

Rigorous assessment of post-thaw MSC quality is essential. Below are detailed protocols for key experiments quantifying apoptosis, metabolic activity, and immunomodulatory potency.

Flow Cytometry for Apoptosis

Purpose: To quantify the percentage of viable, early apoptotic, and late apoptotic/necrotic cells in a freshly thawed MSC population.

• Reagents: Annexin V binding buffer, FITC-conjugated Annexin V, Propidium Iodide (PI) solution, phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA) [19].
• Procedure:
  • Cell Preparation: Harvest and wash MSCs in PBS containing 1% BSA. Resuspend 1.5 x 10^6 cells in 1X Annexin V binding buffer.
  • Staining: Incubate cells with Annexin V-FITC for 10 minutes in the dark. Add PI immediately before analysis.
  • Analysis: Analyze cells using a flow cytometer (e.g., BD FACSCelesta). Use unstained and single-stained controls to set compensation and gates.
  • Gating Strategy:
    • Viable cells: Annexin V-/PI-
    • Early apoptotic cells: Annexin V+/PI-
    • Late apoptotic/Necrotic cells: Annexin V+/PI+ [19].

Metabolic and Clonogenic Assays

Purpose: To evaluate the metabolic health and proliferative potential of MSCs post-thaw.

• Metabolic Activity (Resazurin Reduction Assay):
  • Reagent: Vybrant Assay kit (Non-fluorescent resazurin) [19].
  • Procedure: Seed MSCs at 1000 cells/cm² in triplicate. At days 3, 7, and 10, add resazurin to the culture media. Incubate and measure the fluorescent product (resorufin) at 563/587 nm. Increased fluorescence correlates with higher metabolic activity [19].
• Colony-Forming Unit (CFU) Assay:
  • Reagent: Crystal Violet or Giemsa stain.
  • Procedure: Seed MSCs at low density (e.g., 100-500 cells in a 10 cm dish) and culture for 10-14 days. Fix and stain colonies with >50 cells. Count the number of colonies to determine clonogenic frequency, which is significantly reduced in FT-MSCs [19] [22].

In Vitro Immunomodulatory Potency Assay

Purpose: To assess the functional capacity of MSCs to suppress immune cell proliferation.

• Reagents: Peripheral Blood Mononuclear Cells (PBMCs) from human donors, CD3/CD28 T-cell activator, Carboxyfluorescein succinimidyl ester (CFSE), MSC culture media [23].
• Procedure:
  • PBMC Activation: Isolate and label PBMCs with CFSE. Activate T-cells using CD3/CD28 antibodies.
  • Co-culture: Co-culture activated PBMCs with MSCs (e.g., at a 10:1 ratio) for 5 days. Include controls for non-activated and activated PBMCs without MSCs.
  • Analysis: Analyze PBMCs by flow cytometry to measure CFSE dilution. The suppression of T-cell proliferation is calculated by comparing the percentage of proliferated cells in co-culture versus the activated PBMC-only control. Donor-matched freshly thawed and cultured MSCs can be compared for equivalence [23].

The following workflow diagram encapsulates the key experimental steps for a comprehensive post-thaw assessment.

Diagram 2: Experimental Workflow for Post-Thaw MSC Analysis. A multi-parametric approach is essential to fully characterize post-thaw MSC quality and function.

The Researcher's Toolkit

Successful experimentation in this field relies on specific reagents and tools. The following table details essential materials and their functions.

Table 2: Essential Research Reagents and Tools for MSC Cryopreservation Studies

Category	Reagent / Tool	Specific Function / Example	Citation
Cryoprotectant	Dimethyl Sulfoxide (DMSO)	Penetrating cryoprotectant; prevents ice crystal formation. Often used at 10% in FBS.	[19] [2]
Culture Media	α-MEM with Fetal Bovine Serum (FBS)	Standard expansion medium for MSCs (e.g., α-MEM + 15% FBS).	[19]
Apoptosis Detection	Annexin V & Propidium Iodide (PI)	Flow cytometry-based discrimination of viable, early, and late apoptotic cells.	[19] [23]
Metabolic Assay	Resazurin (Vybrant Assay)	Cell health indicator; reduced by metabolically active cells to fluorescent resorufin.	[19]
Phenotyping	Antibody Panels (CD73, CD90, CD105, CD44, HLA-DR, etc.)	Confirmation of MSC identity and detection of cryopreservation-induced marker loss.	[19] [22]
Functional Assay	PBMCs & CD3/CD28 Activator	In vitro co-culture system to test MSC-mediated suppression of T-cell proliferation.	[23]
Differentiation Kits	Osteogenic & Chondrogenic Kits (e.g., StemPro)	Assessment of multipotent differentiation capacity post-thaw.	[19]

Research Implications and Clinical Translation

The evidence of cryopreservation-induced apoptosis and metabolic compromise has significant ramifications. For preclinical research, it underscores the critical importance of reporting whether freshly cultured or freshly thawed cells are used, as this variable can profoundly influence experimental outcomes and the interpretation of MSC efficacy [7] [14]. A systematic review of preclinical in vivo models found that while the majority of efficacy outcomes showed no significant difference, a portion of in vitro potency assays did favor freshly cultured MSCs, highlighting the context-dependent nature of the impairment [7].

For clinical translation, the use of freshly thawed cells is a practical necessity, especially in acute settings like sepsis or acute respiratory distress syndrome (ARDS) where treatment must be administered within hours [23]. The documented deficits may partly explain the poor engraftment and transient persistence of systemically infused MSCs observed in patients [11]. However, a key finding offers a solution: a 24-hour post-thaw acclimation period in standard culture conditions allows MSCs to recover their immunomodulatory gene expression, reduce apoptosis, and restore T-cell suppressive potency [19]. This suggests that for non-emergency applications, a brief reactivation period could enhance therapeutic efficacy. Furthermore, optimizing cryopreservation protocols, including the exploration of DMSO-free cryoprotectants and controlled-rate freezing, remains an active area of investigation to better preserve cellular function [24] [2].

Cryopreservation is a necessary but double-edged sword in the field of MSC therapeutics. It provides logistical feasibility while imposing a tangible functional cost on the cells. The data conclusively demonstrate that freshly thawed MSCs endure a state of elevated apoptosis and metabolic dysregulation, which translates into attenuated immunomodulatory potency. Researchers must account for this variable in their experimental designs, and clinicians should be aware of the potential for suboptimal performance of immediately administered cells. Future work must focus on refining cryopreservation methodologies and establishing standardized post-thaw quality control metrics that go beyond simple viability to include functional potency assays. Ultimately, a deeper understanding and mitigation of cryo-induced damage will ensure that MSC therapies consistently deliver on their full clinical promise.

The therapeutic potential of mesenchymal stromal cells (MSCs) is primarily attributed to their immunomodulatory properties and paracrine effects rather than their differentiation capacity [25] [26]. These cells interact with both innate and adaptive immune systems, suppressing excessive immune responses and promoting tissue repair through mechanisms involving both cell-cell contact and secretion of soluble factors [27] [21]. However, the clinical translation of MSC therapies faces a significant challenge: cryopreservation, a necessary step for "off-the-shelf" availability, substantially alters MSC immunobiology [2] [11].

Cryopreserved MSCs demonstrate impaired immunomodulatory function and trigger enhanced innate immune reactions post-transfusion compared to their fresh counterparts [11]. This phenomenon centers on two interconnected processes: the Instant Blood-Mediated Inflammatory Reaction (IBMIR) and complement activation. IBMIR represents a rapid innate immune attack characterized by coagulation, complement activation, and inflammatory cell infiltration, leading to significant cell loss following systemic administration [11] [26]. Understanding these cryopreservation-induced alterations is crucial for optimizing MSC-based therapies and improving their clinical efficacy.

Quantitative Evidence: Functional Consequences of Cryopreservation

Extensive research has documented the quantitative functional differences between cryopreserved and fresh MSCs. The table below summarizes key comparative findings:

Table 1: Functional Impairments of Cryopreserved vs. Fresh MSCs

Parameter	Fresh MSCs	Cryopreserved MSCs	Experimental Context	Citation
Viability after serum exposure	~50% reduction after 1h	~80% reduction after 1h	Exposure to 50% normal human serum	[11]
Immunosuppressive capacity	Normal functionality	50% reduction in inhibition	In vitro T-cell proliferation assay	[28]
Complement-mediated lysis	Lower susceptibility	Twice as efficient after 1h	Serum exposure experiments	[11]
Clinical response rate	100% (in limited cohort)	50% (in comparable group)	Treatment of steroid-resistant acute GvHD	[11]
Anti-inflammatory mediator production	Normal responsiveness to stimuli	Reduced production	Response to proinflammatory cytokines	[11]

Table 2: Altered Immunomodulatory Properties Post-Cryopreservation

Immunological Parameter	Impact of Cryopreservation	Functional Consequence	Citation
Responsiveness to inflammatory signals	Reduced reaction to IFN-γ and TNF-α	Impaired context-dependent immunomodulation	[11]
IDO pathway activity	Significantly reduced	Diminished T-cell suppression capacity	[28]
PGE2 production	Impaired	Reduced macrophage polarization to M2 phenotype	[11]
TSG-6 expression	Compromised	Attenuated anti-inflammatory signaling	[11]
Complement activation	Enhanced	Increased C3a/C5a generation, promoting inflammation	[29]

Molecular Mechanisms: IBMIR and Complement Activation Pathways

The Instant Blood-Mediated Inflammatory Reaction (IBMIR)

IBMIR represents a rapid innate immune response triggered when transplanted cells encounter blood. For cryopreserved MSCs, this reaction is significantly amplified through several interconnected pathways:

Diagram 1: IBMIR Triggering by Cryopreserved MSCs

Cryopreservation increases tissue factor (TF) expression on MSCs, initiating the coagulation cascade [11]. This triggers thrombin generation, fibrin clot formation, and platelet activation, resulting in microvascular emboli that physically trap administered cells. Concurrently, recruited innate immune cells (neutrophils, monocytes) infiltrate and directly contribute to MSC destruction [11] [26].

Complement System Activation

The complement system serves as a crucial bridge between innate immunity and MSC immunomodulation. Cryopreservation profoundly alters this interaction:

Diagram 2: Complement Activation by Cryopreserved MSCs

Cryopreserved MSCs activate all three complement pathways (classical, lectin, alternative), leading to C3 cleavage and deposition of C3b fragments on the cell surface [29]. These fragments are subsequently processed to iC3b and C3dg, which serve as opsonins recognized by complement receptors (CR3/CR4) on innate immune cells [29]. Simultaneously, anaphylatoxins (C3a, C5a) recruit and activate neutrophils and monocytes, enhancing phagocytic clearance. The final common pathway generates the membrane attack complex (MAC), directly lysing MSCs [11] [29].

Critically, cryopreserved MSCs exhibit deficient expression of complement regulatory proteins (CD46, CD55), while maintaining CD59 (protectin) which specifically inhibits MAC formation [29]. This imbalance creates preferential activation toward opsonization and phagocytosis rather than direct lysis.

Integrated Immunomodulatory Impairment

The convergence of IBMIR and complement activation creates a detrimental cycle for cryopreserved MSCs:

Diagram 3: Integrated Immunomodulatory Impairment Cycle

Cryopreservation induces cellular stress and membrane damage, increasing TF expression while decreasing complement regulators [11] [29]. This triggers simultaneous IBMIR and complement activation, recruiting and activating innate effector cells that ultimately destroy MSCs. This rapid clearance limits interaction with adaptive immune cells and reduces secretion of immunomodulatory factors, ultimately diminishing therapeutic efficacy [11] [28].

Experimental Approaches: Assessing Cryopreservation Effects

Core Methodologies for Evaluating IBMIR and Complement Activation

Researchers employ several standardized protocols to quantify cryopreservation effects on MSC-innate immunity interactions:

Table 3: Key Experimental Assays for IBMIR and Complement Analysis

Assay Type	Protocol Overview	Key Readouts	Citation
Serum Exposure Test	Incubate MSCs with 50% normal human serum (NHS) vs. EDTA-inactivated serum for 60min at 37°C	Cell viability (%), complement deposition (C3b/iC3b) by flow cytometry, anaphylatoxin release (ELISA)	[11]
Whole Blood IBMIR Model	Mix MSCs with fresh human blood; rotate at 37°C for 0-60min	Platelet consumption (flow cytometry), thrombin-antithrombin complexes (ELISA), leukocyte activation markers	[11]
In Vitro Immunosuppression	Co-culture MSCs with PHA-activated PBMCs; measure proliferation (³H-thymidine)	T-cell proliferation suppression (%), IDO activity (kynurenine production), PGE2 release (ELISA)	[28]
Complement Binding Assay	Incubate MSCs with NHS; stain for C3 fragments, C1q, MBL; analyze by flow cytometry	Mean fluorescence intensity of complement components, comparison of fresh vs. frozen	[29]
Cell Viability & Recovery	Thaw cryopreserved MSCs; assess immediate and 24h post-thaw viability	Trypan blue exclusion, NucleoCounter, post-thaw recovery percentage	[2] [28]

Detailed Protocol: Serum Exposure and Complement Activation Assay

This widely used method directly evaluates complement-mediated cytotoxicity against MSCs:

• Sample Preparation:

  • Prepare cryopreserved MSCs (thawed according to standard protocols) and fresh counterparts from the same donor/passage
  • Adjust cell concentration to 1-2×10⁶ cells/mL in PBS/EDTA with 5-10% human blood type AB plasma

• Serum Incubation:

  • Divide cell suspension into three aliquots:
    • Test: 50% normal human serum (NHS, complement-active)
    • Control 1: 50% NHS with 10mM EDTA (complement-inactivated)
    • Control 2: Serum-free medium
  • Incubate at 37°C for 60 minutes with gentle agitation

• Reaction Termination & Analysis:

  • Stop complement activity by adding 10mM EDTA
  • Assess viability via trypan blue exclusion or fluorescent viability dyes
  • Analyze complement deposition by flow cytometry (anti-C3b/iC3b antibodies)
  • Measure anaphylatoxin release (C3a, C5a) in supernatant by ELISA

• Data Interpretation:

  • Calculate specific lysis: % = [1 - (viable cells in NHS/viable cells in NHS-EDTA)] × 100
  • Compare fresh vs. cryopreserved MSC susceptibility to complement attack [11]

This assay demonstrates that cryopreserved MSCs typically show twice the efficiency in complement-mediated lysis compared to fresh cells after one hour of serum exposure [11].

Detailed Protocol: In Vitro Immunosuppression Potency Assay

Functional immunomodulatory capacity is assessed through T-cell suppression assays:

• MSC Preparation:

  • Culture fresh MSCs or thaw cryopreserved MSCs and allow 24-hour recovery
  • Irradiate MSCs (20-30 Gy) to prevent proliferation while maintaining function
  • Seed in triplicate in 96-well plates at varying ratios (typically 1:10 to 1:100 MSC:PBMC)

• Immune Cell Activation:

  • Isplicate peripheral blood mononuclear cells (PBMCs) from healthy donors
  • Activate T-cells with phytohemagglutinin (PHA, 5μg/mL) or anti-CD3/CD28 antibodies
  • Label with CFSE or add ³H-thymidine for proliferation tracking

• Co-culture & Analysis:

  • Co-culture activated PBMCs with MSCs for 3-5 days
  • Measure T-cell proliferation via ³H-thymidine incorporation or CFSE dilution
  • Analyze supernatant for immunomodulatory factors (IDO, PGE2, TSG-6)

• Data Interpretation:

  • Calculate % suppression = 1 - (proliferation with MSCs/proliferation without MSCs) × 100
  • Cryopreserved MSCs typically show approximately 50% reduced immunosuppressive capacity in this assay [28]

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Research Reagents for Studying Cryopreservation Effects on MSCs

Reagent/Category	Specific Examples	Research Application	Citation
Complement Components	Normal Human Serum (NHS), C3-depleted serum, anti-C3 antibodies	Complement activation and deposition studies	[11] [29]
Cryoprotectants	Dimethyl sulfoxide (DMSO), trehalose, sucrose	Standard vs. novel cryopreservation formulations	[2]
Viability Assays	Trypan blue, calcein-AM/propidium iodide, CCK-8	Cell survival post-thaw and after serum exposure	[11] [30]
Flow Cytometry Antibodies	CD73, CD90, CD105, CD45, CD34, HLA-DR, C3b/iC3b, CD46, CD55, CD59	Phenotype verification and complement deposition	[2] [29]
Cytokines/Chemicals	IFN-γ, TNF-α, PHA, EDTA, Compstatin	Inflammation modeling and pathway inhibition	[29] [28]
Culture Media	DMEM-low glucose, platelet lysate, fetal bovine serum	MSC expansion and maintenance	[30] [28]

The evidence conclusively demonstrates that cryopreservation significantly alters MSC immunobiology, enhancing their susceptibility to innate immune recognition via IBMIR and complement activation while impairing their immunomodulatory functionality. These changes directly impact therapeutic efficacy, as evidenced by reduced clinical response rates in conditions like GvHD [11]. Future research should focus on optimized cryopreservation protocols, including novel cryoprotectant formulations [2], pretreatment strategies to enhance resistance to innate immunity [27], and combinatorial approaches using complement inhibitors [29]. Addressing these cryopreservation-induced challenges is essential for realizing the full clinical potential of MSC-based therapies.

Protocols and Practices: Cryopreservation Methods and Their Direct Influence on MSC Potency

In the realm of regenerative medicine and cellular therapy, Mesenchymal Stem/Stromal Cells (MSCs) represent a highly promising therapeutic tool due to their immunomodulatory properties, tri-lineage differentiation potential, and role in tissue repair. A critical step in the translational pathway of these therapies from the laboratory to the clinic is cryopreservation, which enables the creation of "off-the-shelf" cell products. Among the various methods available, slow freezing with Dimethyl Sulfoxide (DMSO) remains the most widely adopted standard technique for preserving MSCs. While this method ensures long-term storage and logistical flexibility, the process of cryopreservation and the cryoprotectant itself can significantly influence post-thaw cell recovery and, crucially, the functional immunomodulatory properties of MSCs. This technical guide delves into the protocol, its impact on cell viability and recovery, and its implications for the critical research on MSC immunomodulation.

The Slow Freezing Technique with DMSO: A Detailed Protocol

The slow freezing method is designed to minimize intracellular ice crystal formation, a primary cause of cryo-injury, by promoting controlled cellular dehydration.

Mechanism and Step-by-Step Workflow

The core mechanism of slow freezing involves a gradual cooling rate that allows water to exit the cell before it freezes internally. This reduces the mechanical damage caused by intracellular ice crystals [2]. DMSO, a penetrating cryoprotectant, aids this process by lowering the freezing point of the intracellular solution and modulating the osmotic pressure differential across the cell membrane [2] [31].

The following diagram outlines the standard experimental workflow for the slow freezing of MSCs and the subsequent analysis of their recovery and function:

Key Research Reagents and Materials

The successful execution of the slow freezing protocol relies on a set of specific reagents and tools. The table below details these essential components and their functions.

Table 1: Research Reagent Solutions for MSC Slow Freezing

Reagent / Material	Function & Rationale
Dimethyl Sulfoxide (DMSO)	A penetrating cryoprotective agent (CPA). It reduces ice crystal formation by binding to water molecules and depresses the freezing point of the intracellular solution [2] [31].
Basal Freezing Medium	A base solution (e.g., culture medium like DMEM, or Plasmalyte A [32]) into which DMSO is diluted. It provides a stable ionic and nutrient environment for the cells before freezing.
Fetal Bovine Serum (FBS) or Human Platelet Lysate	Often added (e.g., at 20-90%) to the freezing medium. Proteins and other macromolecules act as non-penetrating CPAs, providing additional extracellular protection [28].
Non-Penetrating CPAs (e.g., Sucrose, Trehalose)	Used in some formulations, often in DMSO-free or DMSO-reduced protocols. They stabilize cell membranes osmotically and do not enter the cell [32] [31].
Controlled-Rate Freezer	A device that ensures a consistent, optimal cooling rate (typically -1°C/min to -3°C/min), which is critical for controlled dehydration and high cell survival [2] [32].
Programmable Freezing Container	A passive cooling device (e.g., "Mr. Frosty") filled with isopropanol. It provides an approximate cooling rate of -1°C/min when placed in a -80°C freezer, serving as an alternative to a controlled-rate freezer.

Quantitative Impact on Cell Recovery and Function

The success of the slow freezing protocol is quantified through post-thaw recovery metrics, which can vary based on the specific protocol and cell source.

Cell Viability and Recovery Data

Post-thaw cell recovery is a primary endpoint for evaluating cryopreservation efficacy. The following table summarizes typical outcomes from recent studies using the standard slow freezing technique with DMSO-containing solutions.

Table 2: Impact of Slow Freezing with DMSO on MSC Recovery

MSC Source	Cryopreservation Formula	Post-Thaw Viability	Post-Thaw Recovery	Key Findings
Bone Marrow / Adipose (Multicenter Study)	5-10% DMSO (in-house solutions)	Average ~89.8% (from 94.3% pre-freeze) [32]	Viable cell recovery was ~92.9% for a DMSO-free SGI solution, and 5.6% lower for in-house DMSO solutions [32]	DMSO solutions provide clinically acceptable viability (>70%), though some new formulations may offer comparable or better recovery.
Bone Marrow (BM-MSC)	10% DMSO	Not specified	Cell survival of ~70-80% is achievable with an optimized slow freezing procedure [2]	Slow freezing is recommended for clinical use due to ease of operation and low contamination risk.
Bone Marrow (BM-MSC)	XT-Thrive (Non-DMSO) vs. CryoStor10 (DMSO)	Post-thaw viability: ~87% (Non-DMSO) vs. ~63% (DMSO) [33]	Non-DMSO cryoprotectant maintained significantly higher viability and recovery after extended pre-freeze incubation [33]	Highlights a push towards non-DMSO alternatives to mitigate DMSO-related toxicity.
Umbilical Cord (hUC-MSC) with Hydrogel	2.5% DMSO with Microencapsulation	Sustained viability above the 70% clinical threshold [34]	Microencapsulation enabled a 4-fold reduction in required DMSO concentration while meeting viability standards.	Biomaterial-assisted cryopreservation is a promising strategy for DMSO reduction.

Impact on Immunomodulatory Properties

Beyond simple viability, the effect of cryopreservation on MSC function is paramount, especially their immunomodulatory capacity. Research indicates that the cryopreservation process can alter this critical property.

• Reduced In Vitro Immunosuppression: A key study on clinical-grade BM-MSCs reported that cryopreserved and thawed cells exhibited a 50% reduced performance in an in vitro immunosuppression assay compared to their fresh counterparts. This impairment was linked to the indoleamine 2,3-dioxygenase (IDO) pathway, a major mechanism by which MSCs suppress T-cell proliferation [28].
• Clinical Efficacy Considerations: It is crucial to interpret in vitro findings with caution. The same study notes that reduced in vitro performance "does not necessarily translate to reduced clinical efficacy" [28]. Cryopreserved MSCs have demonstrated success in treating conditions like acute Graft-versus-Host Disease (GvHD) [28].
• Underlying Mechanism: The freezing and thawing process induces significant stress on MSCs, potentially affecting the expression of key immunomodulatory genes and proteins, as well as disrupting cytoskeletal organization and signal transduction pathways necessary for their functional interaction with immune cells.

The following diagram illustrates the conceptual impact of the slow freeze-thaw process on a key immunomodulatory pathway in MSCs:

Discussion and Future Perspectives

The slow freezing technique with DMSO is a robust and standardized method that forms the backbone of current MSC-based therapeutic production. It reliably yields cells with viabilities suitable for clinical application and enables the biobanking required for "off-the-shelf" therapies. However, the evidence of its impact on MSC immunomodulatory function, along with the inherent cytotoxicity of DMSO, drives innovation in the field.

The future of MSC cryopreservation lies in refining these standard protocols. Key research directions include:

• DMSO Reduction and Elimination: As shown in Table 2, strategies like using combination non-penetrating CPAs (e.g., sucrose-glycerol-isoleucine) [32] or biomaterial-assisted cryopreservation (e.g., hydrogel microcapsules) [34] are showing significant promise in reducing or eliminating DMSO while maintaining cell viability and function.
• Standardization of Protocols: The variability in freezing media, cooling rates, and thawing procedures across studies complicates direct comparison. Multicenter collaborative studies, like the one conducted by the PACT/BEST group [32], are essential for establishing standardized, reproducible protocols.
• Functional Potency Assays: Moving beyond viability and recovery metrics, incorporating standardized potency assays that specifically measure immunomodulatory capacity (e.g., T-cell suppression assays) post-thaw is critical for ensuring the clinical efficacy of cryopreserved MSC products.

In conclusion, while slow freezing with DMSO is the current standard technique, a comprehensive understanding of its impact on cell recovery and immunomodulatory properties is essential for researchers and drug development professionals. Ongoing research is actively addressing its limitations, paving the way for safer, more potent, and more reliable cryopreserved MSC therapies.

Cryopreservation serves as a cornerstone for the advancement of mesenchymal stem cell (MSC)-based therapies, enabling the "off-the-shelf" availability required for clinical treatments of acute inflammatory conditions and immune-mediated diseases [35] [23]. The process is historically dominated by slow-freezing methods, which carry an inherent risk of ice crystal formation—a primary source of cryoinjury that can compromise cell viability and function [36]. Within the context of research on MSC immunomodulatory properties, the preservation of these functions post-thaw is paramount for therapeutic efficacy.

Vitrification has emerged as a promising alternative technique. It operates on the principle of ultra-rapid cooling, transforming aqueous cellular environments directly into a glassy, amorphous solid state without forming crystalline ice [35] [37]. This review provides an in-depth technical examination of vitrification, evaluating its potential to minimize ice crystal damage and thereby better preserve the critical immunomodulatory potency of MSCs, a key focus in contemporary biomedical research.

Technical Foundations of Vitrification

Core Mechanism: The Glass Transition

Vitrification differs fundamentally from slow freezing by avoiding ice crystallization entirely. The process employs high concentrations of cryoprotective agents (CPAs) and extremely high cooling rates to achieve a dramatic increase in viscosity until the solution solidifies into a non-crystalline, glassy state [35] [36]. The critical warming rate (CWR) is a key physical parameter, representing the minimum rate required to prevent ice crystallization during the thawing process, a phenomenon known as devitrification [38]. The relationship between cooling velocity, CPA concentration, and the final physical state of the system is critical for successful protocol design.

Comparative Analysis: Vitrification vs. Slow Freezing

The table below summarizes the key technical differences between the two primary cryopreservation methods.

Table 1: Technical Comparison of Slow Freezing and Vitrification

Parameter	Slow Freezing	Vitrification
Fundamental Principle	Controlled, slow dehydration of cells to minimize intracellular ice [35]	Ultra-rapid cooling to achieve a glassy, ice-free state [35] [39]
Cooling Rate	Slow (e.g., -0.3°C/min to -3°C/min) [35] [39]	Very Rapid (completed in minutes) [39]
CPA Concentration	Low (e.g., 10% DMSO) [35] [40]	High (often requiring cocktail formulations) [35] [41]
Primary Ice-Related Risk	Extracellular ice formation and solute damage during freezing [36]	Devitrification (ice formation during warming) [38] [36]
Typical Cell Survival Rate	~70-80% [35]	Often >90% [41] [39]
Operational Complexity	Low; suitable for large-scale application [35]	High; requires precision and can be difficult to scale [35] [38]

Impact on MSC Immunomodulatory Properties

The ultimate value of a cryopreservation method for MSC-based therapies lies in its ability to preserve cellular function, particularly the complex immunomodulatory properties that underpin their therapeutic mechanism.

Functional Potency of Post-Thaw MSCs

A critical study directly compared the immunomodulatory potency of donor-matched fresh (cultured) and cryopreserved-then-thawed MSCs in vitro and in a murine model of polymicrobial sepsis [23]. The findings are summarized below:

Table 2: Comparative In Vitro and In Vivo Potency of Cultured vs. Thawed MSCs

Assay Type	Function Assessed	Key Finding	Significance
In Vitro: Adaptive Immunity	Suppression of activated T-cell proliferation [23]	No significant difference between cultured and thawed MSCs	Thawed MSCs retain key immunosuppressive capacity.
In Vitro: Innate Immunity	Enhancement of monocyte phagocytosis [23]	Thawed MSCs performed comparably to cultured MSCs in restoring phagocytic function	Critical for host defense in sepsis; function is preserved post-thaw.
In Vitro: Barrier Function	Restoration of endothelial monolayer permeability [23]	Both cultured and thawed MSCs significantly reduced permeability post-injury	Suggests thawed MSCs maintain vascular protective effects.
In Vivo: Sepsis Model	Plasma levels of lactate and inflammatory cytokines; phagocytosis by peritoneal cells [23]	Both MSC products significantly improved outcomes, with no significant difference between groups	Provides direct evidence that cryopreserved MSCs are therapeutically effective for acute inflammation.

This research demonstrates that a cryopreserved-then-thawed MSC product can serve as a functionally comparable substitute for freshly cultured cells, a crucial finding for the logistics of clinical treatment for acute conditions [23].

Underlying Cryoinjury Mechanisms from Ice Crystals

The formation of ice crystals—both intracellular and extracellular—during freezing and thawing is a primary source of cell damage [36]. In slow freezing, extracellular ice formation leads to cellular dehydration and osmotic stress, while intracellular ice crystals can cause direct mechanical damage to organelles and the plasma membrane [36]. Although vitrification aims to be ice-free, devitrification during warming can lead to recrystallization, where small ice crystals merge into larger, more destructive ones [36]. These physical injuries can compromise membrane integrity, disrupt cytoskeletal organization, and induce apoptotic pathways, potentially impairing the cells' ability to secrete anti-inflammatory factors or interact with immune cells [23] [36]. By virtually eliminating ice formation, vitrification offers a pathway to mitigate these injuries, potentially leading to better-preserved cellular function.

Advanced Vitrification Methodologies and Protocols

A Representative Protocol: Vitrification of 3D-MSCs in GelMA Hydrogel

Recent innovations aim to overcome the limitations of traditional vitrification. One advanced protocol encapsulates 3D-human MSCs within a GelMA hydrogel microsphere, significantly improving outcomes [41].

Experimental Workflow Overview:

Detailed Methodology:

• Cell Encapsulation: A suspension of human umbilical cord MSCs (hUC-MSCs) is mixed with methacrylated gelatin (GelMA) precursor solution. This mixture is loaded into a microfluidic device to generate uniform 3D-MSCs hydrogel microspheres (3D-MSCsHM) [41].
• CPA Loading and Vitrification: The 3D-MSCsHM are equilibrated in a CPA solution. The GelMA hydrogel provides a protective matrix, allowing for a 25% reduction in the required CPA concentration, thereby reducing CPA toxicity [41]. The samples are then plunged directly into liquid nitrogen for ultra-rapid cooling, achieving vitrification. The entire process from loading to vitrification is completed within 30 minutes [41].
• Thawing and Recovery: For rewarming, samples are rapidly thawed in a 37°C water bath until the ice is dissolved. CPAs are removed by centrifugation, and the GelMA hydrogel is degraded to recover the viable, functional MSCs for analysis and use [41].

Key Outcomes: This innovative approach resulted in 96% post-thaw viability and preserved high mitochondrial integrity and metabolic function. Proteomic analysis indicated that the improved viability was linked to enhanced mitochondrial function and increased antioxidant proteins [41].

The Scientist's Toolkit: Essential Reagents for Vitrification

Table 3: Key Research Reagents and Materials for MSC Vitrification

Reagent/Material	Function/Description	Example/Note
Permeating CPAs	Small molecules that penetrate cells, depressing the freezing point and facilitating vitrification [35] [37].	Dimethyl sulfoxide (DMSO), Ethylene Glycol (EG), Propylene Glycol (PG) [35] [37].
Non-Permeating CPAs	Large molecules that remain outside cells, providing extracellular protection and osmotic balance [37].	Sucrose, Trehalose, Hydroxyethyl Starch, Polymers (e.g., PVP) [35] [37].
Hydrogel Scaffolds	A 3D matrix that encapsulates cells, providing physical cryoprotection and enabling lower CPA use [41].	GelMA (Methacrylated Gelatin) used in microfluidic encapsulation [41].
Serum-Free Freezing Media	Chemically defined, xeno-free media for clinical-grade cryopreservation [37] [40].	CELLBANKER 3, CRYOSTOR [37] [40].
Ice-Blocking Additives	Molecules that actively inhibit ice nucleation and growth [36].	Antifreeze Proteins (AFPs), synthetic polymers, and nanomaterials [36].

Current Challenges and Future Perspectives

Technical Hurdles and Innovative Solutions

Despite its promise, the translation of vitrification, particularly for larger and more complex biological systems, faces significant challenges.

• CPA Toxicity: The high concentrations of CPAs required for vitrification introduce cytotoxicity risks [35] [41]. Future solutions include developing novel, less-toxic CPA cocktails and using protective biomaterials like hydrogels to reduce the required CPA load [41] [36].
• Scalability and Uniform Heat Transfer: Achieving the critical warming rate uniformly throughout a large sample, such as an organ, is physically challenging [38]. Emerging technologies like nanowarming are addressing this. This technique involves perfusing magnetic iron-oxide nanoparticles (IONPs) into the tissue and using an alternating magnetic field to generate rapid and uniform heating from within, successfully demonstrating rewarming of vitrified CPA volumes up to 2 liters [38].
• Devitrification: Ice formation during the thawing process remains a major risk [36]. Research is focused on optimizing warming rates and developing ice-recrystallization inhibitors (IRIs), such as specific synthetic polymers and antifreeze proteins, to suppress this phenomenon [36].

Advanced Monitoring Techniques

Understanding the physical events during vitrification is key to protocol improvement. Advanced real-time monitoring techniques like multi-view cryomacroscopy (MVC) are being developed. MVC uses multiple cameras to observe physical phenomena in large vitrified samples (e.g., 60 ml), including fracturing, crystallization at interfaces, and air bubble formation, which were difficult to capture with previous technologies [42].

Logical Framework for Protocol Development

The following diagram outlines the strategic decision-making process for developing and optimizing a vitrification protocol, integrating solutions to the major challenges.

Vitrification represents a technologically sophisticated alternative to slow freezing, with a fundamental potential to reduce ice crystal damage in cryopreserved MSCs. While slow freezing remains the workhorse for many clinical applications due to its operational simplicity, evidence suggests that optimized vitrification can achieve superior post-thaw viability and better preserve cellular structures critical for function [41] [39]. For the specific field of MSC immunomodulatory research, the paramount finding is that cryopreserved-then-thawed MSCs—whether by slow freezing or vitrification—can retain potent immunomodulatory functions comparable to their fresh counterparts in treating acute inflammatory conditions [23]. The ongoing development of advanced vitrification strategies, including biomaterial-enhanced cryoprotection and novel rewarming technologies, promises to further enhance the feasibility and efficacy of this approach. This progress is crucial for ensuring the reliable, "off-the-shelf" delivery of functionally potent MSCs, thereby accelerating their translation from research tools to mainstream clinical therapeutics.

In the rapidly advancing field of regenerative medicine, mesenchymal stem/stromal cells (MSCs) have emerged as a cornerstone for cell-based therapies due to their multipotent differentiation capacity, immunomodulatory properties, and trophic factor secretion [15]. These cells demonstrate exceptional promise for treating conditions ranging from graft-versus-host disease (GvHD) and autoimmune disorders to myocardial infarction and stroke [15]. The transition of MSC therapies from research laboratories to clinical applications necessitates effective long-term preservation strategies, making cryopreservation an indispensable component of the therapeutic pipeline. Without cryopreservation, MSCs require continuous passaging, which leads to DNA methylation alterations, telomere shortening, and potential genomic instability [2].

At the heart of every cryopreservation protocol lie cryoprotective agents (CPAs), compounds specifically designed to protect cellular integrity during the freezing and thawing processes. These agents function as a double-edged sword: while they are essential for mitigating cryoinjury, they simultaneously introduce their own risks through concentration-dependent cytotoxicity and functional impairment of preserved cells [43] [2] [44]. This paradoxical nature of CPAs creates a significant challenge for researchers and clinicians aiming to develop off-the-shelf MSC products that retain their therapeutic potency after thawing. The global cell cryoprotectant market, valued at over 350 million USD, reflects the critical importance and widespread application of these compounds across biopharmaceutical, scientific research, and medical beauty sectors [45].

Understanding the delicate balance between CPA efficacy and toxicity is particularly crucial when considering the immunomodulatory functions of MSCs, which are highly dependent on cell viability, metabolic activity, and responsiveness to inflammatory signals. This technical guide explores the mechanisms through which CPAs protect MSCs during cryopreservation, examines their cytotoxic effects, and details advanced strategies to mitigate these drawbacks while preserving the critical immunomodulatory properties that make MSC therapies so promising.

Fundamental Mechanisms of MSC Immunomodulation

The therapeutic potential of MSCs largely stems from their sophisticated immunomodulatory capabilities, which involve interactions with both innate and adaptive immune systems through direct cell-to-cell contact and paracrine signaling [15] [46]. Understanding these mechanisms is essential for evaluating how cryopreservation and CPA exposure might compromise MSC function.

Cell-to-Cell Contact-Dependent Immunomodulation

MSCs directly modulate immune responses through surface molecule interactions with various immune cells. They inhibit naive and memory T-cell responses by upregulating intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which are critical for T-cell activation and leukocyte recruitment to inflammation sites [15]. Additionally, MSCs express programmed death-ligand 1 (PD-L1) and PD-L2, which inhibit T-cell proliferation by arresting the cell cycle [15]. The interaction between MSCs and T-cells also induces CD4+CD25+FOXP3+ regulatory T-cells (Tregs) through activation of the Notch1/FOXP3 pathway, enhancing immunosuppressive responses [15]. Furthermore, MSCs affect B-cells through contact-dependent mechanisms that increase survival of quiescent B-cells and inhibit Caspase 3-mediated apoptosis by upregulating vascular endothelial growth factor (VEGF) [15].

Paracrine Immunomodulation

The MSC secretome represents a powerful arsenal of immunomodulatory factors released via extracellular vesicles (exosomes, microvesicles) and soluble mediators [15]. Through paracrine signaling, MSCs inhibit T helper 17 cell (Th17) differentiation by inducing production of IL-10 and PGE2 while inhibiting IL-17, IL-22, and IFN-γ [15]. A particularly crucial mechanism involves the indoleamine-pyrrole 2,3-dioxygenase (IDO) pathway, which depletes tryptophan and generates kynurenines that suppress T-cell proliferation [15] [46]. MSCs also secrete prostaglandin E2 (PGE2), which switches activated M1-like inflammatory macrophages to an M2-like phenotype [15], and transforming growth factor-β1 (TGF-β1), which further contributes to T-cell suppression [46]. The specific factors employed vary based on tissue source, microenvironmental cues, and inflammatory signals, with different MSC populations exhibiting distinct secretory profiles.

Table 1: Key Immunomodulatory Mechanisms of MSCs

Mechanism Type	Immune Cells Affected	Key Molecules/Pathways	Biological Effect
Cell Contact-Dependent	T-cells	ICAM-1, VCAM-1, PD-L1/PD-L2	Inhibition of T-cell proliferation and cell cycle arrest
	T-cells	Notch1/FOXP3 pathway	Induction of regulatory T-cells (Tregs)
	B-cells	VEGF, p38 MAPK pathway	Inhibition of B-cell apoptosis and proliferation
	Monocytes/Macrophages	Phagocytosis, surface receptors	Phenotypic switching to anti-inflammatory phenotype
Paracrine Signaling	T-cells, NK cells	IDO/Tryptophan metabolism	T-cell suppression via tryptophan depletion
	Th17 cells	IL-10, PGE2, IL-17 inhibition	Suppression of Th17 differentiation
	Macrophages	PGE2, TGF-β1	Polarization to M2 anti-inflammatory phenotype
	Multiple immune cells	Extracellular vesicles (exosomes)	Transfer of immunomodulatory miRNAs and proteins

MSCs are isolated from multiple tissue sources, each with distinct immunomodulatory properties. Bone marrow-derived MSCs (BM-MSCs) represent the most extensively studied population, while adipose tissue-derived MSCs (A-MSCs) demonstrate more potent immunomodulatory effects in some contexts [15]. Umbilical cord-derived MSCs (UC-MSCs) offer minimal risk of initiating allogeneic immune responses and are easily collected, making them attractive therapeutic candidates [15]. This source-dependent variability in immunomodulatory potency highlights the importance of considering tissue origin when designing cryopreservation protocols, as different MSC populations may exhibit distinct susceptibilities to cryoinjury and CPA toxicity.

Cryopreservation Methods and CPA Mechanisms of Action

Fundamental Principles of Cryopreservation

Cryopreservation techniques aim to maintain long-term cellular viability and functionality by storing biological materials at ultra-low temperatures, typically in liquid nitrogen at -196°C, where all biochemical processes are effectively suspended [2]. The two primary approaches are slow freezing and vitrification, each with distinct physical mechanisms and CPA requirements.

Slow freezing involves controlled-rate cooling that allows gradual cellular dehydration, minimizing intracellular ice crystal formation [2]. During this process, cells are typically cooled at approximately -3°C/min, enabling water to exit cells before freezing occurs [2]. This method generally employs lower CPA concentrations but exposes cells to prolonged hyperosmotic stress and extracellular ice formation.

Vitrification utilizes high CPA concentrations and rapid cooling rates to achieve a glass-like, amorphous solid state without ice crystal formation [2]. This approach avoids mechanical damage from ice but exposes cells to higher CPA toxicity and osmotic stress during addition and removal phases. Vitrification can be achieved through equilibrium methods, where cells reach osmotic balance with CPAs before freezing, or non-equilibrium methods, which prioritize extreme cooling rates [2].

Classification and Mechanisms of CPAs

CPAs are categorized based on their membrane permeability and mechanisms of action:

Penetrating CPAs are small, non-ionic molecules that cross cell membranes to exert protective effects intracellularly. These include:

• Sulfoxides (e.g., dimethyl sulfoxide, DMSO)
• Diols (e.g., ethylene glycol, propylene glycol, glycerol) [43]

These compounds function by depressing the freezing point of intracellular solutions, reducing ice crystal formation, and stabilizing membrane structures through direct interactions with phospholipid head groups [43] [44].

Non-penetrating CPAs are larger molecules or polymers that remain extracellular, including:

• Saccharides (e.g., sucrose, trehalose)
• Synthetic polymers (e.g., polyvinyl alcohols, polyampholytes)
• Proteins (e.g., antifreeze proteins) [43]

These agents create hypertonic extracellular environments that promote controlled cellular dehydration before freezing, and they may also form vitreous matrices that inhibit ice crystal growth and recrystallization [43] [44].

Table 2: Classification of Common Cryoprotective Agents

CPA Category	Specific Examples	Molecular Mechanisms	Relative Toxicity
Penetrating Agents	Dimethyl sulfoxide (DMSO)	Hydrogen bonding with water, membrane stabilization, ice crystal inhibition	High at elevated concentrations
	Glycerol	Colligative freezing point depression, water substitution	Moderate
	Ethylene Glycol	Rapid membrane penetration, ice crystal inhibition	Moderate to High
	Propylene Glycol	Membrane stabilization, freezing point depression	High
Non-Penetrating Agents	Sucrose	Extracellular osmolyte, controlled dehydration, glass formation	Low
	Trehalose	Water replacement hypothesis, glass formation, membrane stabilization	Very Low
	Antifreeze Proteins	Ice crystal shape modification, recrystallization inhibition	Low
	Polyampholytes	Ice recrystallization inhibition, membrane interactions	Low to Moderate

Physicochemical Basis of CPA Protection

The fundamental protection mechanisms of CPAs operate at the molecular level through several interconnected pathways:

Ice Crystal Inhibition: CPAs interfere with hydrogen bonding between water molecules, reducing ice nucleation temperatures and inhibiting crystal growth [44]. This action minimizes mechanical damage to cellular membranes and organelles.

Glass Transition Enhancement: At sufficient concentrations, CPAs facilitate the transition of cellular water to an amorphous glassy state during cooling, bypassing crystalline ice formation entirely [44]. This vitrification process preserves native molecular arrangements.

Membrane Stabilization: Penetrating CPAs interact with phospholipid bilayers, preventing phase transitions and maintaining membrane integrity during freezing-induced dehydration [43]. Some CPAs may also substitute for water molecules in membrane structures, preserving their fluidity and organization.

Osmotic Regulation: By controlling osmotic gradients across membranes during freezing and thawing, CPAs minimize excessive cell volume fluctuations that can lead to membrane rupture [2].

Cryopreservation-Induced Injuries and CPA Cytotoxicity

Despite their protective benefits, CPAs introduce significant challenges through both direct cytotoxic effects and cryopreservation-induced injuries that collectively impact MSC viability and function.

Fundamental Cryoinjury Mechanisms

The freezing and thawing processes inflict multiple forms of cellular damage, even in the presence of CPAs:

Mechanical Ice Damage: Intracellular and extracellular ice crystals physically disrupt membranes, organelles, and cytoskeletal structures [44]. During slow freezing, extracellular ice formation creates osmotic imbalances that cause cellular dehydration and shrinkage, while rapid cooling promotes lethal intracellular ice formation [44].

Oxidative Stress: Cryopreservation generates excessive reactive oxygen species (ROS) including superoxide radicals, hydrogen peroxide, and hydroxyl radicals [44]. These species damage cellular components through lipid peroxidation, protein oxidation, and DNA fragmentation [44]. The impairment of endogenous antioxidant systems during freezing exacerbates this oxidative damage.

Solution Effects: As ice forms, solutes become concentrated in the remaining liquid phase, leading to protein denaturation, membrane disruption, and pH shifts [44]. These solution effects are particularly pronounced during slow freezing protocols.

Ice Recrystallization: During thawing, ice crystals undergo Ostwald ripening where smaller crystals melt and refreeze into larger, more damaging structures [44]. This recrystallization causes significant mechanical injury to already compromised cellular structures.

Specific CPA Toxicity Mechanisms

CPA cytotoxicity manifests through multiple concentration-dependent mechanisms:

Membrane Disruption: High concentrations of penetrating CPAs like DMSO extract membrane components, alter lipid-protein interactions, and increase membrane permeability, potentially leading to lysis [43] [44]. DMSO specifically induces dehydration near lipid membrane surfaces, fundamentally altering their physical properties [44].

Protein Denaturation: CPAs can disrupt hydration shells around proteins, leading to conformational changes, aggregation, and loss of function [43]. The degree of denaturation correlates with CPA concentration and exposure time.

Metabolic Interference: Some CPAs inhibit key enzymatic processes and mitochondrial function [43]. DMSO has been shown to dramatically alter human cellular processes and the epigenetic landscape in vitro [44].

Osmotic Stress: Rapid addition or removal of CPAs creates severe osmotic gradients that cause damaging cell volume fluctuations [2]. Inadequate CPA removal before transfusion can trigger similar osmotic injury in clinical settings.

Impact of Cryopreservation on MSC Immunomodulatory Function

Cryopreservation negatively affects critical immunomodulatory properties of MSCs through multiple pathways:

Altered Responsiveness to Inflammatory Cues: Cryopreserved MSCs demonstrate impaired upregulation of immunosuppressive enzymes like IDO in response to IFN-γ licensing [47]. This reduced responsiveness diminishes their ability to suppress T-cell proliferation in inflammatory environments.

Increased Immunogenicity: Post-thaw MSCs show enhanced susceptibility to immune recognition and lysis by cytotoxic T lymphocytes [47]. This increased immunogenicity may shorten their persistence in allogeneic applications.

Cell Cycle-Specific Vulnerability: Recent research reveals that MSCs in S-phase are exquisitely sensitive to cryoinjury, demonstrating heightened delayed apoptosis and reduced immunomodulatory function post-thaw [48]. Cryopreservation induces double-stranded DNA breaks in replicating cells, preferentially eliminating the most metabolically active MSCs.

Variable Impact on Therapeutic Efficacy: The functional consequences of cryopreservation vary across disease models. While cryopreserved MSCs maintain efficacy in models of colitis, allergic airway inflammation, and retinal ischemia/reperfusion injury, they fail to induce chondrogenic responses and may be less effective for GvHD treatment compared to fresh MSCs [47].

Table 3: Documented Effects of Cryopreservation on MSC Immunomodulatory Properties

Immunomodulatory Parameter	Impact of Cryopreservation	Functional Consequences
IDO Induction Capacity	Significantly reduced, especially in early post-thaw period	Diminished T-cell suppression via tryptophan depletion
Response to IFN-γ Licensing	Delayed and attenuated IDO upregulation	Reduced immunomodulatory potency in inflammatory environments
Susceptibility to Immune Lysis	Markedly increased, particularly in allogeneic settings	Shortened persistence after transplantation
T-cell Suppression Capacity	Variably affected depending on assay conditions	Context-dependent therapeutic efficacy
Surface Marker Expression	Altered expression of immunoregulatory molecules	Modified interactions with immune cells
Paracrine Factor Secretion	Transient reduction in anti-inflammatory mediators	Diminished trophic support and immunomodulation

Advanced CPA Formulations and Cytotoxicity Mitigation Strategies

Novel CPA Development Approaches

Research initiatives are pursuing multiple strategies to develop CPAs with improved efficacy and reduced toxicity:

Computer-Aided Molecular Design: Advanced computational approaches are identifying novel CPA candidates with optimized molecular properties. Recent screens have highlighted 1-methylimidazole and pyridazine as promising heterocyclic amine candidates with favorable cryoprotective properties and potentially reduced cytotoxicity [49].

Natural Cryoprotectants: Compounds from extremophilic organisms offer biocompatible alternatives to synthetic CPAs. Antifreeze proteins from polar fish, sugars like trehalose from resurrection plants, and natural deep eutectic systems provide effective cryoprotection with minimal toxicity [43].

Polymer-Based Formulations: Synthetic and semisynthetic polymers including polyampholytes and carboxylated poly-L-lysine derivatives inhibit ice recrystallization through membrane interactions and matrix formation while demonstrating excellent biocompatibility [43] [44].

Combination Strategies: Strategic blending of penetrating and non-penetrating CPAs allows concentration reduction of toxic components while maintaining protection. For example, combining reduced DMSO concentrations with sucrose or trehalose mitigates toxicity while preserving cryoprotective efficacy [43] [2].

Biochemical and Cell-Based Protection Strategies

Antioxidant Supplementation: Adding compounds like melatonin to cryopreservation media counteracts ROS-mediated damage through direct free radical scavenging and enhancement of endogenous antioxidant systems [43]. This approach significantly improves post-thaw viability and function across multiple cell types.

Cell Cycle Synchronization: Pre-freezing synchronization of MSCs in G0/G1 phase through serum starvation or pharmacological methods dramatically reduces cryoinjury susceptibility [48]. This strategy prevents apoptosis induced by double-stranded breaks in replicating DNA, preserving viability, clonal growth, and T-cell suppression function at pre-freezing levels.

IFN-γ Pre-licensing: Priming MSCs with interferon-gamma before cryopreservation enhances post-thaw immunomodulatory capacity by pre-inducing IDO expression [47]. However, this approach may increase MHC expression and accelerate immune recognition in allogeneic settings, potentially shortening in vivo persistence [47].

Hydrogel Encapsulation: Three-dimensional encapsulation in natural or synthetic hydrogels provides physical protection during freezing and thawing, reduces ice crystal penetration, and maintains cell-cell contacts that support viability and function [44].

Technical Protocol Innovations

Improved Freezing and Thawing Methodologies: Optimized cooling rates, precise temperature control, and directional cooling techniques minimize ice crystal formation and growth [2]. Similarly, controlled-rate thawing protocols reduce osmotic stress and recrystallization injury.

CPA Loading and Removal Optimization: Sequential addition and removal of CPAs using controlled multi-step protocols allows cellular adaptation to osmotic changes, minimizing volume excursion-related damage [2]. Automated systems with real-time monitoring further enhance process consistency.

Novel Preservation Platforms: Emerging technologies like cryomesh systems, microfluidic CPA exchange, and isochoric freezing methods offer improved heat transfer, more precise osmotic control, and reduced mechanical stress [44].

Diagram 1: CPA Selection and Optimization Workflow. This diagram outlines the strategic decision process for selecting and optimizing CPA formulations for MSC cryopreservation, incorporating pre-treatment optimization steps to enhance post-thaw outcomes.

Experimental Approaches for Evaluating CPA Efficacy and Toxicity

Standardized Assessment Protocols

Comprehensive evaluation of CPA performance requires multi-parametric assessment across multiple endpoints:

Viability and Recovery Metrics: Standard assays include:

• Membrane integrity tests using dye exclusion (trypan blue) or fluorescent viability markers
• Metabolic activity assays (MTT, Alamar Blue, ATP quantification)
• Apoptosis detection via Annexin V/propidium iodide staining
• Clonogenic assays (CFU-F) to assess functional stemness preservation [2] [48]

Immunomodulatory Function Assessments: Critical functional assays include:

• T-cell suppression assays measuring inhibition of PBMC proliferation in response to mitogens or allogeneic stimulation [47] [48]
• IDO activity quantification via kynurenine production or mRNA expression analysis [47]
• Cytokine secretion profiling using multiplex ELISA or Luminex arrays [15] [46]
• Surface marker characterization by flow cytometry to confirm immunophenotype maintenance [2]

Molecular and Structural Analyses: Advanced characterization techniques include:

• Transcriptomic profiling to identify cryopreservation-induced gene expression changes
• DNA damage assessment through γH2AX staining or comet assays [48]
• Mitochondrial function evaluation using JC-1 or TMRM staining
• Cytoskeletal and organellar integrity via immunofluorescence and electron microscopy

Diagram 2: Comprehensive CPA Assessment Protocol. This workflow outlines the multi-parametric approach required to thoroughly evaluate CPA efficacy and toxicity, incorporating viability, functional, immunomodulatory, and molecular analyses.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4: Essential Reagents for CPA Research and MSC Cryopreservation Studies

Reagent Category	Specific Examples	Primary Function	Considerations
Base Cryoprotectants	DMSO, Glycerol, Ethylene Glycol	Fundamental cryoprotection through ice crystal inhibition	Concentration-dependent toxicity; requires optimization
CPA Enhancers	Sucrose, Trehalose, Raffinose	Osmotic regulation, glass formation, membrane stabilization	Reduce required concentrations of toxic CPAs
Biocompatible Polymers	Polyvinyl alcohol, Carboxylated ε-poly-L-lysine	Ice recrystallization inhibition, membrane protection	Variable molecular weights affect efficacy
Antioxidant Systems	Melatonin, Ascorbic acid, N-acetylcysteine	Scavenging of ROS, reduction of oxidative stress	Timing and concentration critical for efficacy
Cell Signaling Modulators	IFN-γ, TNF-α, IL-1β	Pre-licensing to enhance immunomodulatory function	May alter immunogenicity and in vivo persistence
Viability Assessment	Trypan blue, Propidium iodide, Calcein-AM	Membrane integrity evaluation	Multiple assays recommended for accuracy
Functional Assays CFU-F reagents, Differentiation media	Stemness and multipotency evaluation	Requires extended culture periods
Immunomodulatory Assays	PBMCs from multiple donors, Mitogens (PHA)	T-cell suppression capacity measurement	Donor variability requires appropriate controls

The development of optimized CPA formulations represents a critical frontier in advancing MSC-based therapies from research tools to reliable clinical products. The dual nature of CPAs as both protectors and stressors necessitates sophisticated formulation strategies that balance cryoprotective efficacy against cellular toxicity and functional impairment. Current research directions focus on novel CPA discovery through computational approaches, combinatorial formulations that leverage synergistic effects, and cell preconditioning strategies that enhance inherent cryotolerance.

The emerging recognition that cryopreservation differentially affects specific MSC subpopulations – particularly those in active cell cycle phases – suggests that synchronization approaches may dramatically improve post-thaw function [48]. Similarly, the understanding that cryopreservation impacts specific immunomodulatory pathways unevenly indicates that CPA optimization must be tailored to the intended therapeutic application, as MSC functional requirements differ significantly across disease contexts [47].

Future advancements will likely integrate biomaterial science, molecular engineering, and advanced analytics to create next-generation preservation platforms. The combination of ice-binding polymers, targeted antioxidant systems, and physiologically relevant three-dimensional formats holds particular promise for achieving the high viability, retention of immunomodulatory capacity, and clinical scalability required for widespread MSC therapeutic application. As these technologies mature, they will gradually resolve the fundamental challenge represented by the "double-edged sword" of CPAs, enabling more reliable and potent MSC-based treatments for a broad spectrum of inflammatory, autoimmune, and degenerative conditions.

Cryopreservation is indispensable for enabling the off-the-shelf availability of Mesenchymal Stem Cells (MSCs) for therapeutic applications, including their use in modulating immune responses in conditions such as graft-versus-host disease, sepsis, and allergic rhinitis [2] [50] [51]. The process, however, subjects cells to multiple stresses. The formation of intracellular ice crystals can cause direct physical damage to membrane structures and organelles, while osmotic shifts during freezing and thawing can compromise cell integrity [2] [52]. Perhaps most critically for their therapeutic function, cryopreservation can induce molecular changes that potentially alter the immunomodulatory capacity of MSCs [2]. These changes can affect the secretion of bioactive molecules like cytokines, growth factors, and extracellular vesicles, which are crucial for mediating paracrine effects such as promoting tissue repair, angiogenesis, and exerting anti-inflammatory actions [21] [53].

The critical importance of post-thaw handling, specifically the steps of washing and Cryoprotectant Agent (CPA) removal, stems from the need to mitigate two primary risks: the inherent toxicity of CPAs like dimethyl sulfoxide (DMSO) to cells, and the osmotic stress imposed on already compromised cells during CPA dilution [2] [52]. Improper handling at this stage can lead to significant cell loss, reduced viability, and impaired function, ultimately jeopardizing the consistency and efficacy of MSC-based therapies in research and clinical settings [54] [55]. This guide details the protocols and best practices to preserve these vital properties.

Key Principles of CPA Removal

The primary CPA used for MSC cryopreservation is DMSO, typically at concentrations of 5-10% [2] [54] [56]. While essential for preventing ice crystal formation during freezing, DMSO becomes toxic to cells upon thawing, especially at room temperature [2] [52]. Furthermore, the transfusion of stem cells containing DMSO can trigger allergic responses in patients [2]. Therefore, its removal is a clinical necessity.

The process of removal, however, is fraught with risk. The sudden reduction in external CPA concentration creates a large osmotic gradient, causing water to rush into the cells rapidly. This can lead to excessive cell swelling, membrane stress, and potentially cell lysis—a phenomenon known as osmotic shock or volume expansion damage [2] [52]. Consequently, the core principles of effective CPA removal are:

• Minimizing CPA Toxicity: Rapid processing post-thaw to limit cellular exposure to DMSO.
• Managing Osmotic Stress: Employing controlled dilution methods to reduce the steepness of the osmotic gradient across the cell membrane.

Methodologies for Washing and CPA Removal

There is significant heterogeneity in post-thaw processing practices across transplant and research centers [54] [55] [56]. The choice of method often depends on the final cell application (e.g., research vs. clinical infusion), scale, and available equipment.

Centrifugation-Based Washing

This is the most common method for processing MSCs in research and for preparing clinical doses where the product is administered in a small volume.

• Procedure:

  • Thaw Rapidly: Thaw the cryovial in a 37°C water bath or using a validated dry heating device until only a small ice crystal remains [2] [57].
  • Immediate Dilution: Aseptically transfer the cell suspension to a pre-warmed centrifuge tube containing a large volume (e.g., 10-fold excess) of warm culture medium or a buffered solution like normal saline or HBSS. This initial dilution is critical to reduce the external DMSO concentration swiftly [52].
  • Gentle Centrifugation: Pellet the cells using a gentle centrifugation force (e.g., 300-400 x g for 5-10 minutes) to avoid additional mechanical stress [57].
  • Supernatant Removal: Carefully decant or aspirate the supernatant, which now contains the majority of the DMSO.
  • Resuspension: Resuspend the cell pellet in an appropriate final solution, such as infusion medium or culture medium, for subsequent counting and use.

• Considerations:

  • Advantages: Simple, requires no specialized equipment beyond a centrifuge.
  • Disadvantages: Inefficient, can lead to significant cell loss (often 20-30%) as cells are trapped in the pellet or damaged during manipulation [2]. The centrifugation step itself can impose mechanical stress on fragile, post-thaw cells.

Direct Infusion Without Washing

For hematopoietic stem cell grafts, many clinical centers directly infuse thawed products without washing, particularly for autologous transplants [55] [56]. In this practice, the DMSO and cell debris are co-infused with the stem cells.

• Procedure:

  • Thaw the cryobag at the patient's bedside.
  • Connect the bag directly to the patient's IV line for infusion without any post-thaw processing [56].

• Considerations:

  • Advantages: Eliminates the risk of cell loss and manipulation-related damage during washing; faster and simpler.
  • Disadvantages: Exposes the patient to the full dose of DMSO and any products of cellular breakdown, which can lead to adverse reactions like nausea, hypertension, or allergic responses [2] [55]. This method is generally not recommended for MSCs due to the higher sensitivity of their immunomodulatory functions to DMSO toxicity.

Automated Cell Processing

In clinical settings requiring high standards of sterility and reproducibility, automated systems like the COBE 2991 cell processor are used.

• Procedure: These systems automate the steps of dilution, washing, and concentration, providing a closed and controlled environment for processing [54] [56].
• Considerations:
  • Advantages: Standardizes the washing process, improves sterility, reduces manual labor, and can enhance cell recovery by providing more consistent and gentle processing.
  • Disadvantages: High cost of equipment and consumables, requiring specialized training to operate.

The following workflow diagram summarizes the decision-making process and the core steps involved in the centrifugation-based washing method.

The Scientist's Toolkit: Essential Reagents and Materials

Successful post-thaw handling relies on specific reagents and equipment to ensure cell viability and function.

Table 1: Key Reagents and Materials for Post-Thaw Washing

Item	Function	Examples & Notes
Dilution Media	Dilutes CPA rapidly to reduce toxicity and osmotic shock.	Pre-warmed culture media, Normal Saline, HBSS. Serum (e.g., FBS) can aid recovery.
Centrifuge	Pellet cells for supernatant removal.	Swing-out rotors preferred for gentler pelleting.
Sterile Tubes	Hold cell suspension during washing.	Conical centrifuge tubes of appropriate volume.
Cell Viability Assay	Critical quality control post-wash.	Trypan Blue exclusion [56], flow-based assays (e.g., 7-AAD).
Controlled-Rate Thawing	Ensures consistent, rapid thawing.	37°C water bath (risk of contamination) or validated dry thawers [2] [57].
Automated Cell Processor	For clinical-grade, reproducible washing.	COBE 2991; standardizes process in closed system [54] [56].

Quantitative Data on Current Practices and Outcomes

Recent surveys of transplant centers highlight significant variability in post-thaw handling protocols, reflecting the lack of standardized guidelines.

Table 2: Variability in Post-Thaw Processing Practices from Nationwide Surveys

Practice Aspect	Survey Findings	Implication
Washing Practice	53.8% of Korean centers perform post-collection processing (e.g., plasma removal); 46.2% do not [54] [56]. In Spain, 15/31 centers do not wash cryopreserved grafts, while 5 wash systematically and 11 wash based on DMSO dose/patient weight [55].	High variability in whether cells are washed at all, impacting patient DMSO exposure and potential cell loss.
DMSO Concentration	Concentrations in use vary from 5% to 15% [54] [56].	The initial DMSO load directly influences the required efficiency of removal and the risk of toxicity.
Post-Thaw QC Testing	28.6% of patients in the Korean survey did not undergo post-thaw quality assessment [54] [56].	Lack of universal QC testing makes it difficult to correlate processing methods with clinical outcomes.
Thawing Location/Method	78.6% of Korean centers thaw at bedside with a water bath [56].	Bedside thawing without washing maximizes convenience but also patient DMSO exposure.

Detailed Experimental Protocol for Assessing Post-Thaw MSC Function

To rigorously evaluate the impact of the thawing and washing process on MSC immunomodulatory properties, the following experimental protocol is recommended.

Aim: To compare the viability, recovery, and immunomodulatory function of cryopreserved MSCs subjected to different post-thaw washing protocols.

Materials:

• Cryopreserved MSCs (e.g., in 10% DMSO/CryoStor CS10)
• Water bath or dry thawer (37°C)
• Pre-warmed complete culture medium (e.g., DMEM+10% FBS)
• Pre-warmed PBS or HBSS
• Centrifuge
• Trypan Blue solution or automated cell counter
• Tissue culture plasticware
• Mitogen-activated peripheral blood mononuclear cells (PBMCs) for functional assays.

Method:

• Thawing: Rapidly thaw a vial of MSCs by placing it in a 37°C water bath for approximately 2 minutes, until only a small ice crystal remains. Gently agitate the vial.
• Washing Conditions:
  • Condition A (Direct Inoculation): Transfer the entire contents of the vial directly into a T-flask containing pre-warmed culture medium. This avoids osmotic stress from centrifugation but leaves DMSO in the culture.
  • Condition B (Single Wash): Transfer the cell suspension to a tube with 9 mL of pre-warmed medium (1:10 dilution). Centrifuge at 400 x g for 5 minutes. Aspirate supernatant and resuspend in fresh medium.
  • Condition C (Double Wash): Perform Condition B, then repeat the centrifugation and resuspension step once more.
• Cell Counting and Plating: Perform a cell count and viability assessment for each condition using Trypan Blue exclusion. Plate cells at a standardized density for recovery analysis.
• Functional Assays:
  • Viability and Recovery: Calculate total viable cell recovery and percent viability 24 hours post-thaw.
  • Proliferation Assay: Monitor cell growth over 3-5 days using a metabolic assay like MTT.
  • Immunomodulatory Function:
    • Co-culture Assay: Co-culture thawed MSCs with mitogen-stimulated PBMCs (e.g., using PHA) in a transwell system for 3-5 days.
    • T-cell Proliferation: Measure the suppression of T-cell proliferation using a CFSE dilution assay and flow cytometry [21] [50].
    • Cytokine Secretion: Analyze the supernatant for key immunomodulatory cytokines (e.g., increased IL-10, PGE2; decreased IFN-γ, TNF-α) via ELISA or multiplex arrays [21] [51].

The relationship between post-thaw processing, cellular stress, and ultimate immunomodulatory function can be visualized through key signaling pathways, as shown in the following diagram.

The steps following the removal of MSCs from liquid nitrogen are as critical as the freezing process itself. Inconsistent or suboptimal post-thaw handling can directly impair the immunomodulatory functions that make MSCs therapeutically valuable, potentially compromising research data and clinical trial outcomes. The high variability in current practices underscores an urgent need for evidence-based, standardized protocols for washing and CPA removal. By adopting rigorous methodologies, systematically assessing functional outcomes, and clearly reporting handling procedures, the research community can significantly enhance the reliability and translational potential of cryopreserved MSC-based therapies.

Defining Critical Quality Attributes (CQAs) for Cryopreserved MSC Products

The development of effective Mesenchymal Stem/Stromal Cell (MSC)-based therapies faces a significant translational challenge: the functional consequences of cryopreservation. While cryopreservation enables essential "off-the-shelf" availability for clinical applications, growing evidence indicates that the freeze-thaw process fundamentally alters critical biological properties of MSCs [58] [2]. Defining Critical Quality Attributes (CQAs)—the physical, chemical, biological, or microbiological properties or characteristics that must be within appropriate limits to ensure desired product quality—is therefore paramount for clinical success [59]. For cryopreserved MSCs, this requires special consideration of how preservation impacts immunomodulatory function, a core therapeutic mechanism.

The imperative to establish well-defined CQAs stems from both regulatory requirements and demonstrated functional deficits. Cryopreserved MSCs exhibit reduced viability, impaired immunomodulatory properties, and altered secretory profiles compared to their fresh counterparts [58] [11]. These changes directly impact therapeutic performance, as evidenced by clinical observations where patients treated with freshly harvested MSCs in low passage demonstrated a 100% response rate—twice the 50% response rate observed in a comparable group treated with freeze-thawed cells at higher passage [11]. This technical guide establishes a comprehensive framework for identifying, measuring, and controlling CQAs specific to cryopreserved MSC products, with emphasis on preserving immunomodulatory capacity.

Impact of Cryopreservation on MSC Function and Immunomodulatory Properties

Temporal Dynamics of Post-Thaw Recovery

The functional deficits observed in cryopreserved MSCs are not static but evolve during post-thaw recovery. Quantitative studies reveal a complex recovery trajectory where different attributes normalize at varying rates.

Table 1: Post-Thaw Recovery Timeline of Key MSC Attributes

Time Post-Thaw	Viability & Apoptosis	Metabolic Activity	Adhesion Potential	Immunomodulatory Function
Immediate (0h)	Viability reduced; Apoptosis increased [58]	Significantly impaired [58]	Significantly impaired [58]	Strongly impaired; Reduced responsiveness to inflammatory stimuli [11]
4 Hours	Viability still low; Apoptosis peaks [58]	Remains impaired [58]	Remains impaired [58]	Impaired mediator production persists [11]
24 Hours	Viability recovers; Apoptosis drops [58]	Still lower than fresh cells [58]	Still lower than fresh cells [58]	Partial recovery possible but variable [58]
Beyond 24 Hours	Normalizes with culture [58]	Gradual recovery [58]	Gradual recovery [58]	Colony-forming ability and differentiation potential variably affected [58]

This recovery timeline has direct implications for clinical applications. Therapies intended for infusion within hours after thawing must account for these transient deficits, particularly the compromised immunomodulatory capacity during the critical first 24 hours [58] [11].

Consequences for Innate Immune Recognition

Cryopreservation-induced changes trigger heightened recognition and elimination by the host immune system, creating a significant barrier to engraftment and persistence.

Table 2: Cryopreservation Effects on Innate Immune Activation

Immense System Component	Impact of Cryopreservation	Functional Consequence
Complement Activation	Enhanced activation of all three complement pathways [11]	Increased complement-mediated lysis; 2x faster elimination after serum exposure [11]
Coagulation Cascade	Increased tissue factor expression [11]	Triggering of Instant Blood-Mediated Inflammatory Reaction (IBMIR) [11]
Phagocyte Clearance	Enhanced recognition by phagocytes [11]	Rapid clearance following systemic administration [11]
Serum Resistance	Reduced resilience to serum components [11]	50-80% reduction in viable cells after blood exposure [11]

The combined effect of these changes creates a "perfect storm" where cryopreserved MSCs face accelerated elimination upon administration, reducing their opportunity to exert therapeutic effects at target tissues [11].

The diagram above illustrates how cryopreservation-induced cellular damage leads to innate immune activation and ultimately compromises therapeutic efficacy through multiple interconnected pathways.

Defining Critical Quality Attributes for Cryopreserved MSCs

Core CQA Categories and Assessment Methods

A systematic approach to CQA development encompasses multiple attribute categories, each requiring specific assessment methodologies tailored to detect cryopreservation-induced changes.

Table 3: Comprehensive CQA Framework for Cryopreserved MSCs

CQA Category	Specific Attributes	Recommended Assays	Acceptance Criteria
Viability & Apoptosis	Membrane integrity, apoptotic markers, recovery kinetics	Flow cytometry (Annexin V/PI), automated cell counting, time-lapse imaging [58] [11]	>70-80% viability post-thaw; <15% late apoptosis/necrosis [2]
Identity & Purity	Surface marker expression (CD73, CD90, CD105; absence of CD45, CD34, CD14, CD19, HLA-DR) [58] [2]	Multicolor flow cytometry, immunocytochemistry	≥95% positive for markers; ≤2% negative for markers (per ISCT criteria) [58] [2]
Potency & Immunomodulation	Responsiveness to inflammatory stimuli (IFN-γ), immunosuppressive mediator production (IDO, PGE2), T-cell suppression	Co-culture assays with PBMCs, ELISA/Luminex, indoleamine 2,3-dioxygenase (IDO) activity [11] [60]	≥50% inhibition of T-cell proliferation; significant induction of immunomodulatory factors [60]
Functional Capacity	Metabolic activity, adhesion potential, migration capacity, clonogenic potential	MTT/XTT assays, adhesion assays, transwell migration, CFU-F assay [58]	Metabolic activity >60% of fresh control; adhesion >50% of control; CFU-F efficiency within donor-specific range [58]
Differentiation Potential	Osteogenic, adipogenic, chondrogenic differentiation	Lineage-specific staining (Oil Red O, Alizarin Red, Alcian Blue), qPCR for lineage markers	Multilineage capacity maintained post-thaw; quantification of differentiation efficiency [58] [61]
Safety Attributes	Microdamage, complement activation, procoagulant activity	Complement binding assays, tissue factor expression, thrombogenicity testing [11]	Minimal complement activation; low procoagulant potential [11]

Methodological Details for Key CQA Assessments

Immunomodulatory Potency Assay

• Principle: Measure MSC capacity to suppress activated immune cell proliferation in response to inflammatory priming [11] [60].
• Protocol:
  • Thaw and plate MSCs at 10,000 cells/cm² and allow 24-hour recovery.
  • Prime with IFN-γ (10-50 ng/mL) for 24 hours.
  • Seed activated peripheral blood mononuclear cells (PBMCs) labeled with CFSE or similar dye onto MSC monolayer at MSC:PBMC ratios from 1:1 to 1:10.
  • After 3-5 days, analyze PBMC proliferation by flow cytometry.
  • Simultaneously, collect supernatant for IDO activity measurement (kynurenine production via spectrophotometry) or PGE2 quantification by ELISA [11] [60].
• Acceptance Criterion: ≥50% suppression of PBMC proliferation at 1:5 ratio; significant induction of immunomodulatory mediators.

Post-Thaw Functional Recovery Assessment

• Principle: Quantify temporal recovery of metabolic and adhesive functions [58].
• Protocol:
  • Thaw MSCs and plate at standardized density.
  • Assess metabolic activity (MTT/XTT assay) and adhesion capacity at 0h, 4h, and 24h post-thaw.
  • For adhesion assay: plate cells for 2 hours, gently wash, and count adhered cells.
  • Compare to passage-matched fresh controls normalized to 100%.
  • Include apoptosis assessment (Annexin V/7-AAD) at each timepoint [58].
• Acceptance Criterion: Metabolic activity and adhesion >70% of fresh control by 24h post-thaw.

Complement Activation Susceptibility

• Principle: Evaluate cryopreservation-induced vulnerability to complement-mediated lysis [11].
• Protocol:
  • Prepare fresh and cryopreserved MSCs from same donor/passage.
  • Incubate 1×10⁶ cells with 50% normal human serum (complement-active) or heat-inactivated serum control for 60 minutes at 37°C.
  • Stop reaction with EDTA.
  • Assess viability using flow cytometry with viability dyes and complement deposition (C3b, C5b-9 staining) [11].
• Acceptance Criterion: <30% increase in complement-mediated lysis compared to fresh controls.

Essential Research Reagents and Methodologies

A standardized toolkit is essential for consistent CQA assessment across laboratories and manufacturing facilities.

Table 4: Essential Research Reagent Solutions for CQA Assessment

Reagent/Category	Specific Examples	Function & Application
Viability & Apoptosis	Annexin V/7-AAD kits, Propidium Iodide, Calcein-AM	Distinguish viable, apoptotic, and necrotic populations post-thaw [58] [11]
Phenotypic Characterization	Anti-human CD73, CD90, CD105, CD45, CD34, CD14, CD19, HLA-DR antibodies	Verify MSC identity per ISCT criteria pre- and post-cryopreservation [58] [2]
Immunomodulation Assessment	Recombinant human IFN-γ, Anti-CD3/CD28 antibodies, IDO activity assay kits, PGE2 ELISA	Activate MSC immunomodulatory pathways and quantify functional output [11] [60]
Functional Assays	MTT/XTT cell viability kits, Collagen/ Fibronectin-coated plates, Transwell migration plates	Assess metabolic activity, adhesion potential, and migratory capacity [58]
Differentiation Kits	Osteogenic (Dexamethasone, β-glycerophosphate, ascorbic acid), Adipogenic (IBMX, indomethacin, insulin), Chondrogenic (TGF-β, BMP) media	Verify trilineage differentiation potential post-cryopreservation [58] [61]
Complement & Safety	Normal human serum pools, Anti-C3b/C5b-9 antibodies, Tissue factor ELISA kits	Evaluate innate immune activation and thrombogenic potential [11]

The quality control workflow above illustrates the iterative process of assessing CQAs post-cryopreservation and making necessary process adjustments before product release.

Standardization and Reporting Requirements

The development of CQAs for cryopreserved MSCs must occur within a broader framework of standardization to ensure comparability across studies and manufacturing sites. Recent initiatives by the International Society for Cell and Gene Therapy (ISCT) emphasize the need for standardized reporting of critical manufacturing parameters including passage number, cryopreservation methodology, post-thaw recovery protocols, and comprehensive characterization data [60].

Key elements requiring standardization include:

• Cryopreservation methodology: Detailed documentation of cryoprotectant composition (including DMSO concentration and carrier solution), cooling rate (-1°C/min standard for slow freezing), storage conditions, and thawing procedures [58] [2].
• Post-thaw assessment timing: Clear specification of timepoints for CQA evaluation relative to thawing (immediate, 4h, 24h) with justification based on intended clinical use [58].
• Reference materials: Implementation of standardized controls for assays, including reference MSCs and calibration materials for flow cytometry and functional assays [59].
• Reporting criteria: Adherence to minimal reporting standards for MSC clinical trials, particularly for autoimmune diseases, including detailed description of CQAs, manufacturing changes, and potency assay results [60].

Inter-laboratory studies and method validation are essential components of CQA development. As noted by the National Institute of Standards and Technology (NIST), "Developing and validating assays for CQAs as early as possible in the pre-clinical product development process leads to better decision making at each step along the translation process and more confidence that an observed effect is reproducible in the clinical phase" [59].

Defining appropriate Critical Quality Attributes for cryopreserved MSC products requires acknowledging that cryopreservation fundamentally alters cellular properties in ways that impact therapeutic efficacy. The framework presented here emphasizes functional attributes—particularly immunomodulatory capacity—rather than relying solely on traditional viability and phenotypic markers. By implementing this comprehensive CQA approach, developers can better control product quality, predict in vivo performance, and ultimately enhance the clinical success of cryopreserved MSC therapies. As the field advances, continued refinement of these attributes through interlaboratory collaboration and standardized reporting will be essential to realizing the full potential of MSC-based therapies.

Strategies for Recovery: Overcoming Functional Deficits in Cryopreserved MSCs

The therapeutic potential of mesenchymal stem cells (MSCs) in regenerative medicine and immunomodulation is substantially challenged by the practical necessity of cryopreservation. Cryopreservation enables the creation of "off-the-shelf" cellular products, facilitating logistical planning, quality control, and immediate therapeutic availability, particularly for acute conditions [62]. However, this process imposes significant stress on cells, potentially compromising their functional potency—a core attribute defining their therapeutic efficacy. The central thesis of this review posits that while cryopreservation transiently impairs critical MSC functions, a strategically implemented acclimation period of 24 hours post-thaw serves as a crucial recovery phase, reactivating the immunomodulatory and regenerative properties essential for clinical success. This paper examines the direct evidence for this recovery, delineates the underlying mechanisms, and provides a standardized experimental framework for validating MSC potency in research and development.

The Impact of Cryopreservation on MSC Form and Function

Cryopreservation inflicts a spectrum of damage on MSCs, ranging from molecular to functional deficits. Understanding this immediate post-thaw state is essential for appreciating the necessity of an acclimation period.

• Cellular and Phenotypic Changes: Immediately post-thaw (termed "Freshly Thawed" or FT MSCs), cells exhibit a significant decrease in surface markers such as CD44 and CD105, which are involved in cell adhesion and are part of the standard phenotypic characterization of MSCs [63] [19]. There is also a marked increase in apoptosis and metabolic activity, the latter indicative of cellular stress [63].

• Functional Deficits: The most critical impairments are observed in functional assays. FT MSCs show a significant decrease in cell proliferation, clonogenic capacity (the ability to form colonies), and the expression of key regenerative genes [63] [19]. While they retain their basic capacity to differentiate into lineages like osteocytes and chondrocytes, and maintain core immunomodulatory functions, their potency in these areas is substantially diminished compared to their fresh or acclimated counterparts [63].

Table 1: Functional Deficits in Freshly Thawed MSCs and Recovery Post-Acclimation

Functional Parameter	Freshly Thawed (FT) MSCs	After 24-h Acclimation (TT MSCs)	Measurement Method
Viability & Apoptosis	Significantly increased apoptosis [63]	Significantly reduced apoptosis [63]	Annexin V/PI flow cytometry [19]
Proliferation	Significantly decreased [63]	Recovered [63]	Metabolic activity assay (e.g., Resazurin) [19]
Clonogenic Capacity	Significantly decreased [63]	Recovered [63]	Colony-forming unit (CFU-F) assay [63]
Immunomodulation	Maintained, but significantly less potent in arresting T-cell proliferation [63]	Significantly more potent [63]	T-cell proliferation suppression assay [63] [23]
Anti-inflammatory Secretion	IFN-γ secretion significantly diminished [63]	Upregulation of anti-inflammatory genes [63]	Cytokine analysis (e.g., ELISA), Gene expression [63]
Pro-Angiogenic Capacity	Decreased gene expression [63]	Upregulation of angiogenic genes [63]	Gene expression analysis [63]

Experimental Evidence: Documenting the 24-Hour Recovery

The foundational study by Antebi et al. (2019) provides a direct, head-to-head comparison that quantifies the benefits of a 24-hour acclimation period [63] [19]. Their experimental design divided human bone-marrow-derived MSCs into three distinct groups, creating a clear benchmark for comparison:

• FC (Fresh Cells): Cells from existing culture, representing the "gold standard" of functionality.
• FT (Freshly Thawed): Cells thawed and used immediately on the day of experimentation.
• TT (Thawed + Time): Cells thawed and allowed a 24-hour acclimation period in standard tissue-culture flasks prior to experimentation [63] [19].

This model allowed for a systematic analysis of recovery. Key findings from this and corroborating studies include:

• Recovery of Immunomodulatory Potency: While all MSC groups arrested T-cell proliferation, the TT MSCs were significantly more potent than their FT counterparts [63]. This recovery of immunosuppressive function post-acclimation has been confirmed in other models, including in polymicrobial septic animals, where thawed MSCs showed comparable efficacy to cultured cells in improving bacterial clearance and reducing inflammatory cytokines [23].

• Reduction in Apoptosis and Improved Phenotype: The 24-hour period allowed cells to recover from the trauma of thawing, resulting in a significant reduction in apoptosis [63]. Furthermore, the surface marker expression (e.g., CD44, CD105) that was decreased in FT cells was restored in TT cells to levels comparable with fresh controls [63] [19].

• Gene Expression Reactivation: The acclimation period facilitated a concomitant upregulation of key angiogenic and anti-inflammatory genes, which are critical for the paracrine-mediated therapeutic effects of MSCs [63].

Practical Application: A Protocol for Post-Thaw Acclimation

For research and clinical translation, standardized protocols are paramount. The following workflow and detailed methodology outline the key steps for a successful post-thaw acclimation of MSCs.

Detailed Methodology

• Thawing: Rapidly thaw cryovials in a 37°C water bath until only a small ice crystal remains (approximately 2 minutes) [2]. To enhance biosafety, consider using dry heating equipment instead of a water bath to avoid potential microbial contamination from water [2].

• Dilution and Washing: Transfer the cell suspension to a pre-warmed vessel containing a large volume (e.g., 10 mL) of complete culture medium. The presence of protein, such as 2% Human Serum Albumin (HSA), in the thawing solution is critical to prevent significant cell loss (up to 50% loss can occur in protein-free solutions) [64]. Centrifuge the cell suspension to remove the cryoprotectant (e.g., DMSO). Note that the washing process itself can lead to cell loss; therefore, gentle handling and controlled conditions are essential [2] [62].

• Plating and Acclimation: Resuspend the cell pellet in fresh, complete culture medium. Plate the cells at a standard density (e.g., 1000 cells/cm²) [19] and incubate for 24 hours at 37°C with 5% CO₂. This period allows cells to re-adhere, recover their cytoskeleton, and resume normal metabolic and transcriptional activities.

• Post-Acclimation Harvest: After 24 hours, harvest the cells using a standard detachment agent like trypsin/EDTA or TrypLE [19] [65]. The cells are now ready for functional assays or administration.

Table 2: Research Reagent Solutions for Post-Thaw Acclimation

Reagent	Function in Protocol	Key Considerations & References
Human Serum Albumin (HSA)	Essential protein component of thawing and reconstitution solution; prevents massive cell loss during dilution.	Use at 2% in isotonic solution. Critical for maintaining viability and yield during thawing and low-concentration reconstitution [64].
Complete Culture Medium	Base medium (e.g., α-MEM) supplemented with fetal bovine serum (FBS) or human platelet lysate (hPL) and glutamine.	Provides nutrients and signaling molecules for cell recovery during the 24-hour acclimation period [63] [19] [65].
Dimethyl Sulfoxide (DMSO)	Penetrating cryoprotectant used during initial freezing.	Must be thoroughly washed out post-thaw due to cytotoxicity. Concentration typically 10% in freezing medium [63] [2] [62].
Isotonic Saline (0.9% NaCl)	Clinically compatible vehicle for post-thaw reconstitution and short-term storage.	Superior to PBS for maintaining cell stability and viability for up to 4 hours post-thaw [64].
Trypsin/EDTA or TrypLE	Cell detachment agent for harvesting post-acclimation.	Used to lift adherent MSCs from the flask after the 24-hour recovery period [19] [65].

Underlying Mechanisms: How Acclimation Reverses Cryo-Damage

The 24-hour acclimation period is not merely a passive wait but an active recovery phase where MSCs undergo critical processes to regain functional potency. The mechanisms behind this recovery are multifaceted.

• Re-establishment of Cytoskeleton and Adhesion: The cryopreservation and thawing process disrupts the cytoskeleton and cleaves adhesion molecules. The 24-hour period allows MSCs to re-adhere to the plastic substrate, re-organize their actin cytoskeleton, and restore the surface expression of key adhesion molecules like CD44, which is vital for their homing and cell-to-cell contact-mediated immunomodulation [63] [15].

• Transcriptional Reactivation and Protein Synthesis: The stress of cryopreservation dampens global transcription and translation. The acclimation period provides a window for the cells to upregulate key genes involved in angiogenesis (e.g., VEGF) and immunomodulation (e.g., IDO, PGE2) [63]. This renewed synthesis of effector proteins is crucial for restoring paracrine function.

• Recovery of Mitochondrial Function and Energetics: Cryopreservation can impair mitochondrial integrity, leading to metabolic disequilibrium. The 24-hour period allows for the restoration of normal metabolic activity, shifting from a stressed, hypermetabolic state immediately post-thaw to a balanced state supportive of proliferation and specific functions [63] [19].

• Activation of Key Immunomodulatory Pathways: The recovery of immunomodulatory potency is linked to the reactivation of specific signaling pathways. The diagram below illustrates the key pathways that are restored during acclimation, enabling MSCs to effectively suppress immune cell proliferation and polarize macrophages toward an anti-inflammatory phenotype.

The implementation of a 24-hour post-thaw acclimation period is a critical, evidence-based step to ensure that cryopreserved MSCs used in research and clinical trials exhibit their full therapeutic potential. The data compellingly demonstrate that while cryopreservation temporarily impairs MSC function, these cells possess a remarkable capacity for self-repair. Allowing this recovery period is not a logistical hurdle but a scientific necessity to standardize MSC potency assays and maximize the efficacy of cell therapy products. Future work should focus on further optimizing cryopreservation formulations—such as DMSO-free alternatives [2] [62]—and defining more sensitive, mechanism-based potency release assays that can predict in vivo efficacy, moving the field toward more reliable and effective MSC-based therapeutics.

The therapeutic application of mesenchymal stromal cells (MSCs) hinges on the ability to preserve their viability, functionality, and immunomodulatory properties during storage and transport. Cryopreservation is a critical process enabling the "off-the-shelf" availability of these cell therapies, with cryoprotective agents (CPAs) serving as essential components to protect cells from freeze-induced damage [66] [67]. For decades, dimethyl sulfoxide (DMSO) has been the predominant CPA in clinical cryopreservation protocols, while fetal bovine serum (FBS) has been the standard supplement for in vitro MSC expansion [66] [68]. However, growing safety concerns and regulatory pressures have driven innovation toward defined, xenogen-free alternatives.

This technical guide examines recent advancements in DMSO-free cryopreservation solutions and serum-free culture media, with particular emphasis on how these formulations impact the critical immunomodulatory properties of MSCs. As the field progresses toward more standardized and clinically compliant manufacturing, understanding the interplay between preservation methods and MSC function becomes paramount for developing effective cell-based therapeutics.

The Challenge: Limitations of Conventional Formulations

DMSO-Associated Concerns

While DMSO prevents intracellular ice crystal formation and osmotic damage during freezing, its application presents significant challenges. DMSO exhibits dose-dependent toxicity to both cells and patients [66] [67]. Clinical administrations of DMSO-cryopreserved cell products have been associated with adverse reactions including nausea, cardiovascular effects, and anaphylaxis [66]. Although DMSO concentrations in MSC products are typically 2.5–30 times lower than the 1 g/kg dose accepted in hematopoietic stem cell transplantation, concerns persist [66].

From a cellular perspective, DMSO can impact MSC functionality post-thaw. Studies indicate that immediately thawed MSCs may exhibit reduced blood compatibility and altered functional properties compared to freshly harvested cells [66]. Furthermore, conventional post-thaw washing procedures to remove DMSO subject cells to additional stress through centrifugation, potentially compromising viability and function [66].

Serum-Related Complications

The use of FBS in MSC culture systems introduces substantial limitations for clinical applications, including:

• Batch-to-batch variability that compromises experimental reproducibility and manufacturing consistency [69] [68]
• Risk of xenogenic immunization through internalization of bovine antigens, potentially eliciting immune reactions in human recipients [68]
• Potential transmission of zoonotic pathogens and prion diseases [68]
• Introduction of xenoantigens such as N-glycolylneuraminic acid (Neu5Gc), which can be incorporated into human cells and targeted by human antibodies [68]

These concerns have prompted regulatory agencies to discourage animal-derived components in therapeutic cell manufacturing, accelerating the development of serum-free alternatives.

Innovation in DMSO-Free Cryopreservation Strategies

Emerging DMSO-Free Formulations

Recent multicenter studies have demonstrated the feasibility of eliminating DMSO from cryopreservation protocols while maintaining post-thaw MSC quality. The table below summarizes key comparative findings from recent investigations into DMSO-free formulations.

Table 1: Comparison of DMSO-Free vs. DMSO-Containing Cryopreservation Solutions

Solution Type	Composition	Post-Thaw Viability	Cell Recovery	Phenotype/Function	Study
SGI Solution	Sucrose, glycerol, isoleucine in Plasmalyte A	~83% (slightly lower than DMSO controls)	~93% (significantly better than DMSO controls)	Comparable immunophenotype (CD73, CD90, CD105) and global gene expression profiles	PACT/BEST Collaborative [32]
CS10	10% DMSO (commercial control)	~89%	~87%	Standard immunophenotype maintained	Park et al. [70]
CryoStor CS10	10% DMSO	Comparable to other 10% DMSO solutions	Similar across 10% DMSO formulations	Preserved immunomodulatory function in T cell suppression assays	Tan et al. [67]
CryoStor CS5	5% DMSO	Decreasing trend over 6 hours post-thaw	Decreasing trend	10-fold reduced proliferative capacity post-thaw	Tan et al. [67]

The international PACT/BEST collaborative study, involving seven centers across three continents, provided particularly compelling evidence for one DMSO-free approach. Their investigation revealed that MSCs cryopreserved in the novel SGI solution showed slightly lower viability but significantly better recovery of viable cells compared to DMSO-containing solutions, with comparable immunophenotype and global gene expression profiles [32].

Alternative Cryopreservation Mechanisms

DMSO-free strategies employ various mechanisms to protect cells during freezing:

• Non-penetrating CPAs: Sugars like sucrose and trehalose create extracellular hypertonic conditions that draw water out of cells, minimizing intracellular ice crystal formation [66] [32]
• Amino acid additives: Components like isoleucine may stabilize cell membranes during osmotic stress [32]
• Combination approaches: Multi-agent cocktails target different protective pathways simultaneously [66]

Table 2: Advanced DMSO-Free Cryopreservation Techniques

Technique	Mechanism	Key Components	Reported Efficacy	Limitations/Challenges
Slow freezing with sugar alcohols	Partial membrane penetration + osmotic regulation	Glycerol, ethylene glycol	Variable (52%-87% viability depending on source and combination)	Generally lower than DMSO for some MSC sources [66]
Sugar-based combinations	Extracellular cryoprotection + membrane stabilization	Trehalose, sucrose, dextran, ectoine	Up to 95% viability and recovery in optimized formulations [66]	May require additives for optimal performance
Intracellular CPA delivery	Facilitates internalization of non-penetrating CPAs	Electroporation + trehalose/sucrose; nanoparticle encapsulation	72%-91% viability with optimized parameters [66]	Increased complexity; potential for membrane damage
Vitrification	Ultra-rapid cooling to glassy state	High CPA concentrations (e.g., 1.3M trehalose + 2M 1,2-propanediol)	>80% viability with encapsulation [66]	Challenge of devitrification; limited to small volumes

Experimental Protocol: Evaluating DMSO-Free Formulations

For researchers implementing DMSO-free cryopreservation, the following protocol provides a standardized approach for comparison:

Cell Preparation

• Culture MSCs in serum-free or serum-containing media to 80-90% confluence
• Harvest cells using standard detachment methods (e.g., trypsin-EDTA)
• Resuspend in appropriate base medium for counting and viability assessment

CPA Preparation

• Prepare test cryopreservation solutions (e.g., SGI formulation: sucrose, glycerol, isoleucine in Plasmalyte A)
• Prepare control solutions (e.g., 10% DMSO in culture medium)
• Filter-sterilize all solutions (0.2μm)

Freezing Process

• Adjust cell concentration to target density (e.g., 3-9×10^6 cells/mL)
• Mix cell suspension with equal volume of 2× CPA solution to achieve final concentration
• Aliquot into cryovials (1.0-1.5mL per vial)
• Freeze using controlled-rate freezer (standard protocol: -1°C/min to -40°C, then -10°C/min to -100°C)
• Transfer to liquid nitrogen for storage (>1 week recommended before evaluation)

Post-Thaw Assessment

• Rapidly thaw cells in 37°C water bath (2 minutes)
• Dilute gradually with pre-warmed culture medium (optional, depending on formulation)
• Assess immediately (0h) and at intervals post-thaw (2h, 4h, 6h):
  • Viability (Trypan blue exclusion)
  • Apoptosis (Annexin V/PI staining)
  • Recovery (hemocytometer count)
  • Immunophenotype (flow cytometry for CD73, CD90, CD105)
  • Functional assays (T cell suppression, differentiation potential) [32] [67]

Experimental Workflow for CPA Formulation Comparison

Serum-Free Media for MSC Culture

Impact on MSC Characteristics and Function

The transition from serum-containing to serum-free media represents a critical advancement in MSC manufacturing. Comparative studies reveal significant differences in MSC biology when cultured under defined conditions:

Table 3: Serum-Free vs. Serum-Containing Media Effects on MSC Properties

Characteristic	Serum-Free Media	Serum-Containing Media	Functional Significance
Population Doubling Time	More stable across passages	Increases at later passages	More consistent expansion for manufacturing [68]
Cellular Senescence	Reduced	Increased	Extended functional lifespan; better quality cells [68]
Immunogenicity	Lower (reduced Neu5Gc expression)	Higher risk of immune recognition	Safer for allogeneic applications [68]
Genetic Stability	Enhanced	Reduced	Lower risk of transformation [68]
Immunomodulatory Factor Secretion	Maintained or enhanced (PGE2, IDO, IL-6)	Variable	Potent immunosuppressive capacity retained [69]
In Vivo Therapeutic Efficacy	Preserved in disease models (e.g., pulmonary hypertension, pancreatitis)	Effective but with immunogenicity concerns	Clinical potential without FBS-related risks [69] [68]

Notably, MSCs expanded in serum-free media maintain powerful immunomodulatory functions both in vitro and in vivo. They effectively inhibit CD4+ T cell proliferation and apoptosis while secreting high levels of key immunomodulatory factors including PGE2, IDO, COX2, IL-6, and IL-1β [69]. The slightly different cytokine profile (e.g., potentially lower HGF secretion) does not appear to compromise their overall immunosuppressive capacity [69].

Experimental Protocol: Transition to Serum-Free Culture

Media Transition Strategy

• Begin with MSCs previously cultured in serum-containing media
• Implement gradual adaptation over 2-3 passages:
  • Passage 1: 75% original media + 25% serum-free media
  • Passage 2: 50% original media + 50% serum-free media
  • Passage 3: 25% original media + 75% serum-free media
  • Passage 4: 100% serum-free media

Culture Conditions

• Use commercial serum-free media specifically formulated for MSCs (e.g., StemPro MSC SFM XenoFree, MesenCult-ACF)
• For some formulations, pre-coat culture vessels with attachment substrates (e.g., CELLstart)
• Maintain at standard culture conditions (37°C, 5% CO2)
• Passage at 70-85% confluence using animal-free dissociation enzymes

Quality Assessment

• Verify MSC phenotype by flow cytometry (CD73+, CD90+, CD105+, CD14-, CD34-, CD45-, HLA-DR-)
• Confirm differentiation potential (osteogenic, adipogenic, chondrogenic)
• Evaluate population doubling time across multiple passages
• Assess immunomodulatory capacity (T cell suppression assay)
• Check for absence of bovine antigen contamination [68]

Interplay Between Cryopreservation and MSC Immunomodulatory Properties

Mechanisms of MSC Immunomodulation

MSCs exert their immunomodulatory effects through multiple mechanisms, which can be influenced by cryopreservation and culture conditions:

• Soluble factor secretion: IDO, PGE2, TGF-β, HLA-G, IL-6, and other mediators [71] [72]
• Cell-cell contact: Dependent on surface molecules like B7-H4 and adhesion factors [71]
• Extracellular vesicle release: MSC-EVs contain immunomodulatory miRNAs and proteins [53]
• Metabolic reprogramming: Tryptophan depletion via IDO, nitric oxide production [71] [72]

The immunomodulatory function of MSCs is not constitutive but rather licensed by inflammatory cytokines such as IFN-γ and TNF-α in the microenvironment. These cytokines trigger the expression of immunosuppressive factors through signaling pathways like JAK-STAT and NF-κB [71] [72].

MSC Immunomodulatory Mechanisms and Influencing Factors

Impact of Cryopreservation on Immunomodulatory Function

The cryopreservation process and CPA selection can significantly influence MSC immunomodulatory potency through several mechanisms:

• Cell membrane integrity: Damage during freezing/thawing can impair receptor expression and signaling capacity
• Metabolic activity: Altered mitochondrial function post-thaw may reduce energy-dependent immunomodulatory functions
• Gene expression profiles: Cryopreservation stress can modify the expression of immunomodulatory genes
• Secretory capacity: Changes in cytoskeletal organization may affect vesicle trafficking and cytokine secretion

Research indicates that properly optimized cryopreservation maintains critical immunomodulatory functions. Studies comparing fresh versus cryopreserved MSCs have demonstrated similar capacity to inhibit T cell proliferation when cryopreservation is performed under optimal conditions [67]. However, suboptimal freezing or inappropriate CPA selection can diminish this functionality.

Strategic Optimization Approaches

Several strategies can preserve or enhance MSC immunomodulatory properties during cryopreservation:

• Three-dimensional culture: MSC spheroids or 3D collagen matrices better maintain native cell morphology and function, potentially enhancing post-thaw recovery of immunomodulatory capacity [70] [30]
• CPA combination cocktails: Balanced formulations that minimize osmotic stress and ice crystal formation improve recovery of functional cells
• Controlled thawing and recovery: Gradual dilution and optimized post-thaw recovery media support restoration of metabolic activity and function
• Pre-conditioning strategies: Exposure to pro-inflammatory cytokines (IFN-γ, TNF-α) before freezing can enhance post-thaw immunomodulatory potency by priming key pathways [72]

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Reagents for DMSO-Free and Serum-Free MSC Research

Reagent Category	Specific Examples	Function/Application	Considerations
Serum-Free Media	StemPro MSC SFM XenoFree, MesenCult-ACF Plus, NutriStem XF	Defined formulation for MSC expansion without animal components	Some require pre-coating of culture vessels with attachment factors
DMSO-Free CPAs	CryoStor CS10 (control), SGI solution (sucrose-glycerol-isoleucine), trehalose-based formulations	Cryoprotection without DMSO-associated toxicity	May require optimization of freezing rates; efficacy varies by MSC source
Cell Attachment Substrates	CELLstart, Recombinant Human Vitronectin, Collagen I	Facilitate MSC adhesion in serum-free conditions	Coating concentration and uniformity affect cell growth and morphology
Dissociation Reagents	Animal-Free Recombinant Trypsin, Accutase, Collagenase	Cell detachment while maintaining viability	Activity varies with temperature and exposure time; neutralization required
Quality Assessment Tools	Flow cytometry panels (CD73/90/105, CD14/34/45), Annexin V/PI apoptosis kits, T cell suppression assay components	Verify phenotype, viability, and function	Standardized protocols essential for cross-study comparisons

The landscape of MSC cryopreservation is undergoing a significant transformation driven by innovations in DMSO-free and serum-free formulations. Current evidence demonstrates that defined, xeno-free alternatives can effectively maintain MSC viability, recovery, and critical immunomodulatory functions while mitigating safety concerns associated with conventional approaches.

The successful implementation of these advanced formulations requires careful attention to protocol optimization and comprehensive functional validation. As research continues to elucidate the intricate relationships between cryopreservation strategies and MSC immunobiology, the field moves closer to standardized, clinically compliant manufacturing processes that will enable the full therapeutic potential of mesenchymal stromal cells.

The advancement of mesenchymal stromal cell (MSC)-based therapies represents a paradigm shift in regenerative medicine and immunomodulation. These cells possess potent anti-inflammatory and immunomodulatory capabilities, making them invaluable assets for treating conditions ranging from graft-versus-host disease to Crohn's disease and COVID-19-related complications [35] [65]. The transition from laboratory research to clinical applications necessitates reliable preservation methods, with cryopreservation emerging as the cornerstone for maintaining cell viability and function during storage and transport. However, the freeze-thaw process presents substantial challenges to MSC integrity and, crucially, to their immunomodulatory properties.

Recent studies have demonstrated that cryogenic procedures can irreversibly damage cells, potentially compromising their viability and functionality after thawing [65]. Of particular concern is the emerging understanding that cryopreservation and thawing may dampen MSC immunomodulatory and anti-inflammatory activity even after reactivation procedures [65]. This technical guide comprehensively addresses these challenges by examining the critical parameters of cooling rates, storage conditions, and thawing methods, with particular emphasis on preserving the immunomodulatory properties that underpin MSC therapeutic efficacy.

Fundamental Principles of MSC Cryopreservation

Mechanisms of Cell Damage During Cryopreservation

The cryopreservation process subjects cells to multiple physical stresses that can compromise their viability and functionality. During freezing, two primary mechanisms of cell damage occur: dehydration and intracellular ice formation. At slow cooling rates, extracellular water freezes first, increasing the concentration of dissolved solutes in the remaining liquid. This creates an osmotic gradient that draws water out of cells, leading to excessive dehydration and solute concentration effects. Conversely, at rapid cooling rates, water within cells does not have sufficient time to exit, resulting in lethal intracellular ice crystal formation that disrupts membrane structures and organelles [62]. Both scenarios pose significant threats to MSC integrity, particularly to their delicate membrane structures and secretory apparatus essential for paracrine signaling.

The immunomodulatory functions of MSCs are especially vulnerable to cryopreservation-induced damage. These functions largely depend on the cell's ability to produce and secrete trophic factors, express surface molecules involved in immune interactions, and respond dynamically to inflammatory cues. Any compromise to cellular machinery through ice crystal damage or osmotic stress may therefore diminish the therapeutic potency of MSC products, even when basic viability metrics appear acceptable [40] [65].

Cryoprotective Agents: Types and Mechanisms

Cryoprotective agents (CPAs) are essential components of cryopreservation protocols, functioning to minimize freezing damage through several mechanisms. These compounds can be broadly categorized into two classes based on their cellular permeability:

Table 1: Classification of Cryoprotective Agents for MSC Cryopreservation

Category	Mechanism of Action	Examples	Advantages	Disadvantages
Penetrating (Endocellular) CPAs	Enter cells and bind intracellular water, reducing ice crystal formation	DMSO, glycerol, ethylene glycol, propylene glycol	Effective at preventing intracellular ice formation	Higher toxicity, especially at elevated concentrations
Non-Penetrating (Exocellular) CPAs	Remain outside cells, creating osmotic gradient for controlled dehydration	Sucrose, trehalose, ficoll, hydroxyethyl starch, human serum albumin	Lower toxicity, protects against extracellular ice damage	Less effective at preventing intracellular ice formation alone

Penetrating CPAs like dimethyl sulfoxide (DMSO) function by readily crossing cell membranes and forming hydrogen bonds with intracellular water molecules, thereby reducing the freezing point and minimizing ice crystal formation [62]. However, these compounds exhibit concentration-dependent toxicity and can trigger undesirable cellular responses. For instance, DMSO has been shown to increase mRNA levels of the de novo DNA methyltransferase Dnmt3a, accompanied by hyper- or hypomethylation of numerous genetic loci [73]. Non-penetrating CPAs operate primarily in the extracellular space, where they colligatively reduce the electrolyte concentration to which cells are exposed during freezing and modify ice crystal formation dynamics [62]. The optimal cryopreservation strategy typically employs a balanced combination of both CPA types to maximize protection while minimizing toxicity.

Optimization of Cooling Rates and Storage Conditions

Slow Freezing Methodologies

The slow freezing approach represents the most widely adopted method for MSC cryopreservation in both clinical and research settings. This technique involves controlled cooling at rates typically between -1°C/min to -3°C/min, allowing sufficient time for cellular dehydration and minimizing lethal intracellular ice formation [35]. The standard protocol involves mixing MSCs with CPAs, followed by progressive cooling: initially at 4°C for a period, then gradual cooling to -80°C, and finally transfer to liquid nitrogen (-196°C) for long-term storage [35]. This method yields approximately 70-80% cell survival when properly optimized [35].

The cooling rate represents a critical parameter that must be precisely controlled. Rates that are too rapid result in insufficient dehydration and intracellular ice formation, while excessively slow rates prolong exposure to concentrated solutes and cryoprotectant toxicity. For most MSC types, the optimal cooling rate falls within -1°C to -2°C per minute through the critical phase where intracellular water undergoes phase transition [74] [75]. Several devices have been developed to achieve this controlled cooling, including programmable freezing equipment and passive cooling devices such as the "box-in-box" system or alcohol-based containers (e.g., "Mr. Frosty") [75].

Vitrification Approaches

Vitrification represents an alternative approach that utilizes high CPA concentrations and ultra-rapid cooling rates to transform cellular solutions directly into a glassy, amorphous solid state without ice crystal formation [35]. This method employs substantially higher cooling rates (often exceeding -10,000°C/min) combined with elevated CPA concentrations to achieve this vitreous state. Two primary vitrification strategies exist: equilibrium vitrification, which balances cells with specific CPA formulations through controlled concentration and penetration time before rapid freezing; and non-equilibrium vitrification, which prioritizes cooling rate and high CPA concentrations for immediate vitrification upon liquid nitrogen immersion [35].

While vitrification effectively avoids ice crystal damage, it introduces other challenges including CPA toxicity at high concentrations and potential devitrification (ice formation during warming) if rewarming is not sufficiently rapid. Additionally, technical difficulties in handling small volumes and ensuring uniform ultra-rapid cooling limit its application for large-scale MSC banking. Consequently, slow freezing remains the preferred method for most MSC clinical applications despite ongoing research to refine vitrification protocols [35].

Storage Conditions and Duration

Post-freezing storage conditions significantly impact long-term MSC viability and functionality. Liquid nitrogen storage, either in the vapor phase (typically -150°C to -196°C) or liquid phase (-196°C), represents the gold standard for long-term preservation [74]. While both approaches effectively halt metabolic activity, practical considerations favor vapor phase storage to minimize contamination risks from liquid nitrogen [74].

Storage duration represents another critical variable. Analysis of cryopreserved cell banks has demonstrated that storage durations of 0-6 months typically yield the highest cell attachment rates post-thaw, with some studies reporting maintained viability and functionality for periods exceeding 24 months [74]. However, specific data on the maximum safe storage duration while maintaining immunomodulatory potency remains limited and represents an area requiring further investigation.

Table 2: Optimized Cooling Rates and CPA Formulations for Different MSC Types

MSC Source	Optimal Cooling Rate	Recommended CPA Formulation	Cell Recovery	Key Findings
Bone Marrow-derived MSCs	-1°C/min	300 mM ethylene glycol, 1 mM taurine, 1% ectoine (SEGA)	Significantly higher than DMSO controls	Algorithm-optimized formulation preserved functionality better than standard DMSO [73]
Adipose-derived MSCs	-1°C to -2°C/min	Saline with 10% DMSO, 2% HSA	>90% viability	Maintained immunophenotype and anti-inflammatory properties [65]
Various Tissue Sources	-1°C/min	FBS + 10% DMSO	70-80% survival	Standard approach suitable for most MSC types [35]
Jurkat Cells (Reference)	-10°C/min	300 mM trehalose, 10% glycerol, 0.01% ectoine (TGE)	Higher than DMSO at 1°C/min	Cell-type specific optimization crucial [73]

Thawing and Post-Thaw Processing

Thawing Methodologies

The thawing process represents a critical phase where cells are particularly vulnerable to osmotic and mechanical stress. Standard protocols recommend rapid thawing by gently swirling cryovials in a 37°C water bath until ice crystals are completely dissolved (typically requiring less than one minute) [35] [74]. This rapid warming minimizes the devitrification and recrystallization phenomena that can occur during slower warming procedures.

To enhance safety and reduce contamination risk, the use of drying heating equipment instead of water baths has been proposed, particularly in clinical settings [35]. Consistent and uniform warming is essential to prevent localized temperature variations that could compromise cell viability. After complete thawing, immediate dilution of CPAs is necessary to reduce their toxic effects, preferably through dropwise addition of pre-warmed isotonic solution containing protein [76].

Post-Thaw Reconstitution and Storage

Post-thaw handling significantly influences MSC recovery and functionality. Research has demonstrated that the presence of protein in the thawing solution is essential, with up to 50% cell loss occurring when protein-free solutions are used [76] [64]. Human serum albumin (HSA) at 2% concentration effectively prevents thawing- and dilution-induced cell loss [76].

Reconstitution solution composition critically determines post-thaw stability. Isotonic saline has emerged as a superior option compared to phosphate-buffered saline (PBS) or culture medium, ensuring >90% viability with minimal cell loss for at least 4 hours at room temperature [76] [64]. Cell concentration during reconstitution represents another crucial parameter, with dilution to concentrations below 10^5 cells/mL in protein-free vehicles resulting in instant cell loss exceeding 40% and viability below 80% [76].

Table 3: Optimized Thawing and Reconstitution Parameters for MSCs

Parameter	Recommended Protocol	Impact on Cell Recovery	Effect on Immunomodulatory Properties
Thawing Method	Rapid warming in 37°C water bath with gentle agitation	Maintains high viability (>90%)	Preserves immediate responsiveness to inflammatory stimuli [35] [74]
Reconstitution Solution	Isotonic saline with 2% HSA	Prevents up to 50% cell loss during thawing	Maintains secretory function and surface marker expression [76] [64]
Post-Thaw Concentration	≥5×10^6 cells/mL for storage	Prevents instant cell loss (>40%)	Ensures sufficient cell numbers for therapeutic dosing [76]
Post-Thaw Storage Duration	≤4 hours at room temperature in isotonic saline	Maintains >90% viability with no significant cell loss	Limited data, but functionality may decline before viability [76]
CPA Removal	Centrifugation after initial dilution	Reduces DMSO toxicity	May reduce stress-induced alterations in immunomodulatory factor secretion [35]

Impact on MSC Immunomodulatory Properties

Functional Consequences of Cryopreservation

The effect of cryopreservation on MSC immunomodulatory properties represents a critical consideration for therapeutic applications. Current evidence suggests that properly optimized cryopreservation protocols maintain most MSC functions, including immunosuppressive capabilities, differentiation potential, and surface marker expression [40] [65]. However, subtle alterations in function may occur despite maintained viability and standard phenotypic markers.

Research specifically investigating fucosylated MSCs (FucMSCs) engineered for enhanced homing to inflammation sites has demonstrated that cryopreservation conditions significantly impact their anti-inflammatory potency [65]. These specialized cells maintained their immunomodulatory capabilities, including suppression of T-cell proliferation and monocyte inflammatory responses, when cryopreserved using optimized protocols incorporating protein-containing solutions and appropriate cooling rates [65]. This finding underscores the importance of tailoring cryopreservation methods to specific MSC populations and modifications.

Protocol Standardization for Clinical Applications

The transition from research to clinical applications necessitates standardized, reproducible cryopreservation protocols that consistently maintain MSC immunomodulatory properties. Significant variability currently exists in cryopreservation methods, including CPA composition, freezing protocols, storage conditions, and thawing procedures [62] [40]. This variability complicates comparison between studies and introduces uncertainty in therapeutic efficacy.

Development of clinical-grade protocols utilizing defined, xeno-free components represents an essential step toward standardization [76] [65]. The incorporation of human platelet lysate instead of fetal bovine serum, clinical-grade HSA, and defined cryoprotectant mixtures enhances both safety and consistency [76] [65]. Furthermore, protocol simplification improves reproducibility across different laboratories and clinical sites, facilitating the broader application of MSC-based therapies.

Experimental Protocols and Methodologies

Algorithm-Driven Protocol Optimization

Traditional empirical approaches to cryopreservation optimization are time-consuming and often fail to identify truly optimal conditions. Recent advances employ computational algorithms, such as differential evolution (DE) algorithms, to efficiently navigate the multidimensional parameter space of cryopreservation variables [73]. This approach systematically varies solution components and cooling rates to identify optimal combinations with significantly fewer experiments than traditional methods.

The DE methodology involves randomly generating an initial population of solution vectors spanning the parameter space, freezing cells according to these parameters, measuring outcomes (typically live cell recovery), and iterating this process until convergence identifies optimal conditions [73]. Application of this approach to MSC cryopreservation identified an optimal formulation containing 300 mM ethylene glycol, 1 mM taurine, and 1% ectoine (SEGA) cooled at 1°C/min, which outperformed standard DMSO-containing formulations [73]. This methodology can be adapted to optimize for specific functional outcomes beyond simple viability, including preservation of immunomodulatory properties.

Comprehensive Workflow for MSC Cryopreservation

MSC Cryopreservation Workflow and Critical Parameters

Assessment of Post-Thaw Functionality

Comprehensive evaluation of cryopreserved MSCs must extend beyond simple viability metrics to include functional assessments of immunomodulatory capacity. Key assays should include:

• Immunophenotype Characterization: Flow cytometry analysis of standard positive (CD73, CD90, CD105) and negative (CD45, CD34, CD14, CD11b, CD79a, HLA-DR) markers to confirm maintained phenotype [35] [65].
• Immunosuppressive Function: In vitro suppression assays measuring inhibition of T-cell proliferation and modulation of monocyte/macrophage responses [65].
• Secretory Profile: Analysis of cytokine and trophic factor secretion patterns under inflammatory stimulation [40] [65].
• Differentiation Potential: Assessment of adipogenic, osteogenic, and chondrogenic differentiation capacity [35] [40].
• Senescence and Apoptosis: Evaluation of senescence-associated markers and apoptotic activity post-thaw [65].

These functional assessments provide critical information about the therapeutic potential of cryopreserved MSCs beyond basic viability measurements, ensuring that cells maintain their immunomodulatory properties after freeze-thaw cycles.

Essential Research Reagents and Tools

Table 4: Essential Research Reagent Solutions for MSC Cryopreservation

Reagent/Tool	Function	Examples/Specifications	Application Notes
Penetrating CPAs	Intracellular ice formation prevention	DMSO, glycerol, ethylene glycol	DMSO concentration typically 5-10%; clinical-grade preferred for therapeutics [62]
Non-Penetrating CPAs	Extracellular protection, osmotic buffering	Sucrose, trehalose, HSA, hydroxyethyl starch	Trehalose concentration 300 mM in optimized formulations [73]
Protein Supplement	Membrane stabilization during thawing	Human serum albumin (2%), human platelet lysate	Essential for preventing cell loss during thawing [76]
Basal Solutions	Isotonic environment for cryopreservation	Saline, Ringer's acetate, PBS	Isotonic saline superior to PBS for post-thaw storage [76]
Controlled-Rate Freezers	Precise cooling rate control	Programmable freezers, "box-in-box" devices, alcohol chambers	Cooling rate -1°C to -2°C/min optimal for most MSCs [75]
Storage Systems	Long-term preservation at ultra-low temperatures	Liquid nitrogen tanks (vapor or liquid phase)	Vapor phase reduces contamination risk [74]

The optimization of freeze-thaw cycles for MSCs represents a critical frontier in translational regenerative medicine. As research continues to elucidate the subtle effects of cryopreservation on MSC immunomodulatory properties, protocol refinement remains essential for clinical success. The integration of algorithmic optimization approaches, standardized functional assessments, and clinical-grade reagents will advance the field toward more reliable and potent MSC-based therapeutics. Future research directions should prioritize the development of precision cryopreservation protocols tailored to specific MSC subpopulations and clinical indications, with particular emphasis on maintaining the delicate functional attributes that underpin their therapeutic mechanism of action.

The development of Mesenchymal Stromal Cell (MSC)-based therapies represents a frontier in regenerative medicine and immunomodulation. As these advanced therapeutic products move toward clinical application, establishing robust quality control assays that accurately reflect biological potency becomes paramount. This is particularly crucial for monitoring how critical manufacturing processes like cryopreservation impact MSC functionality. Researchers and drug development professionals must understand that functional potency is not merely a regulatory checkbox but a fundamental assessment of therapeutic potential. The dual challenge in the field involves developing assays that are both predictive of in vivo efficacy and practical for routine testing, especially when MSC products are used immediately post-thaw in "off-the-shelf" therapeutic scenarios [77] [11].

The central role of immunomodulation as a primary mechanism of action for MSCs necessitates that potency tests specifically evaluate this functionality. Current evidence indicates that cryopreservation can significantly alter MSC biology, potentially affecting cell surface markers, secretory profiles, and responsiveness to inflammatory signals [19] [11]. Some studies report that freshly thawed MSCs exhibit impaired immunomodulatory function, including reduced responsiveness to interferon-γ (IFN-γ) and diminished production of anti-inflammatory mediators like indoleamine 2,3-dioxygenase (IDO) [11] [18]. Consequently, potency assays must be strategically designed to detect these cryopreservation-induced changes, ensuring that manufactured products consistently deliver the intended therapeutic effect.

The Impact of Cryopreservation on MSC Immunomodulatory Properties

Cryopreservation, while essential for storage and distribution, imposes significant stress on MSCs, potentially altering their critical therapeutic attributes. A growing body of research presents a complex picture of how freezing and thawing processes affect MSC immunomodulatory function, with implications for both product development and clinical application.

Documented Detrimental Effects of Freeze-Thaw Cycles

Multiple independent studies have demonstrated that the cryopreservation process can transiently impair key MSC functions. One comprehensive analysis revealed that freeze-thawed MSCs showed reduced responsiveness to proinflammatory stimuli and an impaired production of anti-inflammatory mediators compared to their freshly harvested counterparts [11]. This same study found that cryopreserved cells demonstrated increased triggering of the Instant Blood-Mediated Inflammatory Reaction (IBMIR) and a stronger activation of the complement cascade, resulting in twice the efficiency in lysis of thawed MSCs after one hour of serum exposure [11].

Further research examining human bone-marrow-derived MSCs immediately post-thaw (termed "Freshly Thawed" or FT cells) found significant reductions in CD44 and CD105 surface markers, increased apoptosis, decreased cell proliferation, and reduced expression of key regenerative genes [19] [4]. These phenotypic and functional changes translated to diminished capacity in functional assays, with FT MSCs showing significantly reduced clonogenic capacity and impaired secretion of IFN-γ, a critical immunomodulatory cytokine [4].

Recovery and Alternative Findings

Importantly, evidence suggests that many cryopreservation-induced impairments may be transient. Several studies indicate that allowing a post-thaw acclimation period of 24-48 hours can facilitate significant functional recovery [19] [4] [18]. One study design compared three groups: Fresh Cells (FC), Thawed + Time (TT, acclimated 24h), and Freshly Thawed (FT). The TT group showed significantly reduced apoptosis with concomitant upregulation in angiogenic and anti-inflammatory genes compared to the FT group [4]. While all MSC groups arrested T-cell proliferation, the TT MSCs were significantly more potent than FT MSCs [4].

Some reports present conflicting data, suggesting that with optimized cryopreservation protocols, thawed MSCs can maintain functionality. One study found that when viability is maintained >95% post-thaw, MSCs remained responsive to inflammatory signals and were able to suppress activated peripheral blood mononuclear cells (PBMCs) [18]. Another investigation reported that thawed and cultured MSCs exhibited comparable immunomodulatory efficacy in both in vitro assays and in vivo septic animal models [23].

Table 1: Comparative Effects of Cryopreservation on MSC Immunomodulatory Properties

Functional Aspect	Freshly Thawed MSCs	Post-Thaw Acclimated MSCs (24h)	Key Findings
Cell Surface Markers	Decreased CD44, CD105 [4]	Recovered to fresh cell levels [4]	Phenotype alterations may be transient
Apoptosis	Significantly increased [4]	Significantly reduced [4]	Early apoptosis peaks immediately post-thaw
T-cell Suppression	Maintained but reduced potency [4] [18]	Enhanced potency, comparable to fresh [4]	All MSC types suppress, but efficacy varies
Anti-inflammatory Mediators	Reduced IFN-γ secretion [4], Impaired IDO production [11]	Recovered production [4] [18]	Responsiveness to inflammatory signals may be impaired
Complement Activation	Increased triggering of IBMIR [11]	Not specifically reported	Contributes to rapid clearance post-infusion
Metabolic Activity	Significantly decreased [4]	Recovered toward fresh cell levels [4]	Metabolic stress is temporary

Established Functional Potency Assays for Immunomodulation

To effectively evaluate MSC immunomodulatory capacity, particularly in the context of cryopreservation effects, researchers employ a suite of functional assays that measure different aspects of immune modulation.

T-cell Proliferation Suppression Assay

The T-cell proliferation suppression assay represents the gold standard for assessing MSC immunomodulatory potency. This assay measures the ability of MSCs to suppress the proliferation of activated immune cells, primarily T-lymphocytes [77] [18].

Detailed Protocol:

• PBMC Preparation: Isolate PBMCs from human blood using Ficoll-Paque density gradient centrifugation. Cryopreserve PBMCs in CryoStor10 at 1°C/min cooling rate and store in liquid nitrogen until use [77].
• MSC Preparation: Culture test MSCs (fresh, freshly thawed, or post-thaw acclimated) in 96-well plates for 24 hours prior to assay initiation [77].
• Co-culture Establishment: Add freshly thawed PBMCs (150,000 cells/well) to MSC cultures at varying MSC:PBMC ratios (typically 1:3 to 1:50) [77] [18].
• T-cell Activation: Stimulate PBMCs with mitogens such as phytohemagglutinin (PHA) or anti-CD3/CD28 antibodies [77].
• Proliferation Measurement: After 3-5 days of co-culture, measure proliferation using one of several methods:
  • ATP-based luminescence at 72 hours [77]
  • CFSE dilution by flow cytometry at 96 hours [77]
  • Bromodeoxyuridine (BrdU) incorporation [77]
• Data Analysis: Calculate percentage suppression relative to activated PBMCs without MSCs.

This assay directly tests a key mechanism of MSC-mediated immunomodulation and can detect cryopreservation-induced functional deficits. Studies using this method have demonstrated that while freshly thawed MSCs maintain some capacity to suppress T-cell proliferation, their potency is often reduced compared to fresh or acclimated cells [4] [18].

Cytokine Secretion Profiling

The cytokine secretion profile of MSCs in response to inflammatory stimulation provides critical insight into their functional potency. This assay measures the production of key immunomodulatory factors that mediate MSC therapeutic effects.

Detailed Protocol:

• MSC Stimulation: Culture MSCs with pro-inflammatory cytokines such as IFN-γ (50 ng/mL) and/or TNF-α (10 ng/mL) for 24-72 hours [18].
• Supernatant Collection: Collect conditioned media at specified time points (e.g., 24, 48, 72 hours).
• Cytokine Measurement: Quantify analyte concentrations using:
  • ELISA for specific cytokines (e.g., IDO via kynurenine production [18])
  • Multiplex bead-based arrays for broader profiling [61]
• Data Interpretation: Compare secretion profiles between experimental groups (fresh vs. cryopreserved).

Cryopreservation has been shown to alter the secretory profile of MSCs, particularly immediately post-thaw. One study reported that IDO expression, a critical immunomodulatory enzyme, was maintained in cryopreserved MSCs when properly processed, though other studies have noted impairments [18].

Short-Term Potency Assays

Traditional T-cell proliferation assays require 3-7 days to complete, creating a significant bottleneck in product release testing. Recent advances have focused on developing short-term potency assays that provide results within 24 hours, making them particularly valuable for assessing cryopreserved products destined for immediate clinical use [77].

Phosphatidyl Serine Externalization Assay:

• Principle: Measures externalization of phosphatidylserine on activated T-cells, an early event in immune activation [77].
• Procedure: Co-culture MSCs with PBMCs mitogen for 2-24 hours, stain with Annexin V, and analyze by flow cytometry focusing on live CD3+ or CD4+/CD3+ populations [77].
• Advantage: Detection possible as early as 2 hours; MSC suppression of PS externalization is dose-dependent and reproducible [77].

TNF-α Release Assay:

• Principle: Quantifies tumor necrosis factor-alpha production by activated PBMCs [77].
• Procedure: Co-culture MSCs with PBMCs for 24 hours with mitogen stimulation; measure TNF-α in supernatant using rapid ELISA [77].
• Advantage: Accumulating signal over time with robust detection of MSC-mediated suppression at 24 hours [77].

These short-term assays correlate well with longer proliferation assays and can effectively discriminate between functional and impaired MSCs, making them particularly valuable for quality control of cryopreserved products [77].

Table 2: Comparison of Functional Potency Assays for MSC Immunomodulation

Assay Type	Duration	Key Measured Parameters	Advantages	Limitations
T-cell Proliferation Suppression	3-7 days	Percentage suppression of activated PBMC proliferation [77]	Gold standard, direct functional measure	Time-consuming, variable donor responses
Cytokine Secretion Profiling	24-72 hours	IDO activity, PGE2, TGF-β, IL-10, etc. [18]	Mechanistic insight, quantifiable	May not reflect integrated function
Phosphatidyl Serine Externalization	2-24 hours	PS exposure on live CD3+ cells [77]	Rapid, flow cytometry-based	Early activation marker only
TNF-α Release Assay	24 hours	TNF-α concentration in supernatant [77]	Rapid, robust, ELISA platform	Single parameter measurement
Phagocytosis Restoration Assay	24 hours	Recovery of monocyte phagocytic capacity [23]	Measures innate immune modulation	Complex flow cytometry setup

The Scientist's Toolkit: Essential Reagents and Materials

Successful implementation of potency assays requires specific, quality-controlled reagents and materials. The following table details essential components for establishing these critical quality control measures.

Table 3: Research Reagent Solutions for MSC Immunomodulation Potency Testing

Reagent/Material	Function/Application	Specification Notes
Peripheral Blood Mononuclear Cells	Immune effector cells for co-culture assays [77]	Cryopreserved pools of 8-10 donors recommended for consistency [77]
Mitogens	T-cell activation for suppression assays [77]	PHA-P, PHA-L, or anti-CD3/CD28 antibodies [77]
Cell Culture Plates	Platform for co-culture experiments [77]	96-well flat-bottomed, tissue culture treated [77]
Flow Cytometry Antibodies	Cell phenotyping and activation marker detection [77] [4]	CD3, CD4, CD14, CD73, CD90, CD105, Annexin V [77] [4]
ELISA Kits	Cytokine quantification [77]	TNF-α, IFN-γ, IDO (via kynurenine detection) [77] [18]
Cell Viability Stains	Assessment of cell health and apoptosis [4]	Acridine Orange/Propidium Iodide, Annexin V/PI, TUNEL assay [77] [4] [18]
Cryopreservation Media	MSC preservation for experimental comparisons [19] [61]	Typically 10% DMSO with protein source (FBS or human serum) [19] [61]
Differentiation Media	Multipotency confirmation post-thaw [4]	Osteogenic, chondrogenic, adipogenic induction cocktails [4]

Experimental Design and Workflow Considerations

Establishing a robust potency testing program requires careful experimental design and understanding of the complex relationships between assay components. The following workflow diagrams illustrate key processes and decision points in MSC potency evaluation.

Potency Assay Selection and Implementation Workflow

Cryopreservation Impact Assessment Strategy

Functional potency testing for MSC immunomodulation represents a critical component in the development of reproducible, efficacious cell therapies. The evidence clearly demonstrates that cryopreservation significantly impacts MSC immunomodulatory properties, though the extent and duration of these effects vary based on processing parameters, cell source, and specific functional endpoints measured. The implementation of robust, potentially short-term potency assays that can predict in vivo performance remains essential for quality control, particularly for products used immediately post-thaw.

Future directions in the field include the development of standardized assay platforms that can be validated across manufacturing facilities, the identification of critical quality attributes beyond basic immunomodulation, and the establishment of correlations between in vitro potency measures and clinical outcomes. As the understanding of MSC mechanisms deepens, potency assays will likely evolve beyond T-cell suppression to include measures of innate immune modulation, tissue protective factor secretion, and extracellular vesicle production. Through continued refinement of these critical quality control tools, the field will advance toward more reliable, potent, and consistent MSC-based therapies that fulfill their promise in regenerative medicine and immunomodulation.

The therapeutic potential of mesenchymal stem cells (MSCs) hinges significantly on their immunomodulatory properties, which enable them to interact with various immune cells and release bioactive molecules that suppress inflammation and promote tissue repair [21]. Cryopreservation serves as a pivotal bridge between MSC production and clinical application, creating "off-the-shelf" therapies ready for urgent medical situations [7] [14]. However, the process itself presents a fundamental paradox: while essential for practical clinical use, cryopreservation introduces variables that may alter the very biological properties that make MSCs therapeutically valuable [2]. Current evidence reveals significant challenges in MSC cryopreservation standardization, including the use of cytotoxic cryoprotectants like dimethyl sulfoxide (DMSO), formation of damaging ice crystals, and osmotic stress during freezing and thawing, all of which can compromise cell viability and functionality [2] [78]. This technical guide examines emerging technologies and standardization approaches designed to preserve and enhance MSC immunomodulatory properties post-thaw, thereby addressing a critical bottleneck in regenerative medicine.

Current Understanding of Cryopreservation Effects on MSC Immunomodulatory Properties

The effect of cryopreservation on MSC functionality has been the subject of extensive preclinical investigation. A comprehensive systematic review of in vivo models of inflammation found that the vast majority (97.7%) of efficacy outcomes showed no statistically significant difference between freshly cultured and cryopreserved MSCs [7]. Among the limited number of outcomes that did show significant differences, the results were split between favoring fresh (2 outcomes) and cryopreserved (4 outcomes) products [7]. This suggests that cryopreservation does not systematically diminish MSC therapeutic efficacy in most applications.

However, in vitro analyses reveal a more nuanced picture, with 13% of potency assays demonstrating significant differences, the majority of which favored freshly cultured MSCs [7]. This discrepancy between in vivo efficacy and in vitro potency measurements underscores the complexity of evaluating cryopreservation effects and highlights the necessity for more predictive potency assays that better correlate with clinical outcomes.

Specific Effects on Immunomodulatory Markers and Pathways

Cryopreservation exerts specific effects on critical immunomodulatory pathways in MSCs. The process can influence the expression of key surface markers and secretion of immunomodulatory factors that mediate MSC interactions with immune cells. Research indicates that cryopreserved MSCs maintain their capacity to express crucial immunomodulatory factors such as prostaglandin E2 (PGE2), tumor necrosis factor-stimulated gene 6 (TSG-6), indoleamine 2,3-dioxygenase (IDO), and vascular endothelial growth factor (VEGF) when stimulated by inflammatory cues [79]. These molecules collectively orchestrate immune suppression through multiple mechanisms including macrophage polarization toward anti-inflammatory M2 phenotypes, inhibition of natural killer cell activity, suppression of T-cell proliferation, and reduction of monocyte recruitment [79].

Interestingly, some studies have documented increased expression of certain mesenchymal progenitor cell-associated markers after cryopreservation. CD73 expression significantly increases on the CD31highCD34high subset of endothelial progenients and supra-adventitial adipose stromal cells (SA-ASC) in thawed microfragmented adipose tissue, while CD105 expression shows significant elevation across multiple progenitor cell populations [78]. Since CD73 and CD105 function as key mediators of immunomodulatory responses, their altered expression patterns post-thaw may represent an adaptive response to cryopreservation stress that could potentially enhance certain immunomodulatory functions.

Table 1: Effects of Cryopreservation on Key MSC Immunomodulatory Properties

Parameter	Impact of Cryopreservation	Functional Significance
Viability	~50% cell loss in MFAT; no significant difference in viability of surviving cells [78]	Impacts dosing requirements for clinical applications
CD73 Expression	Significantly increased on specific progenitor subsets [78]	May enhance adenosine-mediated immunosuppression
CD105 Expression	Significantly increased on multiple progenitor populations [78]	Potential enhancement of TGF-β signaling and immunomodulation
PGE2 Secretion	Maintained after cryopreservation [79]	Supports macrophage polarization and NK cell inhibition
TSG-6 Production	Preserved upon inflammatory stimulation [79]	Maintains anti-inflammatory and anti-recruitment functions
In Vivo Efficacy	No significant difference in 97.7% of preclinical outcomes [7]	Supports clinical translatability of cryopreserved products

Advanced Cryopreservation Technologies

Novel Cryoprotectant Formulations

The development of advanced cryoprotectant formulations represents a critical frontier in preserving MSC immunomodulatory function. While DMSO remains the most widely used cryoprotectant at concentrations typically ranging from 10-15% [78] [80], its toxicity presents significant limitations. DMSO has been associated with alterations in miRNA expression and epigenetic modifications, potentially affecting the fundamental biology of MSCs [78]. Clinical concerns include triggering allergic responses in patients receiving DMSO-containing cell products [2].

Research into alternative cryoprotectants reveals a complex trade-off between toxicity and efficacy. Comparative studies of glycerol, DMSO, ethylene glycol, and propylene glycol show that while glycerol exhibits the lowest cellular toxicity, it produces the worst cryopreservation effects, whereas DMSO demonstrates superior protective capabilities despite its higher toxicity profile [2]. This has spurred investigation into combination approaches using permeating cryoprotectants like DMSO with non-permeating agents such as sucrose or trehalose, which provide extracellular protection and reduce osmotic stress [2]. The development of completely defined, xeno-free cryoprotectant formulations remains an active area of investigation aimed at addressing both regulatory concerns and functional preservation.

Advanced Physical Processing Methods

Controlled Ice Nucleation

Traditional slow freezing methods aim to minimize intracellular ice crystal formation through gradual cooling rates (typically -1°C to -3°C/min), but often fail to prevent damaging ice crystallization completely [2]. Advanced controlled ice nucleation technologies now enable precise management of the ice formation process through:

• Seeded Ice Nucleation: Introduction of ice nuclei at specific temperatures to control crystallization kinetics
• Electromagnetic Field-Assisted Freezing: Application of external fields to organize ice crystal formation
• Pressure-Shift Techniques: Use of pressure fluctuations to regulate supercooling and ice growth

These approaches significantly reduce mechanical damage to cytoskeletal structures and preserve membrane integrity, thereby maintaining surface receptor function essential for immunomodulatory signaling.

Vitrification Techniques

Vitrification represents a fundamentally different approach that avoids ice crystallization entirely by achieving an amorphous glassy state through ultra-rapid cooling combined with high cryoprotectant concentrations [2]. Two primary methodologies have emerged:

• Equilibrium Vitrification: Focuses on achieving osmotic balance between cells and cryoprotectant formulations before freezing, allowing full dehydration and minimizing osmotic stress [2]
• Non-Equilibrium Vitrification: Emphasizes extremely rapid cooling rates combined with high cryoprotectant concentrations to achieve the glassy state almost instantaneously [2]

While vitrification shows promise for reducing cryoinjury, technical challenges remain in scaling the approach for clinical-grade MSC production and ensuring uniform warming to prevent recrystallization during the thawing process.

Post-Thaw Recovery Optimization

The post-thaw recovery period represents a critical window for preserving MSC immunomodulatory competence. Evidence suggests that cryopreserved MSCs may require up to 24 hours of culture post-thaw to fully recover their functionality [7] [14]. Advanced recovery protocols now incorporate:

• Cytokine Priming: Brief exposure to specific cytokines (IFN-γ, TNF-α) to enhance immunomodulatory marker expression
• Metabolic Support: Supplementation with mitochondrial protectants and antioxidants to support energy restoration
• Biomaterial Scaffolds: Use of 3D matrices to provide structural support during recovery

Research demonstrates that embedding MSCs in collagen hydrogels of specific stiffness and seeding density can significantly enhance their immunomodulatory gene expression and matrix contraction capabilities following cryopreservation [79]. Lower collagen concentrations (3.0 mg/mL) combined with higher cell seeding densities (5-7×10^6 cells/mL) create an optimal microenvironment for post-thaw functional recovery [79].

Process Standardization Frameworks

Critical Process Parameters and Quality Attributes

Standardization of cryopreservation processes requires rigorous definition and control of both process parameters and critical quality attributes. The International Society for Cell & Gene Therapy (ISCT) has established minimal criteria for defining MSCs, including plastic adherence, specific surface marker expression (CD73+, CD90+, CD105+, CD45-, CD34-, CD14- or CD11b-, CD79α- or CD19-, HLA-DR-), and trilineage differentiation potential [21] [25]. For cryopreserved products, these criteria must be maintained post-thaw.

Table 2: Critical Quality Attributes for Cryopreserved MSCs with Immunomodulatory Functions

Category	Parameter	Target Specification	Analytical Method
Viability and Quantity	Post-thaw viability	≥70-80% [2]	Flow cytometry with AO/PI staining [78]
	Total nucleated cell count	Dose-dependent; minimal 50% recovery [78]	Automated cell counting/flow cytometry with counting beads [78]
Immunophenotype	CD73/CD90/CD105 expression	≥95% positive [21]	Multicolor flow cytometry
	Hematopoietic marker absence	≤2% positive [21]	Multicolor flow cytometry
	CD271+ stem cell population	Retention post-thaw [80]	Flow cytometry
Immunomodulatory Potency	IDO activity	Induction with IFN-γ stimulation [60]	HPLC/Kynurenine assay
	PGE2 secretion	Response to inflammatory cues [79]	ELISA
	T-cell suppression	Inhibition of proliferation [14]	Co-culture assay
Safety	Microbiological sterility	No microbial growth [78]	BacT/ALERT, Gram stain
	DMSO residue	≤1-5 μg/10^6 cells [78]	HPLC

Standardized Reporting Frameworks for Clinical Translation

The development of minimal reporting criteria for MSC clinical trials represents a significant advancement in standardizing the field. Recent ISCT workshops have emphasized the need for comprehensive reporting of critical parameters including [60]:

• Donor and Manufacturing Information: Age, sex, tissue source, culture expansion conditions, population doubling levels
• Cryopreservation Protocol: Cryoprotectant composition and concentration, cooling rate, storage temperature and duration, thawing method
• Product Characterization: Viability, immunophenotype, potency assays, and sterility testing results
• Functional Assessment: Standardized immunomodulatory potency assays relevant to clinical indication

For autoimmune disease applications, specific recommendations include standardizing IFN-γ priming protocols and reporting IDO activity as a key immunomodulatory mechanism [60]. These frameworks enable meaningful cross-study comparisons and meta-analyses essential for advancing the field.

Experimental Workflows for Evaluating Cryopreservation Effects

Comprehensive Assessment of Immunomodulatory Properties

Diagram 1: Comprehensive workflow for evaluating cryopreservation effects on MSC immunomodulatory properties. The red-to-green color transition in the potency assay cluster indicates increasing biological complexity in functional assessment.

Advanced 3D Functional Assessment Protocol

The evaluation of cryopreserved MSC function in three-dimensional environments provides critical insights into their therapeutic potential. The following protocol assesses immunomodulatory responses within collagen hydrogels [79]:

Materials Preparation:

• Neutralized collagen solution (3.0-4.0 mg/mL bovine dermis-derived atelocollagen)
• Cryopreserved MSCs (passage 4-6)
• Inflammatory priming cytokines (IFN-γ at 25 ng/mL, TNF-α at 10 ng/mL)
• Low-glucose DMEM with 1% FBS and 1% penicillin-streptomycin

Experimental Procedure:

• Cell Preparation: Thaw cryopreserved MSCs and allow 24-hour recovery in complete growth medium.
• Hydrogel Formation: Mix neutralized collagen solution with MSCs at densities of 1×10^6 to 7×10^6 cells/mL.
• Gelation: Dispense 100 μL mixtures into 96-well plates and incubate at 37°C for 1 hour.
• Inflammatory Stimulation: Add medium containing IFN-γ and TNF-α, replace every 48 hours.
• Functional Assessment:
  • Hydrogel Contraction: Measure area reduction daily using ImageJ software.
  • Gene Expression: Analyze immunomodulatory genes (IDO, PGE2, TSG-6) at 24 hours and 5 days.
  • Cell Viability: Assess using CCK-8 assay or calcein-AM/PI staining.
  • Secretome Analysis: Collect conditioned medium for ELISA quantification of immunomodulatory factors.

Quality Controls:

• Include freshly cultured MSCs as comparator
• Validate collagen lot consistency via rheometer analysis of elastic modulus
• Monitor hydrogel contraction kinetics as functional readout of MSC responsiveness

The Scientist's Toolkit: Essential Research Reagents

Table 3: Essential Research Reagents for Evaluating Cryopreserved MSC Immunomodulatory Properties

Reagent Category	Specific Examples	Function & Application
Cryoprotectants	DMSO, trehalose, glycerol, ethylene glycol	Protect against ice crystal formation; require concentration optimization and toxicity assessment [2] [78]
Viability Assays	Acridine Orange/Propidium iodide, DRAQ5, Calcein-AM/PI, CCK-8	Distinguish live/dead cells; assess metabolic activity post-thaw [79] [78]
Flow Cytometry Antibodies	CD73, CD90, CD105, CD34, CD45, CD14, CD19, CD31, CD146, CD271, HLA-DR	Verify immunophenotype per ISCT criteria; identify subpopulations [78] [21] [80]
Inflammatory Primers	Recombinant human IFN-γ, TNF-α	Activate immunomodulatory pathways; potency assay preconditioning [79] [60]
ELISA Kits	PGE2, IDO/kynurenine, TSG-6, VEGF	Quantify secreted immunomodulatory factors [79] [14]
3D Culture Matrices	Bovine dermis-derived atelocollagen (3.0-4.0 mg/mL)	Mimic native extracellular matrix; study mechanotransduction effects on immunomodulation [79]
Cell Culture Media	DMEM-low glucose with 10% FBS, 1% penicillin-streptomycin	Maintain MSC phenotype and multipotency during recovery [79] [80]

Future Perspectives and Research Directions

The future of MSC cryopreservation research will likely focus on several key areas. First, the development of biomimetic cryoprotectant cocktails that specifically stabilize immunomodulatory pathways rather than merely preserving structural integrity represents a promising direction. These advanced formulations may include molecular chaperones that protect key signaling complexes and transcription factors involved in immunoregulation.

Second, advanced potency assays that better predict in vivo efficacy must be standardized and validated. Current research suggests that 3D culture systems incorporating immune cell co-cultures provide more physiologically relevant assessments of MSC immunomodulatory function [79]. The integration of multi-omics approaches (transcriptomics, proteomics, metabolomics) to create comprehensive potency signatures will enable more precise quality control.

Finally, closed-system, automated cryopreservation platforms that minimize process variability will be essential for clinical translation. These systems should incorporate real-time monitoring of critical parameters during both freezing and thawing processes, enabling quality by design rather than retrospective quality testing. As the field progresses toward personalized cryopreservation protocols tailored to specific clinical indications, the standardization of these advanced technologies will be paramount for realizing the full therapeutic potential of MSC-based immunomodulatory therapies.

Fresh vs. Frozen: Comparative Analysis of Immunomodulatory Efficacy In Vitro and In Vivo

Mesenchymal stromal cells (MSCs) possess potent immunomodulatory capabilities, making them promising therapeutic agents for inflammatory and autoimmune conditions [15] [21]. Their therapeutic effects are primarily mediated through two key mechanisms: suppression of adaptive immune responses, particularly T-cell proliferation, and modulation of innate immunity via interactions with monocytes and macrophages [15]. These mechanisms form the basis of critical potency assays used to quality-control MSC products before clinical application.

The increasing reliance on cryopreserved, "off-the-shelf" MSC products introduces critical questions about how freeze-thaw cycles impact these immunomodulatory functions [7] [81]. Some studies suggest that cryopreservation may induce a temporary "stun" effect, potentially dampening MSC potency immediately post-thaw [65] [81]. This technical guide details the experimental methodologies for assessing T-cell suppression and monocyte phagocytosis enhancement, framing these assays within the essential investigation of how cryopreservation affects MSC immunomodulatory properties.

Core Immunomodulatory Mechanisms of MSCs

T-Cell Suppression by MSCs

MSCs inhibit the proliferation and activation of T lymphocytes through both cell-to-cell contact and paracrine secretion. Key contact-dependent mechanisms include engagement of the PD-1/PD-L1 pathway and activation of the Notch1/FOXP3 pathway, which promotes regulatory T-cell (Treg) generation [15]. Simultaneously, MSC-secreted factors like prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and transforming growth factor-β1 (TGF-β1) create an immunosuppressive microenvironment that inhibits effector T-cell function and supports Treg induction [15] [21].

Monocyte Interaction and Phagocytosis Enhancement

A pivotal mechanism of MSC action involves their rapid clearance by monocytes following administration. Tracking studies reveal that infused MSCs briefly reside in the lungs and are phagocytosed by monocytes, which subsequently migrate to various body sites [15]. This phagocytosis induces phenotypic and functional changes in monocytes, switching them from a pro-inflammatory M1-like phenotype to an anti-inflammatory M2-like phenotype via PGE2 secretion [15]. These reprogrammed monocytes then distribute and transfer the immunomodulatory effect of MSCs throughout the immune system.

The diagram below illustrates these two core mechanisms and their functional outcomes.

Quantitative Comparison of Cryopreservation Impact on MSC Potency

Systematic analyses of preclinical studies reveal that the majority of MSC immunomodulatory functions remain intact after cryopreservation. The table below summarizes key comparative findings between freshly cultured and cryopreserved MSCs.

Table 1: Impact of Cryopreservation on MSC Immunomodulatory Properties

Functional Category	Specific Assay/Outcome	Fresh vs. Cryopreserved Performance	Statistical Significance	Reference Support
In Vivo Efficacy	101 distinct outcome measures across disease models	94% (95/101) showed no significant difference	Only 6/257 outcomes significant (p<0.05)	[7]
In Vitro Potency	32 different potency measures	87% (59/68) showed no significant difference	9/68 experiments significant (p<0.05)	[7]
T-cell Suppression	Inhibition of lymphocyte proliferation	Cryopreserved & re-expanded MSCs retained suppression capability	~30% inhibition of metabolic activity maintained	[20]
T-cell Activation Markers	CD25 expression on CD3+CD4+ cells	Decreased expression in co-culture with cryopreserved MSCs	Statistical significance achieved	[20]
Monocyte/Macrophage Effects	Polarization to M2 phenotype	Cryopreserved MSCs retained capacity for macrophage reprogramming	Confirmed via cytokine secretion profiles	[15] [65]
Cell Viability	Post-thaw recovery	Viability typically >70-90% with optimized protocols	Varies with cryoprotectant solution	[2] [32] [20]

Experimental Protocols for Key Potency Assays

T-Cell Suppression Assay

This protocol evaluates the ability of MSCs to inhibit T-cell proliferation, a cornerstone of MSC immunomodulatory potency assessment.

Table 2: Research Reagent Solutions for T-Cell Suppression Assay

Reagent/Cell Type	Specification	Function in Assay
MSCs	Fresh vs. cryopreserved (thawed <24hr)	Test article for immunomodulatory function
Peripheral Blood Mononuclear Cells (PBMCs)	Isolated from healthy donors via Ficoll-Paque density gradient	Source of responder T-cells
T-cell Activator	Anti-CD3/CD28 beads or Phytohemagglutinin (PHA)	Polyclonal T-cell activation
Culture Medium	Alpha-MEM or RPMI-1640 with 10% FBS	Cell growth and maintenance environment
CFSE Dye	CellTrace CFSE Cell Proliferation Kit	Fluorescent labeling for tracking cell divisions
Analysis Method	Flow cytometry with proliferation markers	Quantification of T-cell division inhibition

Methodology:

• Prepare MSCs: Seed fresh or freshly thawed cryopreserved MSCs (cryopreserved for any duration and cultured <24 hours post-thaw) in 96-well plates at varying densities (typically 1:10 to 1:100 MSC:PBMC ratios) [7] [14].
• Isolate and Label PBMCs: Isulate PBMCs from healthy donor blood using Ficoll-Paque density gradient centrifugation. Label PBMCs with CFSE fluorescent dye according to manufacturer's protocol.
• Activate T-cells: Stimulate CFSE-labeled PBMCs with anti-CD3/CD28 beads (1 bead per T-cell) or PHA (1-5 μg/mL).
• Co-culture Setup: Add activated PBMCs to MSC-seeded wells. Include controls (PBMCs alone without MSCs, both stimulated and unstimulated).
• Incubation: Culture for 3-5 days at 37°C, 5% CO₂.
• Analysis: Harvest cells and analyze by flow cytometry. Measure CFSE dilution in CD3+ T-cells to determine proliferation index. Calculate percentage suppression relative to stimulated PBMCs without MSCs [15] [20].

Additional Assessments:

• Analyze T-cell activation markers (CD25, CD69) via flow cytometry [20].
• Measure cytokine profiles (IFN-γ, IL-10, IL-17) in supernatant by ELISA or multiplex assay [15].
• Evaluate regulatory T-cell induction (CD4+CD25+FOXP3+) [15].

Monocyte Phagocytosis Enhancement Assay

This protocol assesses the phagocytosis of MSCs by monocytes and the subsequent functional changes in monocytes, a critical mechanism for MSC-mediated immunomodulation.

Table 3: Research Reagent Solutions for Monocyte Phagocytosis Assay

Reagent/Cell Type	Specification	Function in Assay
MSCs	CM-Dil or PKH26 pre-labeled	Fluorescently-labeled target for phagocytosis
Monocytes	CD14+ isolated from PBMCs	Phagocytic effector cells
Separation Method	CD14+ magnetic bead isolation	Monocyte purification
Culture Medium	Serum-free or with 10% FBS	Phagocytosis environment
Flow Cytometry Antibodies	Anti-CD14, CD16, CD163, CD206	Monocyte phenotype analysis
Cytokine Measurement	IL-10, TNF-α, IL-12 ELISA	Functional polarization assessment

Methodology:

• Label MSCs: Pre-label MSCs with fluorescent membrane dyes (e.g., CM-Dil or PKH26) according to manufacturer protocols.
• Isolate Monocytes: Isolate CD14+ monocytes from PBMCs using magnetic-activated cell sorting (MACS) or adherence purification.
• Co-culture Setup: Seed fluorescently-labeled MSCs (fresh or cryopreserved) in culture plates and add monocytes at appropriate ratios (typically 1:5 to 1:10 MSC:monocyte).
• Incubation: Co-culture for 6-48 hours at 37°C, 5% CO₂.
• Phagocytosis Quantification: Harvest cells and analyze by flow cytometry. Measure percentage of CD14+ monocytes that are double-positive for the MSC fluorescent label. Confirm via confocal microscopy [15].
• Monocyte Phenotype Analysis: Assess surface expression of M2 markers (CD163, CD206) on monocytes that have phagocytosed MSCs compared to control monocytes.
• Functional Assessment: Measure secretion of anti-inflammatory (IL-10) versus pro-inflammatory (TNF-α, IL-12) cytokines by ELISA.

The experimental workflow for both assays, incorporating the cryopreservation variable, is illustrated below.

Impact of Cryopreservation on Assay Outcomes

Technical Considerations for Cryopreserved MSCs

When designing potency assays comparing fresh and cryopreserved MSCs, several technical factors significantly influence outcomes:

• Post-Thaw Recovery Time: Evidence suggests cryopreserved MSCs may require up to 24 hours of culture post-thaw to recover full functionality, as used in systematic review criteria [7] [14] [81]. The immediate "cryo-stun" effect may transiently reduce immunomodulatory capacity.
• Cryoprotectant Composition: Traditional DMSO-containing solutions (5-10%) are effective but carry potential toxicity concerns. Novel DMSO-free solutions containing sucrose, glycerol, and isoleucine (SGI) show promising results with >80% viability post-thaw and comparable immunophenotype [32].
• Freezing Methodology: Controlled-rate freezing generally provides better outcomes than passive freezing at -80°C, though one multicenter study found both methods acceptable [32].

Interpreting Functional Differences

While most studies indicate general preservation of immunomodulatory function after cryopreservation, some subtle differences may emerge:

• T-cell Suppression: Cryopreserved and re-expanded MSCs maintain the ability to inhibit lymphocyte proliferation and downregulate activation markers (CD25, CD69) [20]. However, the magnitude of suppression may be slightly reduced immediately post-thaw [81].
• Monocyte Interactions: The critical process of MSC phagocytosis by monocytes and subsequent monocyte reprogramming appears preserved after cryopreservation [15]. This is significant as this mechanism helps distribute immunomodulatory effects systemically.
• Paracrine Secretion: Cryopreservation may temporarily alter the MSC secretome, affecting cytokine production profiles immediately post-thaw [65] [81]. The recovery of secretory function appears time-dependent post-thaw.

The potency assays detailed herein—T-cell suppression and monocyte phagocytosis enhancement—provide critical tools for evaluating the functional integrity of MSC products following cryopreservation. Current evidence robustly indicates that well-executed cryopreservation largely preserves the immunomodulatory properties of MSCs, with most in vivo and in vitro studies showing no statistically significant differences between fresh and cryopreserved cells [7] [61]. However, transient functional impairment immediately post-thaw warrants consideration in therapeutic timing and dosing strategies.

These standardized assays enable researchers to quantitatively assess the functional consequences of cryopreservation on core immunomodulatory mechanisms, ensuring that cryopreserved "off-the-shelf" MSC products maintain their therapeutic potential for clinical applications in inflammatory and autoimmune diseases.

The therapeutic efficacy of mesenchymal stromal cells (MSCs) hinges significantly on their immunomodulatory capabilities, which include suppressing T-cell proliferation, modulating macrophage polarization, and promoting regulatory T-cell differentiation [50]. Cryopreservation represents a critical technological step for enabling off-the-shelf availability of MSCs for clinical applications, yet its impact on these essential functions remains a subject of intense scientific debate. On one side, substantial evidence indicates that cryopreservation fundamentally impairs MSC immunomodulatory potency; conversely, other studies demonstrate that functional properties can be preserved or recovered post-thaw. This review synthesizes the conflicting evidence, providing researchers with a comprehensive analysis of methodological variables that may account for these discrepant findings and offering guidance for optimizing cryopreservation protocols to maintain therapeutic efficacy.

Evidence of Cryopreservation-Induced Impairment

Key Studies Demonstrating Functional Decline

A foundational 2014 study by Moll et al. provided compelling evidence that cryopreservation adversely affects MSC immunomodulatory function. Their investigation revealed that freeze-thawed MSCs exhibited reduced responsiveness to proinflammatory stimuli, an impaired production of anti-inflammatory mediators, and increased triggering of the instant blood-mediated inflammatory reaction (IBMIR) compared to their freshly harvested counterparts [82]. This impaired cellular function translated directly to diminished therapeutic outcomes in clinical settings. Patients treated with freshly harvested, low-passage MSCs demonstrated a 100% response rate, which was double the 50% response rate observed in a comparable patient group treated with freeze-thawed, higher-passage cells [82]. This striking difference underscores the potential clinical significance of cryopreservation-induced impairment.

A 2019 mechanistic study further elucidated the temporal dynamics of this functional impairment, specifically focusing on the immediate post-thaw period. freshly thawed MSCs (used immediately upon thawing) showed significantly increased metabolic activity and apoptosis, alongside decreased cell proliferation and clonogenic capacity [4]. Crucially, these cells exhibited reduced expression of key regenerative genes essential for their immunomodulatory functions. The same study confirmed that although freshly thawed MSCs maintained their ability to arrest T-cell proliferation, their potency in this regard was significantly diminished compared to acclimated cells [4].

Table 1: Studies Reporting Cryopreservation-Induced Impairment of MSC Immunomodulatory Properties

Study	Key Findings on Impairment	Clinical/Functional Correlation
Moll et al. (2014) [82]	Reduced responsiveness to proinflammatory stimuli; impaired anti-inflammatory mediator production; increased IBMIR triggering.	50% clinical response rate in patients treated with freeze-thawed MSCs vs. 100% with fresh cells.
Chinnadurai et al. (2019) [4]	Decreased expression of angiogenic/anti-inflammatory genes; increased apoptosis; reduced clonogenic capacity immediately post-thaw.	Significantly reduced potency in arresting T-cell proliferation immediately post-thaw.
Moll et al. (2014) [82]	Strong activation of the complement cascade; twice the efficiency in cell lysis after 1h serum exposure.	Faster complement-mediated elimination after blood exposure, reducing engraftment potential.

Methodologies Used in Impairment Studies

The studies reporting impairment typically employ rigorous in vitro functional assays to quantify immunomodulatory capacity. The 2019 study utilized flow cytometry for immunophenotyping (analyzing surface markers like CD44, CD105, CD73, CD90) and Annexin V/propidium iodide staining for apoptosis quantification [4]. Functional assessment included:

• T-cell Proliferation Assays: Co-culture of MSCs with peripheral blood mononuclear cells (PBMCs) to measure suppression of T-cell proliferation.
• Gene Expression Analysis: qRT-PCR to evaluate expression of key immunomodulatory genes (e.g., IDO, TSG-6, PEG2).
• Clonogenic Assay (CFU-f): Seeding MSCs at low density to assess their colony-forming unit capacity, indicating stemness.
• Multipotent Differentiation Assay: Inducing osteogenic and chondrogenic differentiation to confirm lineage potential post-thaw [4].

Evidence of Preserved Potency Post-Cryopreservation

Studies Demonstrating Functional Equivalence

Contrasting with the impairment data, a 2025 study on bone marrow aspirate concentrate (BMAC) found that short-term cryopreservation (4 weeks at -80°C) preserved the functional equivalence of MSCs for cartilage repair [61]. The in vitro results demonstrated that proliferation and multilineage differentiation of MSCs remained similar after the freezing process. In an osteoarthritis rat model, both fresh and frozen BMAC demonstrated significantly improved histology scores of tibial plateau cartilage compared to the PBS control, with no significant difference found between the fresh and frozen treatment groups [61]. This indicates that for specific therapeutic applications, the cryopreservation process may not negatively impact MSC functionality.

The pivotal 2019 study offering a potential resolution to the conflict demonstrated that cryopreservation-induced impairments are not necessarily permanent. While function was compromised immediately post-thaw, a 24-hour acclimation period in standard culture conditions allowed MSCs to regain functional potency [4]. After this recovery period, the "thawed + time" (TT) MSCs showed significantly reduced apoptosis and a concomitant upregulation in angiogenic and anti-inflammatory genes compared to the freshly thawed (FT) group. Furthermore, the TT MSCs were significantly more potent at arresting T-cell proliferation than their FT counterparts, effectively recovering the immunomodulatory capacity that was lost during the freezing and immediate thawing process [4].

Table 2: Studies Reporting Preserved or Recovered MSC Immunomodulatory Properties Post-Cryopreservation

Study	Key Findings on Preservation/Recovery	Clinical/Functional Correlation
BMAC Study (2025) [61]	MSC proliferation and multilineage differentiation preserved after freezing; no significant difference in cartilage repair in OA rat model.	Frozen BMAC retains functional equivalence to fresh BMAC for cartilage repair, enabling single-harvest, multiple-injection strategies.
Chinnadurai et al. (2019) [4]	24-hour post-thaw acclimation period restored gene expression, reduced apoptosis, and enhanced immunomodulatory potency.	TT MSCs were significantly more potent at arresting T-cell proliferation than FT MSCs, regaining function after initial impairment.

Methodologies Used in Preservation Studies

Studies demonstrating preserved function often utilize distinct methodological approaches that may contribute to their outcomes. The 2025 BMAC study [61] employed:

• In Vitro Proliferation Assays: Culturing mononuclear cells from fresh and frozen BMAC to compare growth rates.
• Multilineage Differentiation Assays: Inducing adipogenic, osteogenic, and chondrogenic differentiation to compare differentiation potential.
• In Vivo Animal Model: Using an OA rat model to directly compare the therapeutic cartilage repair capacity of fresh versus frozen BMAC through histological scoring (ICRS score).
• Cell Isolation: Mononuclear cells were isolated using a Ficoll gradient, and MSCs were further purified through plating and passage to P2 for experiments [61].

Critical Analysis of Conflicting Evidence

Resolution Through Technical and Biological Variables

The apparent conflict in the literature can be reconciled by examining key technical and biological variables that differ across studies. The post-thaw recovery period emerges as a critical factor. The 2019 study that systematically compared freshly thawed and acclimated cells from the same source provides a compelling explanation: the impairment is real but potentially transient [4]. The immediate post-thaw period represents a metabolic crisis for MSCs, characterized by oxidative stress and disrupted cytoskeletal organization, from which they can recover given adequate time in supportive culture conditions.

Furthermore, the composition of the cryopreserved product is crucial. The 2025 study showing functional preservation used BMAC, a heterogeneous mixture containing MSCs, hematopoietic stem cells, platelets, growth factors, and cytokines [61]. This complex microenvironment may provide innate protective signals that help buffer MSCs from cryopreservation damage, potentially explaining the preserved functionality compared to studies using purified, culture-expanded MSCs.

Other significant variables include:

• Cryopreservation Methodology: Slow freezing versus vitrification, with the former being more common for MSC preservation [2].
• Cryoprotectant Agent (CPA) Composition: Use of DMSO concentration (typically 10%), often with protein supplements like FBS or human serum albumin [2] [4].
• Cell Passage Number: Higher passage cells may be more vulnerable to cryopreservation-induced damage [82].
• Thawing Procedure: Rapid thawing in a 37°C water bath is standard, but CPA removal techniques (e.g., centrifugation, dilution) vary and can cause additional osmotic stress [2].

Figure 1: Experimental Variables Influencing MSC Immunomodulatory Potency Post-Cryopreservation. The flowchart illustrates how specific methodological choices in cryopreservation protocols, post-thaw processing, cell source/composition, and functional assessment can lead to divergent experimental outcomes regarding MSC immunomodulatory function.

The Scientist's Toolkit: Essential Reagents and Materials

Table 3: Research Reagent Solutions for MSC Cryopreservation Studies

Reagent/Material	Function/Application	Examples & Notes
Cryoprotectant Agents	Protect cells from ice crystal formation during freezing/thawing	DMSO (most common, 10%), glycerol, ethylene glycol; often used with protein supplements like FBS [2] [4].
Cell Culture Media	Expansion and maintenance of MSCs pre-cryopreservation and during post-thaw acclimation	α-MEM or DMEM, supplemented with FBS (10-15%) and growth factors (e.g., FGF-2) [61] [4].
Phenotyping Antibodies	Characterization of MSC surface markers pre- and post-cryopreservation	CD90-FITC, CD105-PerCP-Cy5.5, CD73-APC (positive markers); CD45-PE, CD34-PE, HLA-DR-PE (negative markers) [4].
Differentiation Kits	Verification of multilineage differentiation potential post-thaw	Commercial osteogenic (Alizarin Red staining) and chondrogenic (Alcian Blue staining) differentiation kits [4].
Functional Assay Kits	Quantification of immunomodulatory capacity	T-cell suppression assays (co-culture with PBMCs), apoptosis detection (Annexin V/PI), metabolic activity (Resazurin reduction/Vybrant assay) [4].
Ficoll Gradient	Isolation of mononuclear cells from bone marrow or BMAC	Density gradient medium for isolating MSCs from heterogeneous mixtures like BMAC [61].

The body of evidence regarding cryopreservation's impact on MSC immunomodulatory properties reveals a complex landscape where methodological details critically influence outcomes. The conflict between studies showing impairment versus those showing preservation can be largely explained by variables such as post-thaw recovery time, cellular composition of the cryopreserved product, and specific functional assays employed. The weight of evidence suggests that cryopreservation does induce a transient but significant impairment in immunomodulatory function, which can be mitigated through a 24-hour acclimation period [4] or potentially by preserving MSCs within a supportive cellular microenvironment like BMAC [61].

For researchers and drug development professionals, these findings indicate that protocol standardization is essential. Critical considerations include:

• Implementing a mandatory post-thaw recovery period before functional assessment or administration.
• Carefully evaluating whether to use purified MSCs or heterogeneous cellular products like BMAC based on the therapeutic application.
• Standardizing cryopreservation protocols, including CPA composition and removal methods, to minimize cellular stress.
• Conducting potency assays after the recovery period to ensure cells have regained their immunomodulatory functions before clinical use.

Future research should focus on optimizing cryopreservation and post-thaw recovery protocols specifically designed to preserve immunomodulatory potency, potentially through the use of novel CPAs, targeted pre-conditioning of MSCs, or the addition of cytoprotective agents during recovery. As the field advances toward more widespread clinical application of MSCs, resolving these methodological conflicts will be paramount for ensuring consistent therapeutic efficacy in regenerative medicine and immunomodulatory therapies.

The transition of mesenchymal stromal cells (MSCs) from laboratory research to clinically viable "off-the-shelf" therapeutics hinges critically on effective cryopreservation. This process enables essential logistical flexibility in storage, transport, and timely administration for acute conditions. However, a pivotal question remains: does cryopreservation compromise the core immunomodulatory properties that underpin their therapeutic efficacy in complex immune-mediated diseases? This technical review synthesizes current evidence on the in vivo performance of cryopreserved MSCs, with a focused analysis on preclinical models of sepsis and graft-versus-host disease (GVHD). We present comparative quantitative data, detailed experimental methodologies, and analytical visualizations to guide researchers and therapy developers in evaluating the functional consequences of cryopreservation on MSC potency.

Performance in Specific Disease Models

Sepsis

Experimental Model and Protocol: The cecal ligation and puncture (CLP) model in mice is a gold standard for simulating human polymicrobial sepsis. In a pivotal 2019 study, donor-matched MSCs were compared—some were freshly harvested from culture, while others were cryopreserved, then thawed. These cells were administered intravenously to septic animals. Key functional outcomes were measured 24 hours post-treatment, including the phagocytic capacity of CD11b+ immune cells harvested from the peritoneal cavity and systemic levels of inflammatory cytokines and lactate in plasma [23].

Key Findings on Cryopreserved MSCs:

• Phagocytic Function: Septic mice treated with either fresh or thawed MSCs showed a significant and comparable improvement in the ability of peritoneal immune cells to engulf bacteria. This recovery was substantial, bringing phagocytic function closer to levels observed in sham-operated (non-septic) animals [23].
• Systemic Inflammation: Both fresh and cryopreserved MSC treatments effectively and similarly reduced plasma concentrations of lactate and key pro-inflammatory cytokines. This indicates that thawed MSCs retain the capacity to mitigate critical systemic inflammatory and metabolic dysregulation in sepsis [23].
• In Vitro Correlates: Supporting the in vivo data, co-culture experiments demonstrated that thawed MSCs were equally effective as fresh MSCs in restoring the phagocytic ability of LPS-impaired human monocytes and repairing LPS-induced endothelial monolayer permeability [23].

Graft-versus-Host Disease (GVHD)

Experimental Context: GVHD is a major complication following allogeneic hematopoietic stem cell transplantation, driven by donor immune cells attacking host tissues. MSC-based therapies are leveraged for their potent immunomodulatory effects to suppress this aberrant immune response.

Key Findings on Cryopreserved MSCs:

• Immunomodulatory Potency: A 2014 clinical-scale study found that MSCs cryopreserved for 1-8 months, then thawed and re-expanded in culture, retained critical immunosuppressive functions. These cells effectively inhibited the metabolic activity of stimulated lymphocytes by approximately 30% and reduced the expression of the T-cell activation marker CD25 [20].
• Clinical Response Trend: An analysis of patient responses suggested a trend: individuals treated with freshly harvested, low-passage MSCs exhibited a 100% response rate for steroid-refractory GVHD, which was double the 50% response rate observed in a comparable cohort treated with freeze-thawed, higher-passage cells [82]. This highlights the potential impact of cell processing on clinical outcomes.
• Functional Integrity: Despite the clinical trend, the core immunophenotype (expression of CD90, CD105, CD73) and proliferation capacity of MSCs were unaltered by cryopreservation and subsequent re-expansion, confirming retained cellular identity [20].

Table 1: Summary of In Vivo and Clinical Efficacy of Cryopreserved MSCs

Disease Model	Key Functional Assay	Performance of Cryopreserved vs. Fresh MSCs	Supporting Evidence
Sepsis (CLP Model)	Bacterial Phagocytosis by Peritoneal Cells	Comparable improvement in bacterial clearance [23]	In vivo murine model
	Systemic Inflammatory Cytokines	Comparable reduction in pro-inflammatory markers [23]	In vivo murine model
GvHD (Clinical/Pre-clinical)	T-cell Proliferation Inhibition	Potent suppression retained post-thaw [20]	In vitro co-culture with lymphocytes
	Patient Response Rate	Trend of reduced efficacy (50% vs. 100% with fresh) [82]	Clinical response analysis in patients

Underlying Mechanisms and Functional Pathways

The in vivo efficacy of MSCs is primarily mediated through paracrine signaling and direct cell-to-cell contact, modulating innate and adaptive immune cells. The diagrams below illustrate the core immunomodulatory mechanisms of MSCs and how the cryopreservation process can impact these critical functions.

Diagram 1: MSC immunomodulatory functions are multifaceted, targeting both innate and adaptive immunity. Cryopreservation can differentially impact these critical mechanisms, with some functions more resilient than others.

The experimental workflow for generating and validating cryopreserved MSCs for therapeutic applications involves a multi-stage process, from isolation to final in vivo potency assessment, as visualized below.

Diagram 2: The standard workflow for producing and validating cryopreserved MSCs involves sequential steps from isolation to rigorous functional testing in disease models, ensuring therapeutic potency is retained.

Essential Research Reagent Solutions

The consistency and success of MSC cryopreservation research depend on standardized reagents and solutions. The following toolkit details critical components used in the featured studies.

Table 2: Research Reagent Toolkit for MSC Cryopreservation Studies

Reagent / Solution	Function & Role in Protocol	Example Formulations & Notes
Cryoprotectant (CPA)	Prevents intracellular ice crystal formation and osmotic damage during freeze-thaw [2].	10% DMSO in saline/albumin [65]; 5% DMSO (CryoStor CS5) [67]; Xeno-free, chemically defined media preferred for clinical compliance [83].
Freezing Media Base	Provides osmotic and protein support for cell membrane stability.	Plasmalyte-A with 5% Human Albumin (PHD10) [67]; Commercial serum-free formulations like NutriFreez [67].
Post-Thaw Wash Medium	Dilutes and removes cytotoxic CPAs before administration or assay.	Plasmalyte-A with 5% Human Albumin [67]; Culture medium without serum [2].
Viability Assay Kits	Quantifies live, apoptotic, and necrotic cell populations post-thaw.	Annexin V / Propidium Iodide (PI) for flow cytometry [23] [67]; Trypan Blue Exclusion for immediate viability count [23] [67]; Calcein AM/Ethidium homodimer for live/dead staining [83].
Immunophenotyping Panel	Confirms MSC identity and surface marker profile post-thaw.	Positive Markers: CD73, CD90, CD105 (≥95%+); Negative Markers: CD45, CD34, CD14, CD19, HLA-DR (≤2%+) [2] [84].
In Vitro Potency Assay Reagents	Evaluates retained immunomodulatory function.	CFSE-labeled PBMCs + CD3/CD28 activator for T-cell suppression [23] [20]; Fluorescent E. coli particles for monocyte phagocytosis assay [23]; LPS & FITC-dextran for endothelial permeability assay [23].

Detailed Experimental Protocols

In Vitro T-cell Suppression Assay

This protocol is a cornerstone for evaluating the immunomodulatory potency of MSCs after cryopreservation [23] [20].

• PBMC Isolation and Labeling: Isolate peripheral blood mononuclear cells (PBMCs) from healthy donor blood using density gradient centrifugation (e.g., Ficoll-Paque). Label the PBMCs with a cell proliferation dye such as CFSE (carboxyfluorescein succinimidyl ester).
• MSC Preparation: Thaw cryopreserved MSCs and allow a brief recovery period. Similarly, prepare freshly harvested MSCs as a control. Seed MSCs in a well of a multi-well plate and allow them to adhere overnight.
• Co-culture Setup: Activate the CFSE-labeled PBMCs using a T-cell activator (e.g., anti-CD3/CD28 beads). Add these activated PBMCs to the wells containing the adherent MSCs. A standard MSC-to-PBMC ratio is 1:10, but this should be optimized.
• Incubation and Analysis: Co-culture the cells for 5 days. After incubation, harvest the cells and analyze the PBMCs by flow cytometry. The degree of T-cell proliferation inhibition is determined by measuring the reduction in CFSE dilution in the co-culture wells compared to wells containing activated PBMCs alone.

In Vivo Cecal Ligation and Puncture (CLP) Model

This well-established protocol is used to assess the efficacy of MSCs in polymicrobial sepsis [23].

• Induction of Sepsis: Anesthetize mice according to institutional guidelines. Make a midline abdominal incision, exteriorize the cecum, and ligate a portion of it below the ileocecal valve. Perform a through-and-through puncture of the cecum with a needle (e.g., 21-gauge) to release fecal material into the peritoneal cavity. Return the cecum to the abdomen and close the incision in layers.
• Supportive Care: Immediately after surgery and at defined intervals, administer subcutaneous saline and analgesic for fluid resuscitation and pain management.
• Cell Administration: At a predefined time post-CLP (e.g., 2-4 hours), administer the test articles via intravenous injection. Groups should include: a) Sham-operated controls (cecum exposed but not ligated/punctured), b) CLP + vehicle, c) CLP + fresh MSCs, and d) CLP + cryopreserved MSCs.
• Outcome Measures: At the study endpoint (e.g., 24 hours), collect blood via cardiac puncture to measure systemic biomarkers (lactate, cytokines like IL-6, TNF-α). Perform peritoneal lavage to harvest immune cells. Analyze the phagocytic capacity of CD11b+ cells from the lavage by incubating them with fluorescent bacteria or beads and quantifying uptake via flow cytometry. Survival studies are also a critical long-term endpoint.

The body of evidence indicates that cryopreserved MSCs can retain significant immunomodulatory potency and therapeutic efficacy in complex in vivo disease models like sepsis and GVHD. Key functions such as enhancing bacterial clearance in sepsis and suppressing T-cell proliferation in GVHD appear to be notably resilient to the freeze-thaw cycle. However, the literature is not entirely unanimous, with some studies reporting impaired cellular functions and a trend toward reduced clinical response, underscoring that efficacy is not guaranteed. The ultimate functional integrity of a cryopreserved MSC product is highly dependent on a meticulously optimized protocol encompassing the cryoprotectant formulation, freezing rate, storage conditions, and post-thaw handling. Therefore, rigorous and product-specific validation through the in vitro and in vivo assays detailed in this guide remains indispensable for the successful development of effective off-the-shelf MSC therapies.

The transition of Mesenchymal Stromal Cell (MSC) therapies from research to clinical application presents a critical logistical challenge: should cells be administered fresh or cryopreserved? While cryopreservation offers practical advantages for "off-the-shelf" availability, emerging evidence suggests it may functionally compromise MSC therapeutic efficacy. This review analyzes clinical response trends and the biological mechanisms underlying functional differences between fresh and cryopreserved MSCs, with a focus on implications for immunomodulatory therapeutics. Understanding these correlations is essential for optimizing cell-based product development and clinical trial design, particularly for immune-mediated conditions like graft-versus-host disease (GvHD) and autoimmune disorders.

Clinical Response Data: A Comparative Analysis

Retrospective Clinical Evidence

A pivotal retrospective clinical analysis directly compared patient responses to fresh versus cryopreserved MSC infusions. The study evaluated 44 MSC infusions for complications following hematopoietic stem cell transplantation, primarily for acute GvHD and hemorrhagic cystitis [11].

Table 1: Clinical Response to Fresh vs. Cryopreserved MSC Infusions

Cell Product	Number of Infusions	Complete Response (CR)	Partial Response (PR)	Overall Response Rate (ORR)
Fresh MSCs	9	Data not specified	Data not specified	100%
Cryopreserved MSCs	35	Data not specified	Data not specified	~50%

This analysis revealed a critical trend: patients treated with freshly harvested, low-passage MSCs had a response rate twice that observed in a comparable patient group treated with freeze-thawed, higher-passage cells [11]. This striking difference underscores the potential clinical impact of cell processing and preservation methods.

Immunomodulatory Efficacy in GvHD

GvHD treatment represents the most frequent clinical application of MSCs, providing a robust context for evaluating product efficacy. While cryopreserved MSCs have demonstrated safety and some effectiveness, their performance appears inconsistent compared to fresh alternatives [85] [25]. The first MSC therapy approved by the U.S. FDA for pediatric steroid-refractory acute GvHD is a cryopreserved product, proving that functional cryopreserved products are achievable [25]. However, identifying potency assays that reliably predict the capacity of a specific cryopreserved MSC batch to alleviate GvHD remains challenging, partly due to patient biological variability obscuring trial outcomes [85]. This has spurred the International Society for Cell and Gene Therapy (ISCT) to advocate for standardized reporting of clinical trials using MSCs for autoimmune disorders to improve data interpretation [60].

Mechanisms of Functional Impairment in Cryopreserved MSCs

Altered Immunomodulatory Capacity

The therapeutic effect of MSCs hinges on their immunomodulatory function, which is significantly affected by cryopreservation. Direct in vitro comparisons reveal that freeze-thawed MSCs possess impaired immunomodulatory properties:

• Reduced Responsiveness: Thawed MSCs demonstrate diminished reactivity to pro-inflammatory stimuli, which is essential for triggering their immunosuppressive activity [11].
• Compromised Mediator Production: They exhibit an impaired production of anti-inflammatory mediators, weakening their ability to modulate the immune environment [11].
• Senescence and Differentiation: Post-thaw assessments show increased senescence and reduced differentiation potential in some studies, though other reports indicate these attributes may be preserved with optimized protocols [65] [40].

The diagram below illustrates the cascade of functional impairments triggered by cryopreservation.

Activation of Innate Immune Cascades

Systemically administered MSCs face immediate innate immune responses. Cryopreservation exacerbates this challenge through several mechanisms:

• Complement Activation: Freeze-thawed MSCs demonstrate strong activation of the complement cascade. This results in twice the efficiency in cell lysis after one hour of serum exposure compared to fresh cells [11].
• IBMIR Triggering: The Instant Blood-Mediated Inflammatory Reaction (IBMIR) is more potently triggered by cryopreserved MSCs. This reaction leads to rapid graft destruction through innate immune cascades and effector cell infiltration [11].
• Post-Infusion Clearance: Complement activation products binding to MSC surfaces promote rapid clearance by phagocytes, significantly reducing the number of viable cells reaching target tissues [11].

Optimizing Cryopreservation Protocols for Clinical Use

Methodological Standardization

Given the logistical necessity of cryopreservation for practical cell therapy, significant research focuses on optimizing protocols to preserve MSC functionality. Key parameters for optimization include:

Table 2: Key Parameters in Cryopreservation Protocol Optimization

Parameter	Impact on MSC Function	Optimization Strategies
Cryoprotectant (CPA) Composition	DMSO cytotoxicity; cell viability and function	Reduce DMSO concentration; incorporate non-permeating CPAs (trehalose, sucrose); use defined serum-free freezing media [35] [40] [65].
Freezing Rate Control	Intracellular ice crystal formation; mechanical damage	Employ controlled-rate freezing (~ -1°C/min) to enable gradual dehydration [35] [86].
Cell Density at Freezing	Post-thaw recovery and functionality	Optimize density to minimize apoptosis; typical range 1-5 x 10^6 cells/mL [65].
Thawing and CPA Removal	Osmotic stress; additional cell loss	Rapid thawing (37°C water bath); gradual dilution/removal of CPAs [35] [65].

Evidence from Optimized Protocols

Recent studies demonstrate that protocol optimization can significantly improve outcomes for cryopreserved MSCs. Research on fucosylated human MSCs showed that using specific freezing solutions, such as saline with 10% DMSO and 2% human serum albumin (HSA), helped maintain immunosuppressive capacity, viability, and differentiation potential post-thaw [65]. Furthermore, adding apoptosis inhibitors like the Rho-associated kinase inhibitor during freezing can enhance post-thaw recovery [40]. These findings confirm that targeted optimization of cryopreservation workflows can mitigate functional losses, bridging the efficacy gap with fresh cells.

The Scientist's Toolkit: Essential Reagents and Methods

Table 3: Key Research Reagents and Methods for MSC Cryopreservation Studies

Reagent/Method	Function/Application	Considerations for Use
DMSO (Dimethyl Sulfoxide)	Permeating cryoprotectant; reduces ice crystal formation	Cytotoxic at high concentrations/temperature; clinical dose limitations; typically used at 5-10% [35] [86].
Non-Permeating CPAs (Trehalose, Sucrose)	Accelerate dehydration; enable DMSO reduction	Improve post-thaw viability; reduce osmotic shock during CPA removal [35] [86].
Serum-Free Freezing Media	Defined xeno-free formulation for clinical compliance	Eliminates batch variability and pathogen risk from FBS; formulations may include HSA [40] [65].
Controlled-Rate Freezer	Precisely controls cooling rate (~ -1°C/min)	Standardizes process; critical for reproducible slow freezing [35] [40].
Rho-Associated Kinase (ROCK) Inhibitor	Suppresses post-thaw apoptosis	Enhances cell attachment and survival after thawing [40].
Flow Cytometry for sLeX (HECA-452)	Validates surface marker expression post-thaw	Critical for assessing retention of homing molecules (e.g., on fucosylated MSCs) [65].

The body of evidence consistently indicates a significant efficacy advantage for fresh MSCs over their cryopreserved counterparts in specific clinical settings, with one retrospective analysis showing a 100% versus 50% response rate [11]. This performance gap is mechanistically explained by cryopreservation-induced impairments to immunomodulatory function and increased susceptibility to innate immune destruction [11]. However, cryopreservation remains a practical necessity for the widespread, off-the-shelf availability of MSC therapies.

The future of MSC therapeutics lies not in abandoning cryopreservation, but in systematically optimizing the entire process—from cryoprotectant formulation and freezing rates to post-thaw handling and potency assessment. Furthermore, the emergence of ambient temperature transport technologies and the shift toward cell-free therapies using MSC-derived extracellular vesicles present promising alternatives that may circumvent the challenges of cryopreservation altogether [87] [86]. As the field progresses, developing and universally adopting standardized, potency-based release assays will be crucial to ensuring that cryopreserved MSC products deliver consistent and predictable clinical benefits, ultimately fulfilling their potential as robust and reliable medicines.

The field of regenerative medicine is undergoing a significant transformation, moving away from whole-cell therapies toward sophisticated cell-free alternatives. Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as powerful paracrine effectors that retain the therapeutic benefits of their parent cells while overcoming critical limitations associated with live cell transplantation [88] [89]. These nano-sized, lipid-bilayer enclosed vesicles carry a complex cargo of proteins, lipids, and nucleic acids that mediate intercellular communication and immunomodulation [90]. This shift is particularly relevant in the context of cryopreservation research, as understanding how freezing and thawing procedures affect MSC immunomodulatory properties has become essential for therapeutic development. While cryopreservation enables practical storage and distribution of cellular products, it introduces functional challenges that can compromise therapeutic efficacy, making EV-based alternatives increasingly attractive for clinical applications [3].

The inherent limitations of MSC therapies have accelerated the adoption of EV-based approaches. Live MSCs face challenges including potential tumorigenicity, low engraftment efficiency, and immune rejection risks [89]. Furthermore, cryopreservation—a necessary step for clinical deployment—can significantly impact MSC viability, recovery, and immunomodulatory function post-thaw [3] [19]. MSC-EVs address these concerns by offering superior safety profiles, enhanced stability, reduced immunogenicity, and the ability to cross biological barriers that limit cell-based therapies [89]. As the field advances, research has revealed that the immunomodulatory effects of MSCs are primarily communicated through their secretome rather than direct cell engraftment, solidifying the scientific foundation for EV-based therapeutic strategies [15] [8].

MSC-EVs: Composition, Biogenesis, and Immunomodulatory Properties

EV Classification and Biogenesis

Extracellular vesicles are heterogeneous membrane structures classified primarily by their size, biogenesis pathways, and molecular markers. The three main EV categories include: (1) Exosomes (30-150 nm), which originate from the endosomal system through the formation of intraluminal vesicles within multivesicular bodies that subsequently fuse with the plasma membrane; (2) Microvesicles (100-1000 nm), formed through outward budding and fission of the plasma membrane; and (3) Apoptotic bodies (50-5000 nm), released during programmed cell death [91] [89]. According to International Society for Extracellular Vesicles (ISEV) guidelines, specific markers identify bona fide EVs, including transmembrane proteins (CD63, CD81, CD9) and biogenesis-related proteins (Alix, TSG101) [91].

The following diagram illustrates the primary biogenesis pathways and key markers of MSC-derived extracellular vesicles:

Immunomodulatory Cargo and Mechanisms

MSC-EVs exert their immunomodulatory effects through diverse molecular cargo that modulates both innate and adaptive immune responses. The vesicular contents include immunoregulatory microRNAs (e.g., miR-146a, miR-181c, let-7b), anti-inflammatory proteins (TSG-6, PGE2, TGF-β), and enzymes (IDO) that collectively suppress pro-inflammatory pathways while promoting regulatory immune cell functions [90] [92] [15]. These components enable MSC-EVs to target multiple immune cell populations, including macrophages, T cells, B cells, dendritic cells, and natural killer cells, making them potent modulators of pathological immune responses [90].

The functional effects of MSC-EVs on immune cells are comprehensive. They promote the polarization of macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes through multiple mechanisms, including miR-181c-mediated NF-κB inhibition and let-7b regulation of TLR4/NF-κB/STAT3/AKT signaling [90]. For T cells, MSC-EVs inhibit proliferation and pro-inflammatory differentiation while promoting regulatory T cell expansion through cargo including PD-L1, TGF-β, and CD73-mediated adenosine signaling [90] [15]. The table below summarizes key immunomodulatory components found in MSC-EVs and their specific functions:

Table 1: Key Immunomodulatory Components in MSC-Derived Extracellular Vesicles

EV Component	Type	Target Immune Cell	Immunomodulatory Function	References
miR-146a	microRNA	Macrophages, Microglia	Reduces neuroinflammation via IRAK1/TRAF6/NF-κB pathway	[92]
miR-181c	microRNA	Macrophages	Downregulates NF-κB signaling, reduces CD68+ macrophages	[90]
let-7b	microRNA	Macrophages	Increases macrophage plasticity via TLR4/NF-κB/STAT3/AKT	[90]
PD-L1	Surface protein	T cells	Suppresses T-cell activation and proliferation	[90] [15]
TGF-β	Cytokine	T cells, B cells	Inhibits T-cell proliferation, promotes Treg differentiation	[90] [15]
TSG-6	Protein	Macrophages, T cells	Anti-inflammatory, promotes M2 polarization, increases Tregs	[90]
CD73	Enzyme	T cells	Generates immunosuppressive adenosine from AMP	[90]
PGE2	Lipid mediator	Mast cells, Macrophages	Suppresses mast cell activation, promotes M2 polarization	[90] [15]

Cryopreservation Impact on MSC Function and the Rationale for EV Alternatives

Functional Consequences of Cryopreservation on MSCs

Cryopreservation induces significant functional impairments in MSCs that directly impact their immunomodulatory potency. Research demonstrates that freshly thawed MSCs exhibit reduced surface expression of key markers CD44 and CD105, increased metabolic stress and apoptosis, diminished clonogenic capacity, and downregulation of critical regenerative genes compared to their fresh counterparts [19]. These alterations directly compromise the therapeutic functionality of cryopreserved MSCs, particularly their immunomodulatory capacity, which depends on precise molecular interactions and secretory profiles.

The molecular mechanisms underlying cryopreservation damage are multifaceted. Ice crystal formation during freezing can cause physical damage to membrane integrity and subcellular structures [3]. Oxidative stress from reactive oxygen species (ROS) accumulation leads to protein carbonylation, lipid peroxidation, and DNA fragmentation [91]. Additionally, cryoprotectant agents like dimethyl sulfoxide (DMSO), while necessary for viability, can themselves induce cellular stress, epigenetic modifications, and differentiation in stem cells [19]. These cumulative stresses trigger signaling pathways that ultimately diminish MSC immunomodulatory function, including reduced secretion of critical anti-inflammatory factors like PGE2 and IDO, and impaired response to inflammatory cues in the tissue microenvironment [3] [19].

Functional Recovery and EV Advantages

Notably, research indicates that a 24-hour acclimation period post-thaw allows MSCs to recover significant functionality, including reduced apoptosis, upregulated angiogenic and anti-inflammatory gene expression, and restored potency in arresting T-cell proliferation [19]. However, this recovery period introduces logistical challenges for clinical applications where immediate administration is often preferred.

The comparative advantages of MSC-EVs in this context are substantial. EVs maintain functional stability after freeze-thaw cycles with preserved biological activity, overcoming a critical limitation of cell-based therapies [89]. They exhibit lower immunogenicity than whole cells, reducing risks of immune reactions [88] [89]. Their nanoscale size enables enhanced tissue penetration and ability to cross biological barriers like the blood-brain barrier [89]. Furthermore, EVs can be engineered for enhanced targeting and loaded with specific therapeutic cargo, offering precision not achievable with cell therapies [91] [92]. The following table quantitatively compares key functional attributes between cryopreserved MSCs and their derived EVs:

Table 2: Functional Comparison: Cryopreserved MSCs vs. MSC-Derived Extracellular Vesicles

Parameter	Freshly Thawed MSCs	MSCs Post-24h Acclimation	MSC-Derived EVs
Viability/Recovery	Significantly reduced [19]	Recovered to near baseline [19]	High post-thaw [89]
Apoptosis Rate	Significantly increased [19]	Significantly reduced [19]	Not applicable
Metabolic Activity	Significantly increased [19]	Normalized [19]	Not applicable
Phenotypic Markers	Decreased CD44, CD105 [19]	Recovered expression [19]	Stable marker profile [89]
Immunomodulatory Potency	Maintained but reduced [19]	Significantly enhanced [19]	Equal or superior to MSCs [90] [89]
T-cell Proliferation Inhibition	Significant arrest [19]	Significantly more potent [19]	Effective inhibition [93] [90]
Pro-inflammatory Cytokine Suppression	IFN-γ secretion diminished [19]	Normalized anti-inflammatory function [19]	TNF-α, IFN-γ, IL-17 reduction [92]
Storage Stability	Requires cryopreservation with viability loss [3]	Requires culture facilities [19]	Long-term at -80°C with minimal activity loss [89]

Experimental Approaches for Evaluating MSC-EV Immunomodulation

Standardized Methodologies for EV Isolation and Characterization

Robust EV research requires standardized methodologies for isolation and characterization. Tangential flow filtration (TFF) has emerged as a scalable, GMP-compatible method for EV concentration, allowing separation based on molecular weight cutoffs (e.g., 5, 10, 30, or 100 kDa) [93]. Alternative methods include differential ultracentrifugation, size exclusion chromatography, and precipitation techniques [91]. For functional fractionation, studies combine TFF with ultracentrifugation to separate soluble factors from vesicular components, enabling mechanistic studies of specific secretome fractions [93].

Comprehensive EV characterization follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines, employing nanoparticle tracking analysis for size distribution and concentration, transmission electron microscopy for morphological assessment, and flow cytometry with MACSPLEX kits for surface marker profiling (CD63, CD81, CD9) [93] [91]. Western blot analysis further confirms the presence of EV-enriched proteins (Alix, TSG101) and absence of contaminants [89]. Protein quantification via fluorimetric assays (Qubit) and multiplexed protein panels (ProCartaPlex) provides additional quality control and cargo characterization [93].

Assessing Immunomodulatory Potency: Key Assays

Evaluating the immunomodulatory effects of MSC-EVs requires sophisticated immune cell-based assays that measure specific functional outcomes. The experimental workflow typically involves isolating EVs from MSC cultures, then applying them to various immune cell systems to quantify functional responses:

Critical functional assays include NF-κB and IRF pathway reporter systems using specialized cell lines like THP-1 Dual cells to evaluate innate immune modulation [93]. For T-cell response assessment, dye dilution assays (e.g., CFSE) combined with flow cytometry quantitatively measure proliferation inhibition, while intracellular staining for cytokine production (IFN-γ, IL-17, IL-4, IL-10) characterizes T-helper polarization [93] [92]. Macrophage polarization assays evaluate surface marker expression (CD80, CD86, CD206) and functional phenotypes through phagocytosis assays and nitric oxide production [90]. Additional methodologies include mixed lymphocyte reactions for allogeneic response assessment, ELISpot assays for antigen-specific immune cell quantification, and gene expression analysis of key immunomodulatory pathways in target cells [92].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Essential Research Reagents for MSC-EV Immunomodulation Studies

Reagent/Category	Specific Examples	Research Application	Key Functions
EV Isolation Kits	TFF membranes, Ultracentrifugation, Size exclusion columns	EV separation and concentration	Isolate EVs based on size, density, or surface properties
Characterization Tools	MACSPLEX EV kits, Nanoparticle tracker, TEM	EV quantification and validation	Determine size, concentration, and surface markers
Reporter Cell Lines	THP-1 Dual cells (NF-κB/IRF)	Pathway activity screening	Monitor innate immune pathway activation (NF-κB, IRF)
Cell Culture Models	PBMCs from human donors, Primary immune cells	Functional immunomodulation assays	Evaluate EV effects on relevant human immune cell populations
Proliferation Assays	CFSE, CellTrace dyes	T-cell proliferation measurement	Track cell division cycles via dye dilution by flow cytometry
Cytokine Detection	ProCartaPlex multiplex panels, ELISA kits	Cytokine secretion profiling	Quantify multiple inflammatory/anti-inflammatory mediators
Flow Cytometry Antibodies	CD3, CD4, CD8, CD25, CD69, FoxP3	Immune cell phenotyping	Identify and characterize immune cell populations and activation states
Molecular Biology Kits	qPCR assays, miRNA mimics/inhibitors	Mechanistic studies	Modulate and measure specific molecular pathways

Engineering Strategies for Enhanced EV Therapeutics

EV engineering approaches amplify the natural immunomodulatory properties of MSC-EVs through precise cargo manipulation. Preconditioning strategies expose MSCs to inflammatory cytokines (IFN-γ, TNF-α) or hypoxic conditions before EV collection, enhancing their anti-inflammatory cargo [15]. For more targeted approaches, genetic engineering of parent MSCs through transfection with miRNA mimics (e.g., miR-146a, miR-181c) or CRISPR/Cas9 systems creates EVs with customized molecular compositions [92] [8]. These engineered EVs demonstrate enhanced therapeutic efficacy, as evidenced by miR-146a-enriched EVs significantly attenuating experimental autoimmune encephalomyelitis through superior suppression of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-17) and enhanced neuroprotection [92].

Advanced engineering methodologies further enhance EV therapeutic potential. Direct loading techniques including electroporation, sonication, saponin permeabilization, and freeze-thaw cycles enable incorporation of exogenous therapeutic agents [91]. Surface modification approaches employ genetic engineering to express targeting ligands or immune-modulatory molecules on EV membranes, improving tissue-specific delivery and potency [91] [89]. These engineering strategies collectively address limitations of native EVs while creating platforms for customizable, precision immunomodulation capable of targeting specific inflammatory pathways with reduced off-target effects.

The transition to MSC-derived extracellular vesicles as cell-free therapeutic agents represents a paradigm shift in regenerative medicine and immunomodulation strategy. The compelling advantages of EV approaches—including their superior safety profile, functional stability through cryopreservation, and molecular engineering flexibility—position them as transformative alternatives to cell-based therapies. Current research challenges include standardizing EV manufacturing processes, establishing potency assays correlated with clinical outcomes, and developing scalable GMP-compliant production systems [89] [8].

Future directions will likely focus on engineering precision-targeted EVs with enhanced immunomodulatory cargo, developing combination therapies that leverage synergistic effects, and establishing comprehensive biobanking approaches for therapeutic EV products. The integration of EV technologies with emerging fields including artificial intelligence for cargo design and microfluidics for manufacturing will further accelerate clinical translation. As these advancements mature, MSC-derived EVs hold exceptional promise for treating diverse inflammatory and autoimmune conditions, offering targeted immunomodulation without the limitations of cell-based approaches or the functional vulnerabilities of cryopreserved MSCs.

Conclusion

The cryopreservation of MSCs presents a necessary compromise between logistical feasibility and therapeutic potency. While the process can induce acute cellular stress, impair immunomodulatory function, and activate detrimental innate immune responses, the deficits are not necessarily permanent. Evidence indicates that strategic interventions, particularly a post-thaw acclimation period, can significantly restore functional potency. The future of MSC-based therapeutics hinges on the development of optimized, standardized cryopreservation protocols that minimize cellular damage and rigorously validate product function through relevant potency assays. Furthermore, the emerging field of MSC-derived extracellular vesicles offers a promising alternative to circumvent the challenges of cell viability and storage altogether. For researchers and clinicians, a thorough understanding of these factors is paramount for designing effective clinical trials and advancing the successful translation of MSC therapies into routine practice.

References

• 1. Mesenchymal stromal cells conditioned by peripheral blood ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12333171/]
• 2. Effects, methods and limits of the cryopreservation on ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03954-3]
• 3. Impact of Cryopreservation and Freeze-Thawing on ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9045030/]
• 4. Cryopreserved mesenchymal stem cells regain functional ... [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-2038-5]
• 5. Clinical mesenchymal stem cell products experience ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4274232/]
• 6. Comparison of freshly cultured versus cryopreserved ... [https://elifesciences.org/articles/75053]
• 7. Comparison of freshly cultured versus cryopreserved ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9286731/]
• 8. Exploring the therapeutic potential of MSC-derived ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04616-8]
• 9. From “stem” to “stromal”: Reframing the nomenclature of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12553919/]
• 10. Therapeutic and Clinical Potential of Adipose-Derived ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12610433/]
• 11. Do Cryopreserved Mesenchymal Stromal Cells Display ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4381870/]
• 12. TSG-6 Protein Is Crucial for the Development of Pulmonary ... [https://www.sciencedirect.com/science/article/pii/S0021925820653479]
• 13. Advancements in mesenchymal stromal cells for treating ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12382037/]
• 14. Comparison of freshly cultured versus freshly thawed ... [https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01437-z]
• 15. Mesenchymal Stem Cell Immunomodulation: Mechanisms ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7751844/]
• 16. Human Mesenchymal Stem Cells Display Reduced ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3806428/]
• 17. Primary Mesenchymal Stem and Progenitor Cells from ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3406666/]
• 18. Cryopreserved Mesenchymal Stromal Cells Maintain ... [https://www.nature.com/articles/srep26463]
• 19. Cryopreserved mesenchymal stem cells regain functional ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6716839/]
• 20. Expanded cryopreserved mesenchymal stromal cells as an ... [https://www.sciencedirect.com/science/article/abs/pii/S1045105614000049]
• 21. Mesenchymal stem cells in treating human diseases [https://www.nature.com/articles/s41392-025-02313-9]
• 22. Comparative analysis of cryopreserved adipose stem cells ... [https://www.nature.com/articles/s41598-024-83255-0]
• 23. Thawed Mesenchymal Stem Cell Product Shows ... [https://www.nature.com/articles/s41598-019-54462-x]
• 24. Modeling and typical cases analyze at the cell-scale of ... [https://www.sciencedirect.com/science/article/abs/pii/S0011224025000161]
• 25. Mesenchymal stromal cell therapy: Progress to date and ... [https://www.sciencedirect.com/science/article/pii/S1525001625000930]
• 26. Mesenchymal stromal cell therapies: immunomodulatory ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01855-9]
• 27. Recent advances to enhance the immunomodulatory potential ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9537745/]
• 28. The Utilization of Freezing Steps in Mesenchymal Stromal ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01627/full]
• 29. Mesenchymal Stromal Cells Engage Complement and ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021703]
• 30. Immunomodulatory properties of mesenchymal stem cells ... [https://link.springer.com/article/10.1007/s11626-025-01109-z]
• 31. Cryostorage of Mesenchymal Stem Cells and Biomedical ... [https://www.mdpi.com/2073-4409/11/17/2691]
• 32. Cryopreservation of mesenchymal stem/stromal cells using ... [https://www.sciencedirect.com/science/article/abs/pii/S1465324924007734]
• 33. 138 Mesenchymal Stem/Stromal Cells XT-THRIVE, A NON- ... [https://www.sciencedirect.com/science/article/pii/S1465324925002026]
• 34. Hydrogel microcapsulation technology reduces the DMSO ... [https://www.sciencedirect.com/science/article/pii/S2352320425002123]
• 35. Effects, methods and limits of the cryopreservation on ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11441116/]
• 36. Ice Inhibition for Cryopreservation: Materials, Strategies, ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7967093/]
• 37. Cryopreservation: A Review Article - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9756256/]
• 38. Physical vitrification and nanowarming at liter-scale CPA ... [https://www.nature.com/articles/s41467-025-63483-2]
• 39. What's the difference between slow freezing and vitrification? [https://extendfertility.com/slow-freezing-vs-vitrification/]
• 40. The impact of cryopreservation on bone marrow-derived ... [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-02136-7]
• 41. Vitrification of 3D-MSCs encapsulated in GelMA hydrogel [https://www.sciencedirect.com/science/article/pii/S014181302500265X]
• 42. A new device for study of cryopreservation by vitrification [https://www.sciencedirect.com/science/article/pii/S0011224025001464]
• 43. Natural Cryoprotective and Cytoprotective Agents in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9145333/]
• 44. Overcoming ice: cutting-edge materials and advanced ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11887326/]
• 45. Cell Cryoprotectant Strategic Roadmap: Analysis and ... [https://www.archivemarketresearch.com/reports/cell-cryoprotectant-328193]
• 46. The immunomodulatory properties of mesenchymal stem ... [https://www.sciencedirect.com/science/article/abs/pii/S1567576910002067]
• 47. Function of Cryopreserved MSCs with and without IFN-γ pre ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5397371/]
• 48. Identification of a fundamental cryoinjury mechanism in ... [https://www.sciencedirect.com/science/article/pii/S0011224023000913]
• 49. A circular exploration of cryoprotective agents for stem cells ... [https://www.sciencedirect.com/science/article/pii/S2772508125000328]
• 50. Immunomodulatory Functions of Mesenchymal Stem Cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12572674/]
• 51. The Immunomodulatory mechanism and research progress ... [https://pubmed.ncbi.nlm.nih.gov/40251675/]
• 52. Cell Cryopreservation: Common Protocols, Thawing Tips ... [https://www.genfollower.com/cell-cryopreservation-thawing-guide/]
• 53. Mesenchymal stromal cell extracellular vesicles as immune ... [https://www.sciencedirect.com/science/article/pii/S0166223625001948]
• 54. Current practices in peripheral blood stem cell processing ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12283502/]
• 55. A survey of cell processing practices for hematopoietic ... [https://www.sciencedirect.com/science/article/abs/pii/S146532492400971X]
• 56. Current practices in peripheral blood stem cell processing ... [https://www.bloodresearch.or.kr/journal/view.html?pn=search&uid=2734&vmd=Full]
• 57. Protocols and Best Practices for Freezing Cells [https://www.stemcell.com/cryopreservation-basics-protocols-and-best-practices-for-freezing-cells]
• 58. Quantitative assessment of the impact of cryopreservation on ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-02054-2]
• 59. Identifying and Measuring Critical Quality Attributes - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK475684/]
• 60. Defining minimal criteria for peer-reviewed reporting of ... [https://www.sciencedirect.com/science/article/pii/S1465324925007443]
• 61. Short-Term Cryopreservation Preserved the Function of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12524150/]
• 62. Cryostorage of Mesenchymal Stem Cells and Biomedical Cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9454587/]
• 63. Cryopreserved mesenchymal stem cells regain functional ... [https://pubmed.ncbi.nlm.nih.gov/31464641/]
• 64. Reconstitution and post-thaw storage of cryopreserved ... [https://www.sciencedirect.com/science/article/pii/S2352320423000275]
• 65. Optimizing cryopreservation conditions for use of ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1385691/full]
• 66. Dimethyl sulfoxide in cryopreserved mesenchymal stromal cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12362920/]
• 67. Key quality parameter comparison of mesenchymal stem ... [https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1412811/full]
• 68. Comparative analysis of mesenchymal stem cells ... [https://www.nature.com/articles/s41598-022-12467-z]
• 69. Serum-free media and the immunoregulatory properties of ... [https://pubmed.ncbi.nlm.nih.gov/24603109/]
• 70. Comparison of Cryopreservation Media for Mesenchymal ... [https://pubmed.ncbi.nlm.nih.gov/38011543/]
• 71. Immunomodulatory properties and therapeutic application of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3074211/]
• 72. Immunomodulatory properties of mesenchymal stem cells ... [https://www.nature.com/articles/s41423-023-00998-y]
• 73. Algorithm-driven optimization of cryopreservation protocols ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5769925/]
• 74. Optimisation of cryopreservation conditions, including storage ... [https://bmcmolcellbiol.biomedcentral.com/articles/10.1186/s12860-024-00516-6]
• 75. Development of a reliable low-cost controlled cooling rate ... [https://www.sciencedirect.com/science/article/abs/pii/S1465324910703789]
• 76. Reconstitution and post-thaw storage of cryopreserved human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10154666/]
• 77. Short-term assays for mesenchymal stromal cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10562633/]
• 78. Cryopreservation and Validation of Microfragmented Adipose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12295665/]
• 79. Immunomodulatory properties of mesenchymal stem cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12628475/]
• 80. Successful isolation of viable stem cells from cryopreserved ... [https://jeo-esska.springeropen.com/articles/10.1186/s40634-023-00596-x]
• 81. Cryopreserved or Fresh Mesenchymal Stromal Cells [https://pubmed.ncbi.nlm.nih.gov/27837556/]
• 82. Do cryopreserved mesenchymal stromal cells ... - PubMed [https://pubmed.ncbi.nlm.nih.gov/24805247/]
• 83. Dealing with Cryopreservation Challenges in Mesenchymal Stem Cell Culture - Atlantis Bioscience Pte Ltd [https://www.atlantisbioscience.com/blog/dealing-with-cryopreservation-challenges-in-mesenchymal-stem-cell-culture/]
• 84. Immunomodulatory Properties of Mesenchymal Stromal Cells [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.637725/full]
• 85. Current perspectives on mesenchymal stromal cell therapy ... [https://www.nature.com/articles/s41423-023-01022-z]
• 86. From cold chain to ambient: Benefits, risks, and evidence ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12593556/]
• 87. Trends in mesenchymal stem cell-derived extracellular ... [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1625787/full]
• 88. Frontiers | Immunomodulatory and Regenerative Effects of... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.591065/full]
• 89. Mesenchymal stem cell-derived extracellular vesicles for ... [https://www.nature.com/articles/s41419-022-05034-x]
• 90. Immunomodulatory potential of mesenchymal stem cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9968735/]
• 91. Engineered extracellular vesicles: a breakthrough approach to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12093887/]
• 92. and neuroprotective Immunomodulatory of... effects [https://pubmed.ncbi.nlm.nih.gov/40991997/]
• 93. Size-dependent immunomodulation by MSC secretome: soluble factors... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04670-2]